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4Abstract:
The reinforcing properties of nicotine depend partly on cholinergic projections from the
pedunculopontine tegmental (PPTg) and laterodorsal tegmental (LDTg) nuclei to
midbrain dopamine neurons in the ventral tegmental area (VTA) and substantia nigra
pars compacta (SNc). Neuronal activation was investigated using Fos expression in
these areas following acute (0, 0.1, 0.4, 0.8mg/kg) or chronic systemic nicotine (0, 0.1,
0.4, 0.8, 1.0mg/kg given once per day for 5 days). We also examined co-localization of
Fos expression in bNOS and TH positive neurons to determine what populations of
neurons were activated by nicotine.
Acute nicotine resulted in dose related Fos expression, with the biggest increase seen
after 0.4mg/kg nicotine, but no co-localization occurred with bNOS in the PPTg/LDTg.
Surprisingly, nicotine also failed to activate midbrain dopamine neurons. After animals
were sensitized to nicotine there was a similar dose response curve in Fos expression,
but the biggest increase was seen after 0.8mg/kg nicotine. Chronic nicotine, like acute,
also preferentially activated non-cholinergic neurons in the LDTg and PPTg and non-
dopamine neurons in the SNc and VTA.
Further experiments looked at the mechanisms of Fos expression after nicotine
administration. Fos expression in the LDTg/PPTg and SNc/VTA was suppressed after
d-amphetamine, despite an increase in locomotor activity, suggesting that the increased
Fos expression after chronic nicotine was not simply due to the locomotor activating
effects of sensitized nicotine. Blocking autoreceptors in the dopaminergic midbrain by
haloperidol pre-treatment did not increase Fos expression in dopamine neurons
indicating that the inhibitory mechanism was not dependent on local autoreceptors.
5Novel methods of visualising and lesioning GABA neurons in the mesopontine
tegmentum and midbrain were also examined.
The data suggest that the mechanisms by which dopamine is involved in the
pharmacological actions of passively administered nicotine are more complex than was
first thought and that the role of non-dopamine neurons in the VTA (possibly GABA or
glutamate containing) are also important.
6Abbreviations:
5HT 5-Hydroxytryptamine; serotonin
6-OHDA 6-Hydroxydopamine
ABC Avidin/Biotin Complex
ACh Acetylcholine
ADS Antibody diluting solution
ANOVA Analysis of variance
A-O Action-Outcome
aPPTg Anterior pedunculopontine tegmental nucleus
ARAS Ascending reticular activating system
ATP Adenosine triphosphate
bNOS Brain derived nitric oxide synthase
CaMK Calmodulin-dependent kinase
cAMP Cyclic adenosine monophosphate
CeA Central amygdala
ChAT Choline acetyltransferase
CLi Caudal linear nucleus
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CREB cAMP response element binding protein
CS+ Conditioned stimulus
DAB 3,3-diaminobenzidine tetrahydrochloride
DAMGO Try-D-Ala-Gly-MePhe-Gly(ol)
DAT Dopamine transporter
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EAA Excitatory amino acid
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fr Fasciculus retroflexus
FR Fixed ratio
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GAD Glutamate decarboxylase
HRP Horseradish peroxidase
i.p. Intraperitoneal
ICSA Intracranial self-administration
7ICSS Intracranial self-stimulation
IEG Immediate early gene
IF Interfasciculus nucleus
IgG Immunoglobin
iGluR Ionotropic glutamate receptors
ISH In-situ hybridization
IVSA Intravenous self-administration
KI Knock-in’
KO Knock-out’
LC Locus coeruleus
LDTg Laterodorsal tegmental nucleus
LHb Lateral habenula
LTS Low threshold inward Ca2+ spike
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mfb Medial forebrain bundle
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MOR Mu-opioid receptor
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STN Subthalamic nucleus
TH Tyrosine hydroxylase
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VAchT Vesicular acetylcholine transferase
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Chapter 1: Theories of Addiction
1.0 Introduction
Tobacco is a highly addictive drug, found in cigarette and cigar smoke as well as in
chewing tobacco, thought to account for over 3 million deaths a year. However, this is
expected to rise to over 10 million by the year 2020. Although education and social
changes have attempted to curb this increase, tobacco use is the fourth most common
cause of disease (World Health Organisation, 2007). Nicotine is not generally thought
of as a hard drug, but with continued use it is often as difficult to abandon as heroin or
cocaine (Laviolette & van der Kooy, 2004). Initial symptoms of nicotine addiction can
be present after only a few cigarettes, and there are profound changes seen in synaptic
physiology of the brain systems associated with reinforcement after a single exposure
to nicotine (Mansvelder et al., 2003). Improved understanding of this would lead to the
development of effective treatments for fighting nicotine addiction and dependence and
could also lead to a more advanced comprehension of the addictive properties of other
abused drugs, including heroin, cocaine and alcohol.
Despite the prevalence of smoking behaviour, research into nicotine addiction has been
lacking compared with that of other drugs such as amphetamine or cocaine. In recent
years this imbalance has been corrected but nonetheless there is still much that we don’t
know about the basic mechanisms of nicotine in the brain. This thesis intends to
examine the fundamental mechanisms of systemic nicotine in the brain using
immediate early gene expression as a correlate of neural activity. The effects of both
acute and chronic nicotine will be examined in order to determine changes in neural
activity after a single dose and subsequent changes after continued exposure. Both the
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dopaminergic midbrain and the cholinergic regions of the mesopontine tegmentum will
be examined for changes in Fos expression. The dopamine projections originating in
the midbrain have been the focus of much research in to addiction since Olds & Milner,
(1954) discovered that rats would repeatedly bar press for electrical stimulation in
certain parts of the brain. The cholinergic mesopontine tegmentum, although much less
studied in terms of reinforcement, is a source of major excitatory input to the midbrain.
Recent research has indicated a role for these neurons in influencing the activity of
dopamine during self-administration of drugs (Lanca et al., 2000a; Alderson et al.,
2004a). Fos expression after d-amphetamine will also be examined to determine the
degree to which Fos expression is the result of the locomotor activating effects of
nicotine. Finally, nicotine induced Fos expression after pre-treatment with D2
antagonist, haloperidol, will also be examined in order to localise the mechanism of
nicotine action. Two additional experiments were also done, firstly to find a reliable
method of visualising -amino butyric acid (GABA) neurons in the laterodorsal
tegmental nucleus (LDTg), pedunculopontine tegmental nucleus (PPTg), substantia
nigra pars compacta (SNc) and ventral tegmental area (VTA), and secondly to assess a
new neuropeptide-toxin conjugate for its capacity to produce a specific GABA lesion in
the VTA.
1.1 Theories of addiction
1.1.0 Reward and reinforcement
The terms reward and reinforcement are often confused in the literature concerning
drug addiction. Reward is the positive value that an individual attributes to a stimulus.
The appetitive nature of a stimulus can change according to the state of the animal. For
example a hungry animal will find food more rewarding than a sated animal.
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Reinforcement occurs when the connection or stimulus-response bond between a
situation or stimulus and the response becomes strengthened. The animal learns to
associate the increased frequency of their response with the increased frequency of the
reinforcer. A stimulus that is intrinsically rewarding may lead to an increase in
behaviour, but the subjective feelings of pleasure associated with reward are not a
requisite part of reinforcement.
There are a number of theories as to why taking certain drugs leads to compulsive,
addictive behaviour. There are two theories based on the fact that “organisms emit
approach responses to safety” (Ikemoto & Panksepp, 1999, pg 6). This can either mean
approaching reward or avoiding aversive stimuli. The proponent process theory states
that addiction is driven by the positive or euphoric properties of the drug. Opponent
processes, on the other hand, are based on negative reinforcement and the need to avoid
the dysphoria associated with withdrawal. There are also two theories of addiction
based on associative learning concepts that attempt to explain the effects of drugs on
learning mechanisms at both a psychological and neural systems level of explanation.
Schultz et al., (1997) hypothesized that the dopamine system functions as a reward
predictor, using associative learning to generate a ‘prediction error’ signal in order that
an organism may work to reduce error and increase responses that result in reward.
Robinson & Berridge, (1993) stated that the dopamine system serves to attribute
‘incentive salience’ to stimuli that are associated with drugs. Both theories postulate
that drugs of abuse cause changes in the midbrain dopamine areas, and that this
underlies the psychological factors associated with addiction.
1.1.1 Proponent process theory
Positive reinforcement theories state that drug taking is compulsive because of the
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euphoria that is produced. Although this seems intuitive, there is in fact no evidence
that this is the case. The theory also fails to explain what specific action of the drug is
reinforcing and why it becomes more effective with increased drug use. It is difficult to
believe that the memory of euphoria alone would incite addicts to compulsively seek
drugs to the deficit of all other behaviour. Post-addicts (volunteers with histories of
heroin abuse) were found to self-administer morphine despite reporting no difference
between the drug and placebo showing that subjective pleasure was not necessary to
maintain responding (Lamb et al., 1991). Addicts are often quoted as saying they no
longer get any pleasure from the drug and don’t understand why they ‘want’ it. Rat
studies suggest that the affective and reinforcing properties of drugs are mediated by
separate neural systems (Wyvell & Berridge, 2001). The proponent process theory fails
to explain this difference between liking and wanting.
1.1.2 Opponent process theory
Alternatively, it is thought that drug-seeking behaviour is reinforced because of the
state that it alleviates. This is based on the distressing withdrawal symptoms an addict
experiences on cessation of drug use. There are a number of problems with this theory.
Importantly, the maximum periods of drug self-administration do not coincide with
times of maximum distress, craving is actually at its highest during the drug high
(Robinson & Berridge, 1993). It is also true that addicts can be at risk of relapse for
years after the end of withdrawal symptoms. Advocates of this theory believe this can
be explained by conditioned withdrawal, stimuli that are associated with withdrawal
also come to elicit symptoms by association. However, addicts deny any experience of
this and do not cite it as a reason for their relapse (Robinson & Berridge, 1993). Escape
from distress could explain some features of addiction, for example the positive
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reinforcing effects of a drug could be enhanced during withdrawal due to anhedonia,
but there are too many discrepancies for it to be considered the most important factor in
addiction.
1.1.3 Associative learning
Because theories based on reward, or the lack of it, fail to adequately explain many of
the elements of addiction, contemporary theories have turned back to reinforcement and
rules of learning to explain the abnormal patterns of behaviour seen in addicts.
Associative learning theories are based on the fact that normal stimulus-response (S-R)
and action-outcome (A-O) learning is altered in relation to drugs. The changes in neural
mechanisms precipitated by drugs are thought to lead to abnormally strong S-R habit
learning and the drug user is rendered increasingly powerless to cravings elicited by
conditioned cues. The subjective feelings of craving can be so strong that the addict is
insensitive to outcome – often leading to the loss of family, friends, job and home.
Colwill and Rescorla, (1985) attempted to explain how A-O learning, which is goal
directed, and S-R learning, compulsive habit formation, could be based on the same
mechanism. In goal-directed learning the animal learns the association between the
response and the incentive value of the outcome. With habit, the stimulus itself
becomes salient enough to elicit a response, but the stimulus no longer evokes a
representation of the goal. In action-outcome leaning, the reward value controls
responding. For instance, when a reward was devalued by aversion conditioning (the
reward was with paired with lithium chloride to induce nausea), subsequent responding
to the reward decreased. In stimulus-response learning the reward was only important
during the initial learning stages and responding was unaffected by aversion training. It
is possible that this where the difference between drug and natural reward lies because
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it has been shown that neither cocaine nor alcohol can be devalued in the way that a
natural rewards such as food or sucrose can (Dickinson et al., 2002; Miles et al., 2003).
1.1.4 Reward Expectation
In the past the associative learning during classical conditioning of a reward following a
stimulus was thought to be based on the contingency, the probability that one event is
dependent on the occurrence of another, and contiguity, the proximity in time and space
of two events. More recent theories of learning hypothesize that expectancy of reward
is more important than either contingency or contiguity. Sutton, in 1978, developed a
psychological model of classical conditioning that used learning rules “driven by
changes in temporally successive predictions” (Sutton & Barto, 1998, pg 22). Schultz
and colleagues (1997; 1998) developed a similar model based on Hebbian learning. A
‘prediction error’ signal based on expectancy of reward is generated by dopamine so
the system can correct behaviour and learn. In order for dopamine to be involved in this
role it would need the capacity to represent temporal relationships. The ability to carry
information about future rewards was demonstrated by the fact that after learning there
was a decrease in cell response to the delivery of reward and an increase at the onset of
a conditioned stimulus. For learning to be dependent on errors in prediction, a system is
needed that reports the current best guess. There are several informational or structural
requirements of this kind of ‘prediction error’ signal. It needs to have access to both a
representation of the phenomena to be predicted, and to current predictions in order to
make a comparison. It also needs the capacity to influence plasticity in the structure that
makes predictions, and finally a wide broadcast of the error signal so that different
modality stimulus can be used to make and respond to predictions. These requirements
are fulfilled by the dopamine system, which has neurons that respond with fast, short
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duration signals in response to both sensory stimuli and the delivery of reward. The
midbrain dopamine neurons also have connections with widespread targets involved in
a number of sensory and motor processes.
Although it was developed as a computational model, this model of learning is
biologically plausible and has been experimentally tested on Macaca fascicularis
monkeys. The learning theory predicts that the error between the actual and predicted
reward determines whether or not learning occurs. Using Kamin’s Blocking paradigm,
Waelti et al., (2001) showed that learning was blocked when the prediction error was
non-existent. In initial learning, dopamine is activated by reward, but this becomes a
more stimulus driven response as it becomes more predictable. The blocking test
generates differential prediction errors by training a target stimulus simultaneously with
a pre-trained stimulus. If the pre-trained stimulus has already been established as a
predictor of the reinforcer, the reinforcer on compound trials is expected and generates
a minimal prediction error. In this situation, learning about the target is blocked,
demonstrating that prediction errors rather than simple stimulus reinforcer pairings play
a crucial role in learning.
Responses of dopamine neurons were also recorded during the experiment and it was
found that even in circumstances where two stimuli were given identical training, there
were different responses of dopamine neurons depending on the status of the pre-
trained stimulus. In trials where it was concluded that learning did not occur due to a
lack of error signal, there were no dopamine neurons that responded solely to that
stimuli. In trials where learning did occur nearly half of the dopamine neurons recorded
responded solely to that stimuli.
There are two ways in which psychostimulant drugs could take over this system. If
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drugs are intrinsically reinforcing, the pharmacological actions of the drug would
amplify the rewarding signal. Sustained increases in extracellular dopamine would
produce an exaggerated reward signal. This means that dopamine would increase after
weak signals, resulting in learning. Alternatively if the drug is not intrinsically
rewarding, the pharmacological actions of the drug would mimic the response to a real
reward. This artificial reward signal would lead to focusing and plasticity effects on
post synaptic sites. An enhanced dopamine signal could override depressant neuronal
responses following stimuli resembling rewards, novel stimuli and particularly salient
stimuli that are frequent in everyday life (Schultz, 1997). These exaggerated reward
signals could explain how drugs hijack a system used to mediate natural rewards.
However it has been postulated that drug and natural rewards are mediated by
independent but overlapping mechanisms (Bowman et al., 1996). The problem with the
reward expectancy theory is that they do not attempt to distinguish between the two
populations of dopamine neurons found within the midbrian; the SNc and the VTA.
This may be important as there are two separable dopamine pathways that originate in
the midbrain; the nigrostriatal system which sends projections from the substantia nigra
(SN) to the dorsal striatum, and the mesolimbic system which sends projections from
the VTA to the nucleus accumbens (NAcc). The theory also fails to explain the role of
dopamine in negative contexts as they restrict this system to being a predictor of reward
signals.
1.1.5 Incentive sensitization
There are three particular features of addiction that are unexplained by the previous
theories. Cravings, and the fact that cravings intensify with continued drug use, cannot
be explained by either positive or negative reinforcement theories. They also fail to
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account for the fact that the euphoric effect of the drug decreases with continued use.
The conditioned stimuli (CS+) associated with euphoria or withdrawal are not thought
to be strong enough to explain the fact that addiction is a chronic relapsing disorder. In
an attempt to explain this and a number of other points, Robinson & Berridge, (1993;
2001) have developed the incentive-sensitization theory. They believe that abused
drugs recruit the associative learning systems normally used by natural rewards as the
animal attempts to maximise reward. Incentive learning of motivation refers to
processes involving environmental stimuli detected by distance receptors predicting the
perception of unconditioned stimuli (UCS), which allows animals on future occasions
to effectively seek out and anticipate various rewards in their environment (Ikemoto &
Panksepp, 1999). This directs the focus of the system to specific targets associated with
drugs and leads to increased directional attribution of importance or incentive salience
on drug related stimuli. While habits are not intrinsically compulsive, these stimuli
increasingly come to control behaviour because the neural system that mediates
‘wanting’ becomes progressively sensitized.
Sensitization is the gradual and incremental increase in responsiveness of a system that
occurs in response to a stimuli, in this case to drugs of abuse. It is suggested that the
neural system responsible for the mediation of ‘wanting’ through associative learning
processes is predominantly the mesocorticolimbic dopamine system. It appears that the
development of sensitization is mediated by the VTA, as microinjections of
amphetamine in the VTA sensitized rats to subsequent administration of amphetamine,
but the same did not occur in the NAcc (Vezina & Stewart, 1990). The progressive
sensitization of the mesolimbic system results in enhanced dopamine release upon each
successive intake of the drug meaning increased or incentive-salience to contextual
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stimuli.
The ability of conditioned contextual stimuli to enhance dopamine function in the
midbrain and the attribution of increasing incentive salience to drug associated stimuli
is thought to be experienced subjectively as craving. It has been theorized by Robinson
& Berridge, (1993) that repeated drug use alters the brain in such a way that what
appeared subjectively to be a single psychological process: liking and wanting, is
exposed as two separate processes. The hedonic aspect of reward (liking) and the
mechanisms that shape approach behaviour (wanting) are thought to be regulated by
separate neural systems. This occurs because while ‘wanting’ is sensitized, the system
that mediates reward develops compensatory mechanisms resulting in tolerance to the
euphoric effects of the drug. This means that cravings can never be satisfied, leading to
compulsive use. Wyvell & Berridge, (2001) showed that increased dopamine made rats
work harder for unrewarded CS+, but it didn’t make the solution taste nicer. This goes
some way to explain the continued use of drugs by addicts who report no pleasure
associated with taking the drug.
Incentive sensitization attempts explains the separation between the initial ‘liking’ of
the drug, and the gradual change to ‘wanting’, and the compulsive nature of this
change. This contrasts to the pleasure seeking theory which assumes the incentive
motivation of the drug is due only to subjective pleasure. The incentive-sensitization
theory also attempts to explain relapse by positing that the neuroadaptations underlying
sensitization are long-lasting or perhaps even permanent.
Each theory does contribute to explaining different patterns of addiction. The theory
postulated by Schultz et al. (1998) could explain the early stages of addiction. The
transferred response of dopamine from delivery of reward to onset of stimulus may be
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the neural correlate of the attribution of incentive salience to the stimulus. Enhanced
dopamine may mean faster learning and increased attribution of incentive salience. The
later stages of addiction, for instance the compulsive reaction to stimuli and cravings,
are better explained by incentive sensitization and the progressive sensitization of the
dopamine response. Although both reward prediction errors and incentive-sensitization
explain a lot of the issues surrounding addiction, they do not take into account the
complex interaction of social, cultural and economic factors. They also fail to address
initial experimentation with drugs or casual patterns of use. While, positive and
negative reinforcement obviously have a lot of problems, addicts do report being driven
by euphoric properties or trying to avoid withdrawal, so they probably do play some
role in drug use and abuse.
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Chapter 2: Anatomy
2.0 Introduction
This chapter describes some of the anatomy of the regions thought to be involved in
reinforcement. Both the reward expectation and incentive sensitization theories
attribute increases in reinforcement behaviour to changes in the mesolimbic dopamine
system which originates in the midbrain. Although the midbrain is the primary region
associated with reinforcement, the mesopontine tegmentum is thought to be important
due to its ability to regulate the activity of dopamine neurons.
2.1 The SNc and VTA
The midbrain dopamine system is comprised of the retrorubral field (RRF; A8), SN
(A9) and VTA (A10). A8, A9 and A10 are terms given to the dopamine neurons in
each of these structures in the classification of Dahlstrom & Fuxe (1964). Figure 1
shows an example section in the midbrain and the corresponding section from the Rat
Atlas (Paxinos & Watson, 1997) detailing the boundaries of each nuclei and its
subdivisions. The SN has been divided into two regions based on presence or absence
of dopamine neurons. The majority of the dopaminergic SNc sits dorsal to the
GABAergic substantia nigra pars reticulata (SNr), although some dopaminergic
neurons extend into the centre of the SNr. The VTA appears to be continuous with the
dorsal SNc and contains similarly scattered neurons while the more ventral part of the
SNc contains closely packed neurons many of which have long vertically oriented
dendrites directed into the SNr. The VTA can be divided into several subregions
including the parabrachial pigmented nucleus (PBP) and the paranigral nucleus (PN).
The PN is the ventral portion of the VTA and contains small to medium neurons that
A B
A:  Regional delineation adapted from Paxinos & Watson (1997).  B:  TH staining in the midbrain.  The ventral tegmental area (VTA) 
consists of three subregions; the parabrachial pigmented nucleus (PBP), the paranigral nucleus (PN) and the interfascicular nucleus 
(IF).  The substantia nigra (SN) consists of the substantia nigra pars compacta (SNc) and the substantia nigra pars reticulata (SNr).  The 
medial lemniscus (ml) divides the dopamine neurons of the SNc and VTA. Scale bar = 200µm
Interaural = 3.00 mm Bregma = -6.00 mm
Figure 1:   The midbrain dopamine region
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are round, stellate (star-shaped) or spindle shaped, while the PBP mostly contains
medium sized neurons. Some researchers also include the interfasciculus nucleus (IF), a
group of very small tightly packed neurons, and the caudal linear nucleus (CLi),
containing small to medium round, stellate and spindle shaped neurons, which is
situated medially at the posterior end of the VTA (Phillipson, 1979b). Studies have also
divided the VTA into a posterior region, usually at the level of the mamillary nucleus
(MN), and an anterior region, at the level of the fasciculus retroflexus (fr) and the
medial terminal nucleus of the optic tract (MT; Ikemoto et al., 1997b).
2.1.1 Cellular Properties
Neurons in the VTA and SNc can be divided into three types based on their
electrophysiological profile. The three types have been named principal, secondary and
tertiary, based on the relative amounts of each type of cell in the midbrain (Lacey et al.,
1989; Cameron et al., 1997). Principal neurons are thought to make up the vast majority
of neurons in the A9 and A10 regions (Grace & Onn, 1989; Lacey et al., 1989; Johnson
& North, 1992b; Cameron et al., 1997). They are presumed to be dopaminergic based
on their immunoreactivity to tyrosine hydroxylase (TH) and the fact that they
hyperpolarise in response to dopamine via D2 receptors (Cameron et al., 1997). In
vitro, dopamine neurons lack the ability to generate bursts of action potentials
indicating that there is an external source of control to bursting activity. The most likely
sources of control are projections from the frontal cortex, the subthalamic nuclei (STN)
and the cholinergic mesopontine tegmentum. When the LDTg is inactivated in
anaesthetized animals the midbrain dopamine neurons no longer fire in bursts (Lodge &
Grace, 2006). These projections are thought to control burst firing by excitatory amino
acid (EAA) stimulation of dopamine neurons, becuase an N-methyl-D-aspartate
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(NMDA) glutamate antagonist is sufficient to block burst firing (Overton & Clark,
1997). Although neurons in the VTA and SNc are not distinguishable by
electrophysiology, it is thought that there is a larger population of burst firing dopamine
cells in the VTA than in the SNc (Grenhoff et al., 1986). Since burst firing is
conditional on EAA afferents the difference in burst firing is likely due to the origin
and type of projection each region receives. Burst firing is an essential characteristic of
midbrain dopamine neurons because it increases Ca2+ in the nerve terminal which
increases the probability that neurotransmitter is released (Overton & Clark, 1997).
Secondary neurons are thought to be GABAergic because they can be stained for
glutamate decarboxylase (GAD) and hyperpolarise to met-enkephalin (met-ENK) via
-opioid receptors (Cameron et al., 1997). These neurons can be clearly deliniated from
principal neurons on their electrophysiological properties. Tertiary cells, more recently
characterised than either primary or secondary cell types, are less well studied, although
a number of studies recognise that there are neurons that are neither primary nor
secondary in nature (Johnson & North, 1992b; Cameron et al., 1997; Ungless et al.,
2004). These neurons are relatively difficult to recognise as they have a very similar
electrophysiological and morphological profile to primary neurons. They also have a
similar distribution throughout the midbrain (Cameron et al., 1997). However, these
neurons hyperpolarise in response to both dopamine and met-ENK as well as 5-
hydroxytryptamine (5-HT), but they are not immunoreactive for GAD. Less than a third
contain TH so the majority are neither dopamine nor GABA containing (Cameron et
al., 1997). A recent study has proposed that there is a population of glutamatergic
neurons in the VTA based on a group of neurons containing second vesicular glutamate
transporter (vGlut2) mRNA (Yamaguchi et al., 2007) so it is possible that future studies
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may find that some tertiary neurons correspond to vGlut2 containing neurons.
Dopaminergic, GABAergic and the presumed glutamatergic neurons have been found
to have overlapping distributions throughout the VTA. In the anterior VTA, the
majority of TH was found in the PBP while the more medial region of the VTA was
found to contain most of the vGlut2 containing neurons. Overall the number of TH
neurons greatly exceeded the number of glutamatergic neurons. In the medial VTA the
majority of the TH containing neurons were found in the PBP rather than the PN. The
medial PN was the only region of the brain in which vGlut2 containing neurons
outnumbered TH neurons. The posterior VTA contained 5-10 times more TH than
vGlut2 containing neurons, the majority of which were found in the dorsally located
PBP. vGlut2 was rarely co-expressed with either TH or GAD in the VTA (Yamaguchi
et al., 2007). GABA neurons make up the majority of neurons found in the SNr and are
also found intermingled with dopamine neurons in the SNc and VTA (Maloney et al.,
2002; Perrotti et al., 2005). Some dopamine neurons were found to co-express TH and
GAD65 in the medial SNc and VTA (Gonzalez-Hernandez et al., 2001). Up until
recently dopamine neurons were thought to be most important neurons in this area and
a number of motor and cognitive functions were thought to depend upon their integrity.
However, new studies are beginning to highlight the importance of the non-
dopaminergic neurons of the midbrain in regulating dopamine activity.
2.1.2 Connectivity
The ascending connections of the midbrain dopamine neurons can be divided into two
pathways, the nigrostriatal and the mesolimbic. The nigrostriatal system originates in
the SNc and ascends via the medial forebrain bundle (mfb) and internal capsule to the
dorsal striatum (or caudate putamen) and the globus pallidus (GP; Beckstead et al.,
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1979). The mesolimbic system consists mainly of projections from the VTA to the
NAcc, the thalamus, the posterior hypothalamus, the central, lateral and medial
amygdala nuclei, the bed nucleus of the stria terminalis, the nucleus of the diagonal
band, the lateral septal nucleus and the frontocingulate cortex (Beckstead et al., 1979).
The projections from the VTA to the NAcc tend to target the more medial portions of
the shell, while projections from the SNc are thought to terminate in the core and lateral
shell but not the medial shell. It was also found that the more dorsal parts of the VTA
sent projections to the more ventral region of the NAcc, suggesting a topographic
pattern of projections (Brog et al., 1993). Projections to the VTA do not originate from
highly specific areas of the brain but form an elongated formation stretching from the
prefrontal cortex (PFC) to the brainstem (Geisler & Zahm, 2005). Injections of
horseradish peroxidase (HRP) retrograde tracer in the VTA label a number of structures
that have descending projections to the VTA including the cortex, the basal forebrain,
hypothalamic areas, the habenular nuclei, the parafascicular nuclei. A small number of
neurons was also found in the anterolateral, basolateral, medial and central divisions of
the amygdala. Structures with ascending projections to the VTA include the raphe
nuclei and the mesencephalic and pontine reticular formation (Phillipson, 1979a). A
recent study, using a much more sensitive retrograde tracer that is taken up by synapses
regardless of the amount of activity, was able to compose a more detailed picture of
VTA afferents. For example, projections to the VTA were found to originate in the
NAcc shell but not the core. Labelling was also found in greater abundance than
originally thought and in a larger number of structures including various hypothalamic
nuclei and both the LDTg and PPTg in the mesopontine tegmentum (Geisler & Zahm,
2005). Anterograde labelling from various forebrain structures confirmed these
findings. Many structures that sent projections to the VTA also innervated other regions
29
which in turn innervated the VTA. This pattern indicates that the VTA forms the hub of
an anatomical network of projections (Geisler & Zahm, 2005). Functionally this allows
for the integration of large amounts of information which can then be used to
coordinate immediate responses or be relayed to other regions for more specific and
detailed analysis.
2.1.3 Dopamine Receptor Subtypes
There are at least 6 different types of dopamine receptor subtype found throughout the
brain, but these are divided into two groups that display similar pharmacological
properties: D1-like and D2-like. D1-like receptors are thought to activate adenylyl
cyclase, which controls the influx of Ca2+ into the cell, while D2-like receptors inhibit
adenylyl cyclase, inhibiting inward Ca2+ currents (Missale et al., 1998). Both D1 and
D2 receptors are also thought to be able to stimulate the release of intracellular Ca2+
stores (Missale et al., 1998). Dopamine receptors are found distributed thoughout the
nigrostriatal and mesolimbic system in the brain. When directly compared D1 receptors
are generally found in greater densities (Boyson et al., 1986). Using quantitative
autoradiography, which uses radiolabeled ligands to determine the tissue distributions
of receptors, Boyson et al., (1986) found 3 times the density of D1 receptors to D2
receptors in the dorsal striatum and NAcc, while in the midbrain dopamine areas there
were 11-13 times the number of D1 receptors compared with D2 receptors. More
sensitive immunohistochemical methods have found D1 receptors in a number of
regions including various regions of the cortex, the hippocampus, the SNr, the
amygdala and the striatum . In the prefrontal cortex and hippocampus, receptors were
found both pre- and postsynaptically. D2 receptors were found in the striatum (Missale
et al., 1998), the NAcc, various nuclei of the cortex, the amygdala, hypothalamus as
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well as the VTA and SNc. In the NAcc D2 receptors were limited to GABAergic
neurons in the NAcc core but neurotensin containing neurons in the septal pole of the
NAcc shell. Although both D1 and D2 type receptors were found in the striatum, they
were found not to co-localise (Missale et al., 1998). The majority of regions that
contained D2 receptors, the NAcc, cortex, amygdala and hypothalamus, were also
found to contain projections from the VTA. However, both the dorsal and ventral
regions of the striatum as well as the midbrain are thought to contain more D1 than D2
receptors. As D1 receptors are thought to be excitatory, while D2 receptors play an
inhibitory role, this may have functional implications. Those projections from the VTA
which contain D2 receptors can inhibit downstream actions. However, the fact that the
receptor type in the striatum is predominantly D1 indicates a largely excitatory role for
these neurons.
2.2 The LDTg and PPTg
The cholinergic system is distributed throughout the brain but is divided into three main
projections systems originating in the LDTg and PPTg, the basal forebrain and the
medial septum. There is also a significant population of cholinergic interneurons within
the striatum. Due to its association with the mesolimbic and nigrostriatal systems the
LDTg and PPTg will be considered in more detail. The cholinergic regions of the
mesopontine tegmentum includes the pedunculopontine tegmental nucleus (PPTg; Ch5)
and the laterodorsal tegmental nucleus (LDTg; Ch6). The Ch5/Ch6 nomenclature was
introduced as an alternative method of distinguishing cholinergic neurons based on
projection site rather than traditional boundaries (Mesulam et al., 1983). The Ch5/Ch6
neurons sit at the junction of the pons and midbrain. The LDTg can be found in the
central gray, anterior to the noradrenergic locus coeruleus (LC). The PPTg extends
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from the tip of the cerebellar peduncle to the posterior SN (Paxinos & Watson, 1997).
The PPTg is divided into two areas based on the density of the cholinergic neurons. The
posterior PPTg (pPPTg) pars compactus is made up of a dense cluster of neurons that
surround the tip of the superior cerebellar peduncle. The anterior PPTg (aPPTg) pars
dissipatus region of cholinergic neurons is a region of diffuse cholinergic neurons
stretching from the pars compactus to the SN (Lavoie & Parent, 1994b). The LDTg and
PPTg form a continuous chain, sometimes called the caudal cholinergic column (Satoh
& Fibiger, 1985), and are dissociable by location and projection site, rather than by
cellular properties. Figure 2 shows an example section in the mesopontine tegmentum
of the LDTg, and posterior PPTg and the corresponding section from the Rat Atlas
(Paxinos & Watson, 1997) detailing the boundaries of each.
The LDTg and PPTg are mostly made up of cholinergic neurons, indeed the outline of
these regions is usually described in terms of the cholinergic neurons. Until recently it
was only the cholinergic neurons that were considered to be part of the LDTg and
PPTg, while the non-cholinergic neurons situated adjacent to the PPTg were classified
as the midbrain extrapyramidal area (Rye et al., 1987). However there are actually
populations of both GABAergic and glutamatergic neurons interspersed with the
cholinergic neurons (Clements & Grant, 1990; Ford et al., 1995). The fact that it is
impossible to separate out these populations either by function or connectivity makes it
unlikely that they are dissociable populations of neurons. Recent evidence points to the
importance of the non-cholinergic projections from this area (Maloney et al., 1999;
Lanca et al., 2000b; Verret et al., 2005), indicating that it may be valuable to view these
populations as interdependent. However, until much of the neurochemistry and
interconnections of these regions are untangled, the precise borders of the LDTg and
A B
Fig 6.  The cholinergic mesopontine tegmentum region.  A:  Regional delineation adapted from Paxinos & Watson (1997).  B:  bNOS 
staining in the laterodorsal tegmental nucleus (LDTg),  the pedunculopontine tegmental nucleus (PPTg) and the subpeduncular 
tegmental nucleus (SPTg). The PPTg is bordered medially by the superior cerebellar peduncle (scp) and laterally by the lateral 
lemniscus (ll), while the cuneiforn nucleus (CnF) sits just dorsal to the PPTg. Scale bar = 200µm
Interaural = 0.60 mm Bregma = -8.40 mm
Figure 2:   The mesopontine tegmentum
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PPTg remain unclear. Due to this fact future references to the LDTg or PPTg will refer
to both cholinergic and non-cholinergic populations unless otherwise specified.
2.2.1 Cellular properties
There has been a limited amount of research into the electrophysiological properties of
the neurons within the LDTg and PPTg. Table 1 gives a brief outline of possible cell
types found in the LDTg and PPTg. Typically these neurons are divided into two or
three different classes based on ionic mechanism and burst firing properties. However,
closer inspection of this literature reveals five different types of neuron.
Type I neurons, identified by the low threshold Ca2+ spike (LTS), are burst firing
neurons found throughout the LDTg as well as in both the posterior and anterior
regions of the PPTg. Type II neurons were identified by the A-current and are non-burst
firing. Neurons displaying long and short duration action potentials were found in both
the LDTg and PPTg (Takakusaki et al., 1997; Koyama et al., 1998). Takakusaki et al.,
(1997) found a very distinct bimodal distribution of spike duration for Type II neurons
in the PPTg. Type II neurons are found in the LDTg as well as scattered throughout the
entire length of the PPTg (Kang & Kitai, 1990; Kamondi et al., 1992; Takakusaki et al.,
1996; Takakusaki & Kitai, 1997). However they increased in number along the
posterior-anterior axis of the PPTg so that the majority were found in the anterior
region (Takakusaki et al., 1996). Long duration neurons, which made up about 70% of
the Type II neurons, were only found in the anterior PPTg, while the remainder, short
duration neurons, were found throughout the PPTg.
Type III neurons, often grouped with type II, had both the transient inward current
followed by the LTS (Kamondi et al., 1992; Takakusaki et al., 1996). Although these
Table 1: Classification of cell type in the LDTg and PPTg.
Type Membrane properties Classification AP Duration Region Identity
Type I LTS Bursting ? LDTg/PPTg Non-cholinergic
Type IIa A-current Non-bursting Short AP LDTg/PPTg Some cholinergic
Type IIb A-current Non-bursting Long AP ? /aPPTg Some cholinergic
Type III A-current + LTS Tonic &/or phasic Long AP ? /aPPTg Some cholinergic
Type IV Neither ? ? ? Non-cholinergic
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were very similar to type II neurons in terms of membrane properties, the majority of
these neurons were in fact non-cholinergic (Takakusaki et al., 1996; Takakusaki &
Kitai, 1997). Type III neurons all had action potentials over 1.6ms in length, and as
Takakusaki et al., (1997) did not distinguish between type IIb, with an A-current and
long action potentia, and type III, with an A-current followed by an LTS they were
assumed to have similar properties. Type IV neurons were not extensively
characterised. They were simply those neurons that show neither the LTS of type I
neurons nor the A-current of type II (Kang & Kitai, 1990). They were found both in
and around the cholinergic core of the PPTg.
Type I and III neurons tended to be small to medium sized neurons that were spindle,
triangle or polygonal shaped and had 3-6 primary dendrites. Type II neurons had a
soma that was twice the size of Type I or III, they were fusiform or polygonal with 5-7
primary dendrites (Kang & Kitai, 1990). Type II and III neurons tended to have a more
prominent dendritic arborisation than Type I neurons (Takakusaki & Kitai, 1997).
Studies that examining the PPTg neurons consistently failed to find choline
acetyltransferase (ChAT) or Nicotinamide adenine dinucleotide phosphate (NADPH)
labelling in Type I neurons, indicating that they were non-cholinergic (Kang & Kitai,
1990; Leonard & Llinas, 1990; Takakusaki et al., 1996; Takakusaki & Kitai, 1997).
Neurons from the LDTg seemed to be more difficult to identify as both Leonard &
Llinas, (1990) and Wilcox et al., (1989) found that neurons with a LTS were non-
cholinergic but several studies have identified some type I neurons as cholinergic.
Indeed Luebke et al., (1992) found that 83% of low threshold bursting neurons were
labelled by NADPH. The explanation for this could lie in the fact they were recording
from neonatal rats, while most studies used adult rats and guinea pigs.
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Approximately half of Type II and III neurons (50-65%) were found to be cholinergic.
In the PPTg, Takakusaki et al., (Takakusaki et al., 1997) found approximately equal
distributions of cholinergic and non-cholinergic regardless of whether neurons had
action potentials of short duration (Type IIa) or long duration (Type IIb). This differed
somewhat to results found by Koyama et al., (1998) when LDTg neurons were
examined. They found that nearly all neurons that displayed a long action potential
were immunopositive for ChAT, while all of the short action potential neurons were
immunonegative. There were two major differences between these experiments which
may account for this discrepancy. Firstly Koyama et al., (1998) recorded in vivo from
the LDTg while Takakusaki et al., (1997) recorded in vitro from the PPTg. It is
possible that the neurons from different regions had different intrinsic properties, or it
may be that by recording in vitro the properties of the neurons were compromised
somehow. Type IV neurons were thought to be exclusively non-cholinergic (Kang &
Kitai, 1990).
2.2.2 Connectivity
The connections of the PPTg, and to some extent the LDTg, have been studied
extensively using a number of different retrograde and anterograde tract tracing
techniques. They have been found to project to and receive input from a large number
of regions ranging from the cortex to the spinal cord. The connections of the PPTg have
recently been categorised by Winn, (2006) into 6 groups based on region, and this also
holds true for the connections of the LDTg. There are two groups of descending
afferents, firstly to the spinal cord and secondly to other elements of the brainstem
including the pontine and medullary reticular formation as well as the motor trigeminal.
Retrograde labelling studies suggest that approximately 5-15% of cholinergic neurons
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in the LDTg and PPTg have descending projections to elements of the brainstem.
However the majority of the projections to the spinal cord may be non-cholinergic
(Mitani et al., 1988; Rye et al., 1988; Jones, 1990; Skinner et al., 1990a; Skinner et al.,
1990b). The third group contains more localised interconnections with serotonergic and
noradrenergic elements of the ascending reticular activating system (ARAS; Semba &
Fibiger, 1992; Honda & Semba, 1994). The ARAS is an ascending arousal system
thought to regulate the level of forebrain wakefulness, consisting of a group of closely
associated monoaminergic and cholinergic nuclei in the brain. Both the LDTg and
PPTg also have connections with the corresponding contralateral nucleus, as well
connections between the ipsilateral LDTg and PPTg (Cornwall et al., 1990; Semba &
Fibiger, 1992; Steininger et al., 1992). The fourth group is a collection of ascending
connections with the various nuclei of the thalamus. Both the LDTg and PPTg show
strong cholinergic innervation of the thalamus (Hallanger et al., 1987), indeed it is
thought that 60% of mesopontine cholinergic neurons project to the thalamus and this
accounts for 90% of the total input from the LDTg and PPTg (Sofroniew et al., 1985).
The fifth group of projections are inputs from the LDTg and PPTg are to sites of non-
specific cortical input such as the lateral hypothalamus and the nucleus basalis
magnocellularis, from which originates the majority of the cholinergic input to the
cortex (Semba et al., 1988; Semba & Fibiger, 1992). The final group describes a
thorough pattern of connectivity with corticostriatal circuitry. The PPTg in particular is
often thought of as an integral part of the basal ganglia (Mena-Segovia et al., 2004).
The LDTg and PPTg have reciprocal connections with several regions in the midbrain
including the dopaminergic VTA and SNc as well as the GABAergic SNr. Connections
with the STN, as well as the dorsal and ventral pallidum, have also been traced from the
LDTg and PPTg. Evidence of direct connections with the dorsal and ventral striatum
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have also been found in some studies (Steininger et al., 1992; Brog et al., 1993) but not
others (Zahm et al., 1999). Connections have also been found with the central
amygdala (CeA) and the superior colliculus (SC) (Beninato & Spencer, 1986; Zahm et
al., 1999).
Despite this regional classification it seems as if the internal topography of the LDTg
and PPTg is organised functionally, indeed many neurons project to numerous regions.
The projections from the LDTg are thought to regulate limbic functions, while the
PPTg is thought to regulate sensory and motor functions. This is especially true in the
thalamus because while the PPTg was retrogradely labelled after injections in all
thalamic regions, the LDTg was only labelled following injections of tracer in the
anterior, laterodorsal, central medial, and mediodorsal nuclei, the limbic components of
the thalamus (Hallanger et al., 1987).
2.3 Connections of the dopaminergic midbrain and LDTg/PPTg
The projections from the LDTg and PPTg may be crucial in regulating the burst firing
activity of dopaminergic neurons in the midbrain. As bursting activity in dopamine
neurons is associated with a higher probability of neurotransmitter release, the LDTg
and PPTg are well placed to influence motivationally relevant behaviour (Overton &
Clark, 1997). Cholinergic axons have been shown to synapse with dopamine neurons in
the SNc (Bolam et al., 1991), and retrograde tracer injections in the SNc have identified
projections originating from ChAT and glutamate positive neurons in the PPTg
(Lavoie & Parent, 1994a).
Injections of a retrograde tracer in the VTA demonstrated that the majority of
projections to the VTA from the mesopontine tegmentum could be traced back to the
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LDTg (Figure 4; Oakman et al., 1995; Oakman et al., 1999). Cornwall et al., (1990)
showed that in the anterior part of the VTA anterograde labelling traced from the LDTg
was mainly found ventrally around the mamillary peduncle, fasciculus retroflexus and
in the interfascicular nucleus. In the more posterior parts of the VTA, retrograde
labelling was found more in the ventral paranigral regions than in the dorsal
parabrachial region. The medial terminal nucleus also received a strong innervation
from the LDTg (Cornwall et al., 1990).
More detailed analysis of cholinergic projections from the mesopontine tegmentum to
the midbrain suggests that terminals synapse with both TH and GABA containing
dendrites. Projections from the LDTg to the VTA were traced with anterograde tracer
and were found to form excitatory asymmetric synapses with NAcc projecting
dopamine neurons and inhibitory symmetric synapses with NAcc projecting
GABAergic neurons. Midbrain dopamine and GABA neurons that projected to the
prefrontal cortex had a mixture of excitatory and inhibitory synapses with projections
from the LDTg (Omelchenko & Sesack, 2005). Cholinergic terminals, labelled with
vesicular acetylcholine transferase (VAChT), in the VTA were found to form excitatory
synapses preferentially with NAcc projecting dopamine neurons, while forming
inhibitory synapses with both NAcc and prefrontal projecting GABAergic neurons
(Omelchenko & Sesack, 2006). This could indicate that the excitatory synapses with
prefrontal projecting neurons in the VTA, identified by anterograde tracing, are in fact
with non-cholinergic projections from the LDTg. The data suggest that there is a very
defined topographical pattern to the projections from the LDTg to the midbrain
dopamine neurons which may be of some functional significance. The LDTg sends
excitatory projection to the ventral regions of the VTA (Cornwall et al., 1990), which in
Figure 3: Projections from the LDTg and PPTg to the dopaminergic midbrain (by
permission of Prof. Philip Winn)
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turn sends projections to the more dorsal parts of the NAcc (Brog et al., 1993).
Both retrograde and anterograde tracing studies have identified the SNc as receiving
projections from the PPTg (Edley & Graybiel, 1983; Jackson & Crossman, 1983). The
PPTg sends cholinergic projections to both the VTA and the SNc (Figure 4). The
posterior PPTg, along with the LDTg, projected to the VTA, while the anterior part of
the PPTg was thought to project mainly to the SNc (Oakman et al., 1995; Oakman et
al., 1999). Axons from both cholinergic and non-cholinergic neurons within the lateral
PPTg have been shown to project to the SNc (Takakusaki et al., 1996). Retrograde
tracers injected into the SN labelled a significant number of cholinergic neurons in the
PPTg and were gradually more numerous towards the anterior region of the PPTg.
Conversely, the non-cholinergic neurons that were retrogradely labelled from the SN
increased in number from the anterior to posterior regions of the PPTg. A population of
glutamatergic neurons that projected to the SN was also found running the entire length
of the PPTg. However, results from this study may not represent projections solely to
the SNc because part of the retrograde tracer injection fell outside the boundary of the
dopamine neurons in the SNr (Lavoie & Parent, 1994c). Projections from the SNc to
the PPTg were found to terminate in the non-cholinergic region medial to the
cholinergic neurons, the MEA (Steininger et al., 1992), while projections to the
cholinergic region of the PPTg originated in the SNr (Spann & Grofova, 1992).
2.4 Nicotinic Acetylcholine Receptors
Nicotinic acetylcholine receptors (nAChRs), found in both the peripheral and central
nervous system are ligand gated receptors meaning that they open and close in response
to a chemical messenger, in this case acetylcholine or nicotine. They are made up of 5
receptors subunits, and can form heterogeneous receptors, made up of more than one
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type of subunit, or homogeneous receptors made up of a single subunit type (Changeux
et al., 1998; Picciotto et al., 2000). nAChRs have influence beyond their initial domain
because they are able to generate complex Ca2+ responses to activation by rapid ionic
signals. Both the route of entry and the amount of Ca2+ is that is able to enter the cell
are related to the subunit composition, for example,  homomeric receptors are
thought to have the highest permeability to Ca2+. Intracellular Ca2+ can be increased
either by direct permeation or through activation of voltage operated Ca2+ channels
(VOCCs).  and  subunits are associated mostly with VOCCs whereas  subunits
are able to generate Ca2+ independently (Dajas-Bailador & Wonnacott, 2004).
The location of the nAChR is also responsible for determining the downstream effect of
nicotine.  subunits were found in higher concentrations in the VTA, compared with
the SNc, but they had a lower overall density than  subunits, which were more evenly
distributed throughout these areas (Wooltorton et al., 2003). Activation of SN
dopamine neurons were thought to be mediated by two types of post-synaptic nicotine
receptor. When muscarinic, GABAergic and glutamatergic transmissions were blocked,
miniature postsynaptic currents induced by nicotine were blocked by
Methyllycaconitine (MLA), an antagonist selective for , and dihydro-beta-
erythroidine (DHE), selective for receptors containing the subunit (Matsubayashi
et al., 2004). This suggests that SN dopamine neurons are activated by nicotine through
and subunit containing receptors.
Another factor that can affect the function of selective subtypes is rapidity of
desensitization; a subunit that is rapidly desensitized will not be functional during
chronic application or infusion of the neurotransmitter. Although  subunits were
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more numerous in the midbrain, they desensitize to a much lower dose of nicotine than
the  subunits, meaning that the continued presence of nicotine has a greater effect on
the  subunits (Pidoplichko et al., 1997; Wooltorton et al., 2003). However, very high
doses of nicotine result in faster desensitization of the  subunit than of other
subunits. This means that the effects of nicotine during high or low levels of nicotine,
such as those found during or after smoking, will operate through different receptor
types.
While the properties and location of a receptor are very important, the type of neuron
containing the receptors must also be identified. Using single cell patch clamp
recording in rats and mice (both wild-type and receptor subtype specific), the SN and
VTA dopamine neurons have been found to contain both  and 
subtypes. GABA neurons in both regions contained subtypes but the SN
additionally contained  subtypes. The homomeric  receptor subtypes
were encountered in less that half of dopamine or GABAergic neurons in the SN or
VTA (Klink et al., 2001). 80% of receptors on cholinergic neurons in the LDTg and
PPTg were thought to be  receptor subunits, the other 20% were thought to be mostly
 subunits. Non-cholinergic neurons also contained  mRNA implying that nicotine
may have difference regulatory actions on different neuronal populations (Azam et al.,
2003). The high permeability, the ability to generate Ca2+, as well as the high
concentration of receptors containing the  subunit in the cholinergic neurons of the
mesopontine tegmentum and the fact that they are less prone to desensitization than
other receptor subtypes all point to the fact that this receptor subtype could be critical in
determining the response to nicotine.
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nAChRs are located on neurons within the midbrain as well as in the mesopontine
tegmentum, meaning they are well placed to influence reinforcement both directly in
the mesolimbic system and through ascending topographic projections from the LDTg
and PPTg. Because of the major excitatory input into the midbrain, the LDTg and PPTg
is being increasingly studied in relation to addiction. The particularly pertains to
nicotine addiction because nicotine is an agonist at the nAChRs found throughout the
SNc/VTA and LDTg/PPTg. Both the VTA and SN are thought to influence behaviour
through projections to the NAcc and striatum, which respectively make up the
mesolimbic and nigrostiatal dopamine systems.
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Chapter 3: The mesolimbic system as a common final pathway of reinforcement
3.0 Introduction
A variety of drugs that have different modes of action all require the mesolimbic
dopamine system to be intact in order to be reinforcing, indicating a universal pathway
in the processes involved in reinforcement. Various behavioural paradigms have been
developed for use with rodents that are thought to test the reinforcing value of drugs in
a manner that mimics drug seeking or drug taking situations that humans face. The
most common are conditioned place preference (CPP), intracranial self-stimulation
(ICSS) and intravenous or intracranial self-administration (IVSA, ICSA). The aim of
using these behavioural paradigms is to measure the value of reinforcement and
discover the mechanism by which reinforcment occurs. Many of the drugs that humans
can become addicted to have been found to be reinforcing in these paradigms. These
types of tests are necessary because the site of action for drugs and the mechanisms by
which they work can be studied at a depth that is simply not possible in human
participants.
3.1 Mesolimbic system
The involvement of the dopamine system in reinforcement can be tested by measuring
the changes in dopamine activity at different sites within the mesolimbic dopamine
system during testing. It is possible to measure dopamine efflux using a number of
methods including in vivo microdialysis, which extracts and measures levels of
molecules in the extracellular fluid using a semi-permeable probe, and
chronoamperometry which measures changes in the dopamine oxidation level. In order
to study the effects of functional changes in this system on reinforcement paradigms it
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is necessary to manipulate the system. This can be done by lesioning the dopamine
system using the relatively specific neurotoxin 6-hydroxydopamine (6-OHDA) which
targets dopamine and norepinephrin containing neurons, or by making non-specific
lesions in various regions. A more selective method of determining the mechanisms of
reinforcement are to block specific receptors types. This is different to lesioning
neurons as different receptor types can be found on different types of neurons, for
example nicotinic receptors were found on both dopaminergic and non-dopaminergic
cells in the midbrain (Klink et al., 2001; Azam et al., 2002). So while lesioning can
determine the cell type involved in mediating the response to nicotine, blocking
receptors can assess receptor involvement across the different systems.
3.1.0 Conditioned place preference
In CPP experiments the animal has the opportunity to explore two environments, one of
which is repeatedly paired with a positive motivational stimuli, it involves measuring
the amount of time spent in each environment with photocell beams. This can be done
using a biased procedure, meaning that the drug or saline is paired with the initially
preferred compartment or a non-biased procedure, meaning that the pairing of the
compartment and drug is randomised. If more time is spent in the compartment paired
with the drug this indicates that the drug is reinforcing. Electrolytic lesions of the NAcc
block the capacity of morphine to induce a CPP but had no effect on the ability of the
rats to acquire a context-specific tolerance indicating that the NAcc may mediate
reward and not simply the ability to associate morphine with specific chambers in the
apparatus (Kelsey et al., 1989). Equally effective at reducing the reinforcing effects of
drugs were dopamine receptor antagonists which compete with dopamine to occupy the
receptor and subsequently reduce the influence of dopamine. Both D1 and D2
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dopamine receptor antagonists were equally effective at blocking CPP of d-
amphetamine when injected systemically before conditioning. However, only the D1
receptor antagonist was able to block CPP when injected after conditioning but before
testing. This indicates that while both receptor types are influential in establishing the
CPP, only the D1 receptors are involved in the continuing expression of a CPP. This
suggests that D1 and D2 receptors were involved in learning the association between
drug and environment, and D1 receptors were involved in the continuing rewarding
effect of the drug. These results were found to be specific to the mesolimbic system as
the ability to block CPP was limited to microinjections of d-amphetamine in the NAcc,
not the striatum (Hiroi & White, 1991). These experiments show the importance of the
mesolimbic dopamine system and dopamine receptors in the establishment and the
continued expression of a CPP.
3.1.1 Self-stimulation
ICSS is a method of directly stimulating the mesolimbic dopamine system by surgically
implanting electrodes in one of a number of regions including the mfb, the group of
fibres projecting from the VTA to the NAcc, as well as the VTA itself. Animals are
placed in a chamber with free access to a lever, pressing this lever results in the direct
stimulation of the neurons surrounding the tip of the electrode. The animals quickly
learn to lever press to the exclusion of other behaviours. This method has established
that electrical stimulation of the mesolimbic dopamine system can evoke increased bar
pressing, indicating that the dopamine system is important in reinforcement. Fibiger et
al., (1987) showed that a 6-OHDA lesion that reduced dopamine levels in the NAcc
and striatum by over 90% resulted in a large reduction in the number of bar presses
made by the animal, indicating the necessity of dopamine in maintaining reinforcement.
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Later experiments narrowed down the population of neurons involved by giving
animals bilateral microinjections of a dopamine antagonist into various brain regions. It
was found that reinforcement behaviour was much more sensitive to the blockade of
dopamine in the NAcc than in the striatum (Stellar & Corbett, 1989). ICSS has also
been used to test the reinforcing value of drugs of abuse, as application of a drug that is
reinforcing during ICSS will lower the threshold of stimulation needed to maintain
responding. Amphetamines injected directly into the NAcc have been shown to
decrease the stimulation frequency needed to sustain responding in an ICSS paradigm
(Colle & Wise, 1988), indicating that increased dopamine in the NAcc reduced the
amount of electrical stimulation needed to maintain the same level of reinforcement.
These experiments indicate that the mesolimbic dopamine system regulates
reinforcement but that drugs also interact with this natural reward system.
3.1.2 Self-administration
IVSA and ICSA involve the animals bar pressing to self-stimulate the dopamine
reinforcement system, either intravenously or intracranially, by drugs. There is a large
body of literature on IVSA of addictive drugs as it is thought to have more validity than
other paradigms when comparing with human studies. Self-administration studies
replicate the drug-seeking and drug-taking behaviour found in humans and can even
lead to compulsive use to the extent that normal behaviour patterns can no longer be
seen. This can be measured on a number of different schedules including fixed ratio
(FR), which measures the total number of responses, and progressive ratio (PR), which
measures the ‘break point’, the highest number of responses an animal will do for a
single reward. The fixed ratio schedule, a measure of reinforcement, is used to train
animals to respond and is thought to be less demanding than the progressive ratio
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schedule since the task remains constant over a number of trials and sessions. The
progressive ratio schedule is a deceptively difficult task as the reward contingency is
continually changing. This schedule is thought to be a measure of reward as it measures
how hard an animals will work for a drug. The mesolimbic dopamine system has been
implicated in changes in IVSA behaviour. Lesioning dopamine neurons with 6-OHDA
in the NAcc resulted in a decrease in cocaine IVSA in a manner that did not resemble
extinction. The rate of recovery of self administration correlated with remaining
dopamine levels in the NAcc (Roberts et al., 1980). This was followed up by selective
lesions of the post-synaptic neurons in the NAcc using kainic acid, as opposed to the
dopaminergic inputs, which similarly disrupted IVSA of cocaine (Zito et al., 1985).
Similar results were also found for the self administration of d-amphetamine (Lyness et
al., 1979).
Studies have suggested that the preferential site of dopamine release after systemic
cocaine or amphetamine is the NAcc, rather than the dorsal striatum (Carboni et al.,
1989). Several studies by Wise and colleagues (Wise et al., 1995a; Wise et al., 1995b)
have shown that IVSA of different types of drugs are all able to increase extracellular
dopamine in the NAcc. Cocaine was found to increase dopamine by 200-800% in
phasic fluctuations that were time locked to lever presses. Heroin resulted in much
smaller dopamine increases of 150-300%. Dopamine levels were found to reach a
plateau, rather than fluctuate, falling to baseline only after access to the drug had been
terminated. This could be due to the different sites of action for each drug. However,
both drugs, regardless of the method, were able to increase dopamine levels in the
NAcc. Animals compensated for drug dose by adjusting their response rate, suggesting
that animals were able to maximise reward by regulating the level of dopamine in the
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mesolimbic system. Recent studies have suggested a dissociation between the core and
shell of the NAcc although the precise function of each is still to be determined. The
core, but not the shell, was demonstrated to be important in acquisition of instrumental
behaviour when responding for heroin, but not to mediate reward (Alderson et al.,
2001b). Ito et al., (2000) found that while extracellular dopamine was increased in both
the NAcc core and shell during cocaine IVSA, only the core showed increases during
presentation of a non-contingent CS+. This could again indicate that the core is
involved in associative behaviour but not reward. The association of dopamine with
reinforcement was confirmed further by findings that dopamine in the NAcc was
correlated with the number of bar presses during operant responding rather than the
amount of reward received (Sokolowski et al., 1998). The fact that similar results have
been found during IVSA of different types of drugs strongly implicates the NAcc in
reinforcement.
These methods have established that dopamine, and particularly dopamine in the
mesolimbic system, is a vital component in the actions of many addictive drugs.
Lesions of the NAcc were found to reduce the rewarding or reinforcing effects of a
number of drugs (Roberts et al., 1980; Fibiger et al., 1987; Kelsey et al., 1989). The
CPP of morphine, cocaine and amphetamine all depend upon the integrity of the NAcc
and blocking dopamine receptors was found to block acquisition and maintenance of
CPP (Hiroi & White, 1991). The reinforcement that occured during electrical
stimulation was also been shown to be due to dopamine projections from the VTA to
the NAcc and drugs that increase dopamine reduce the amount of electrical stimulation
needed to maintain a similar level of responding (Colle & Wise, 1988). IVSA is
thought to be the model of reinforcement that has the most validity for human
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behaviour. Responding for cocaine, amphetamine and heroin can all be disrupted by
lesioning dopamine neurons in the mesolimbic system, and abused drugs have been
shown to increase extracellular dopamine during IVSA (Lyness et al., 1979; Roberts et
al., 1980; Zito et al., 1985; Wise et al., 1995a; Wise et al., 1995b; Alderson et al.,
2001b). The evidence from a number of differenct paradigms suggests that the
mesolimbic system is a common final pathway in the reinforcing effects of drugs of
abuse.
3.2 Nicotine and the mesolimbic system.
Dopamine is a vital component in the regulatory action of most addictive drugs and the
mesolimbic dopamine system is thought to be a key site controlling behavioural
processes relating to reinforcement. The NAcc is thought to play a key role in this and a
number of addictive drugs, including nicotine, have been shown to increase activity in
this region. The specific site of action and the mechanism by which each drug increases
dopamine activity may be different for each drug but key to all seems to be the ability
to increase dopamine. Psychostimulant drugs such as amphetamine and cocaine are
thought to be reinforcing partly through their action as a substrate at the dopamine
transporter or the ability to block dopamine transporters in the NAcc, blocking reuptake
and thus increasing the total amount of available dopamine. Non-psychostimulant drugs
such as morphine and heroin are thought to be reinforcing by a more indirect route.
They increase the release of dopamine in the NAcc through the disinhibition of
dopamine neurons in the VTA, possibly by the hyperpolarisation of local GABAergic
neurons. This section examines the methods by which nicotine increases dopamine
activity in the mesolimbic system. There are a number of methods by which the actions
of nicotine can by examined. Firstly, neurochemical release in different regions of the
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brain can be determined after passive nicotine administration, both acute and chronic.
Secondly the electrophysiological response of different populations of neurons can be
studied, and thirdly the location of neural activity can be examined by quantifying
immediate early gene response to nicotine. The mechanisms of all three measures can
be considered by pretreating animals with drugs that block specific receptor types. This
can be done systemically to determine the overall contribution of a single system, such
as the glutamate system, or alternatively the location of receptor mechanisms can be
studied by blocking receptors using microinjections within a certain region of the brain,
such as glutamate receptors located in the VTA.
Although it acts as a psychostimulant, nicotine is thought to be reinforcing through its
site of action in the VTA, which indirectly increases dopamine release in the NAcc.
However, the precise mechanism that causes this is unknown. Using microdialysis,
acute systemic nicotine has been shown to increase somatodendritic dopamine release
in the VTA by 145% (Rahman et al., 2003). The result of this increased activity in the
VTA leads to a subsequent increase in activity in the NAcc. Acute intravenous nicotine
has been found to increase dopamine release in the NAcc, specifically in the shell but
not in the core (Nisell et al., 1994; Nisell et al., 1997). These regional differences
between the NAcc core and shell are thought to correspond to functional differences as
the core has largely been associated with motor functions while the shell is thought to
involved in limbic functions, particularly motivation. This increase in activity was
thought to mediated by local nicotine receptors on the dopamine neurons in the VTA as
simultaneous application of nicotinic antagonists mecamylamine or DHE attenuated
the effects of nicotine (Nisell et al., 1994; Rahman et al., 2003). Because of the
complexity of the behavioural response to nicotine it is thought that a number of
50
receptor types in the VTA interact in order to mediate this response. Sziraki et al.,
(2002) have found that the dopaminergic response to nicotine in the VTA was
controlled by not only nicotinic and dopaminergic receptors but also by muscarinic,
GABAergic and glutamatergic NMDA receptors.
Pretreatment with nicotine also resulted in increases in dopamine activity in the VTA
after a nicotine challenge. Rahman et al., (2003) showed that after 5 days of chronic
nicotine somatodendritic dopamine release increased by 136%. This slight attenuation,
compared with 145% increase after acute nicotine, was thought to be due to
desensitization of the nAChRs. The downstream responses to chronic nicotine seem to
be similar to those after acute nicotine. Using microdialysis Benwell & Balfour, (1997)
have demonstrated that pre-treatment with nicotine leads to increased dopamine release
in the NAcc core but no significant changes in the dorsal striatum. It was suggested that
these differences were due to the larger number of dopamine transporters in the
striatum, which would lead to faster re-uptake of dopamine from the extracellular
space. However, blocking these transporters with nomifensine had no effect on the
results, suggesting that the NAcc was indeed more responsive to nicotine. A more
recent study has further determined the site of sensitivity to chronic nicotine by
showing that the core of the NAcc was sensitized to the effects of nicotine while the
shell of the NAcc became more tolerant (Cadoni & Di Chiara, 2000).
Both intravenous and systemic nicotine have been shown to increase the firing rate and
the percentage of actions potentials fired in bursts in dopamine neurons of the
mesolimbic system (Schilstrom et al., 1998; Erhardt et al., 2002). However, this has
been shown to be preceded with a fast inhibitory phase (Erhardt et al., 2002). This adds
to evidence that nicotine has been found to activate both dopaminergic and non-
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dopaminergic neurons in the VTA (Yin & French, 2000). However, the response of the
dopamine neurons in the VTA was much more robust than non-dopamine neurons due
to the fast desesitization of the non-dopaminergic neurons. This desensitization of what
were probably GABAergic neurons was thought to disinhibit the dopamine neurons,
which facilitated the response to nicotine. The mechanism by which nicotine increased
the electrophysiological activity of dopamine neurons is unknown. While both Erhardt
et al., (2002) and Schilstrom et al., (2004) both found evidence for a glutamatergic
mechanism, a more recent study has found that carbachol induced bursting activity in
dopamine neurons was not affected by glutamatergic or GABAergic mechanisms but
was mediated by both muscarinic and nicotinic receptors (Zhang et al., 2005).
However, since carbachol stimulates both muscarinic and nicotinic receptors, while
nicotine only stimulates nicotinic receptors, the mechanism for promoting burst firing
in the VTA may be different.
A further method of investigating the regional impact of nicotine on the brain is to
examine activation of the second messenger cascade. By looking at the differences in
Fos expression between saline treated and nicotine treated animals, the additional
recruitment of neuronal populations by nicotine can be quantified. Acute systemic
nicotine has resulted in increased Fos expression in a number of regions within the
mesolimbic dopamine system, the majority of studies agreed that the largest increases
were to be found in the NAcc and especially in the core of the NAcc (Mathieu-Kia et
al., 1998; Schilstrom et al., 2000b). However, some studies have also reported
increases in striatal activity (Kiba & Jayaraman, 1994). These inconsistencies could be
due to the effects of nicotine outside the mesolimbic dopamine system as
microinjections of nicotine directly into the VTA increased Fos activity in the NAcc
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(Panagis et al., 1996). The mechanism by which nicotine increased dopamine activity
was thought to be a combination of nicotinic, dopaminergic and glutamatergic as
activity in the NAcc was reliably attenuated by mecamylamine, a nAChR antagonist,
SCH23392, a D1 antagonist, as well as AP5, MK801 and CPP, NMDA antagonists
(Kiba & Jayaraman, 1994; Panagis et al., 1996; Schilstrom et al., 2000b).
Chronic nicotine has also been found to induce Fos, in the terminal fields of the
midbrain dopamine neurons, but again the results are far from conclusive. Mathieu-Kia
et al., (1998) found increases in both the shell and core of the NAcc over and above that
found after saline or acute nicotine, but no changes in the striatum. This was consistent
with results from microdialysis studies suggesting that only the NAcc was sensitive to
pre-treatment with nicotine (Benwell & Balfour, 1997). However, Shim et al., (2001)
found increased Fos expression in both the NAcc shell and the striatum after chronic
nicotine. There were two major differences in the experimental procedures of these
experiments which could account for the disparity in the results. Mathieu-Kia et al.,
(1998) gave the animals 0.35mg/kg nicotine 3 times a day for 14 days and sacrificed
the animals after 90min, whereas Shim et al., (2001) gave animals a higher dose,
0.4mg/kg nicotine, but only twice a day for 7 days. They sacrificed animals after the
longer time of 2h. The regimen of giving animals nicotine 3 times a day, used by
Mathieu-Kia et al., (1998), resulted in a total nicotine dose of 1.05mg/kg each day,
which was also more similar to the 1.0mg/kg nicotine each day used by Benwell and
Balfour, (1997). Both Mathieu-Kia et al., (1998) and Benwell & Balfour, (1997) found
activity in the NAcc but not in the striatum after 14 days of nicotine pre-treatment,
whereas Shim et al., (2001) found increases in the striatum after 7 days. It is also
possible that there were different latencies to activity in different regions depending on
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the type and origin of inputs to each area. The immediate recording in microdialysis
and the shorter sacrifice time of 90min used by Mathieu-Kia et al., (1998) may have
been too short to detect slower changes in the striatum.
In a study directly comparing the effect of acute and chronic nicotine on Fos
expression, activity was found to be increased in the NAcc over the striatum. However
there was significantly less activity in either area after chronic nicotine, compared with
animals given acute nicotine (Salminen et al., 1999). This change in sensitivity is easily
explained by desensitization of nicotine receptors in the brain after chronic activation
and this supports the similar results found by Rahman et al., (2003) after in vivo
microdialysis, which showed greater dopamine release in the VTA after acute than after
chronic nicotine.
The changes in nicotine induced dopamine activity seem to be regulated by
mechanisms throughout the mesolimbic system. Both increased dopamine release and
increased firing in dopamine neurons has been found in the VTA leading to increased
dopamine release and Fos expression in the NAcc. It has been demonstrated that the
dopamine activity in the NAcc is critical in controlling reinforcement and it is possible
that the core of the NAcc is the specific site of action rather than the shell. This nicotine
induced dopamine activity seems to be controlled by a number of different
mechanisms, including both nAChRs and NMDA receptors, but the location of these
receptors has yet to be determined.
The mesolimbic dopamine system has also been demonstrated to be the common final
pathway of abused drugs in mediating reinforcement behaviour. We have seen how
nicotine is able to increase dopamine release as well as firing rate and burst firing in
these regions. However, it is also necessary to demonstrate that nicotine is able to act as
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a reinforcer of behaviour. The models that are used to measure reinforcement were
described earlier. The following section looks at the evidence that nicotine is indeed
reinforcing using these models and that it is mechanisms within the mesolimbic
dopamine system that mediate this kind of behaviour.
A number of studies have found that the locomotor activity induced by nicotine is
mediated by midbrain dopamine neurons. Due to this, locomotor activity can be used as
a visual measure of activity in the midbrain region that can be compared with measures
of reinforcement. Acute nicotine has been shown both to increase or decrease
locomotor activity at high doses but this difference was probably dependent on the
procedure used (Benwell & Balfour, 1992; Balfour et al., 1998; Alderson et al., 2005).
However, the involvement of the midbrain dopamine neurons cannot be disputed. Louis
& Clarke, (1998) found that 6-OHDA lesions of the ascending dopamine neurons
blunted the locomotor response to nicotine. Intra-tegmental injections of nicotine in
drug naïve rats led to a significant increase in locomotor activity (Panagis et al., 1996).
This increase was reversed by pre-treatment with mecamylamine, a nicotine receptor
antagonist, which indicated that stimulation of nAChRs in the VTA played a role in
mediating the actions of dopamine neurons in response to nicotine (Panagis et al., 1996;
Schoffelmeer et al., 2002).
Nicotine and nicotinic agonists have also been found to be reinforcing in a number of
paradigms, and the midbrain is involved in mediating this response. The efforts to
condition a place preference to systemic nicotine have had mixed results, but recent
studies have found that doses of nicotine between 0.1 and 1.4mg/kg induced a
significant CPP when a biased procedure was used (Le Foll & Goldberg, 2005; Spina et
al., 2006). The mechanism of CPP has been studied using agonists for different
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receptors. Spina et al., (2006) found that acquisition of a nicotine induced CPP could be
prevented by microinjections of a D1 but not a D2 antagonist in the NAcc shell, but
once the CPP had been established neither antagonist had any effect on CPP
expression. This indicates that it was the initial learning or ability to associate that was
impaired when dopamine receptors were blocked rather than the perception of the
rewarding effects of nicotine. This is different to results found when testing
amphetamine CPP, as both D1 and D2 were found to block CPP acquisition. However,
the experiments on nicotine CPP used direct injections of dopamine antagonists into the
NAcc rather than systemic injections indicating that the effects of D1 receptors are
specific to the NAcc, while the effects of D2 receptors occur outside the NAcc. The
VTA has also been implicated in nicotine induced CPP as both carbachol and cystine,
agonists at nicotine receptors, have been shown to produce a CPP when injected
directly into the VTA. In fact, Ikemoto et al., (2002) found that it was specifically
activating nicotine receptors in the posterior region of the VTA that induced CPP, while
injections in the anterior VTA and regions dorsal to the VTA had no effect. These data
implicate the posterior VTA and NAcc shell in mediating the reinforcing effects of
nicotine.
ICSS can also show the reinforcement potential of nicotine as a number of studies have
shown that nicotine lowered the threshold required to maintain responding (Ivanova &
Greenshaw, 1997; Harrison et al., 2002). This suggests that nicotine was increasing
sensitivity to the rewarding effects of electrical stimulation of the lateral hypothalamus.
Nicotine also decreased the threshold for self stimulation in the VTA, showing the
importance of the VTA and the mesolimbic system. Both nicotinic and dopaminergic
mechanisms have been shown to be involved in this process by examining the effects of
56
nicotine after blocking receptors. Both mecamylamine, a non-specific nicotinic receptor
antagonist, and DHE which is thought to be more selective, blocking 2 nicotinic
receptors, has been shown to reduce the effects of nicotine on ICSS (Ivanova &
Greenshaw, 1997; Harrison et al., 2002). Direct blockade of  receptors in the VTA
by MLA also attenuated the effects of nicotine (Panagis et al., 2000). The role of the
dopamine receptors is less clear because D1 receptor antagonist SCH23390 reduced the
rewarding effects of nicotine but the involvement of the D2 receptor is still in question.
Although D2 receptor antagonist, haloperidol has been shown to attenuate the effects of
nicotine, eticlopride, another D2 antagonist, had no effect on ICSS thresholds after
nicotine. However, it is possible that haloperidol had an effect on reinforcement that
was not directly due to blocking D2 receptors. Muscarinic, serotonergic and
glutamatergic receptor antagonists were all shown to have no effect on ICSS thresholds
after nicotine administration (Ivanova & Greenshaw, 1997; Harrison et al., 2002).
A more direct model of reinforcement is self administration and the ability of nicotine
to support self administration has been demonstrated many times (Corrigall et al., 1994;
Donny et al., 1999; Lanca et al., 2000a; Alderson et al., 2006). Corrigall et al., (1994)
showed the importance of the VTA in nicotine IVSA as microinjections of DHE into
the VTA reduced responding suggesting that nicotinic receptors in this area were
important. Grottick et al., (2000) also demonstrated that DHE reduced nicotine IVSA,
but that MLA, a selective  antagonist, did not suggesting the selective involvement
of receptors containing the 2 subunit in IVSA of nicotine. Similar injections of DHE
directly into the NAcc had no effect on nicotine IVSA, suggesting that nicotine acts in
the VTA and the subsequent changes in dopamine release in the NAcc (Nisell et al.,
1994) were simply the consequence of this. Atropine, a muscarinic receptor antagonist
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had no effect suggesting that nicotine reinforces behaviour directly through the
activation of nicotine receptors. The attenuating effect of DHE was found to be
specific to nicotine as there was no effect on responding for cocaine or food (Grottick et
al., 2000).
A method that more directly investigates the site of nicotine’s action is intracranial self
administration. As the drug is administered directly into discrete regions of the brain
the reinforcing mechanisms can be determined in terms of these regions. Using both
nicotine and cholinergic agonist carbachol, Ikemoto and colleagues, (Ikemoto & Wise,
2002; Ikemoto et al., 2006) have found that the posterior VTA was more sensitive to
the reinforcing effects of nicotine than the anterior VTA or regions dorsal to the
posterior VTA. Neostigmine, which disrupts the breakdown of acetylcholine, is self
administered in the same way as nicotine and carbachol. This suggests that nicotine
acted to enhance natural levels of acetylcholine in the VTA. This was further confirmed
by the fact that both nicotinic antagonist, DHE, and muscarinic antagonist,
scopolamine, were able to attenuate responding for carbachol in the posterior VTA. The
ability of D1 receptor antagonist SCH23390 to attenuate responding for carbachol
suggests that the general enhancement of acetylcholine led to a change in activity in
midbrain dopamine neurons.
So far it has been demonstrated that a number of behaviours induced by nicotine were
dependent on the mesolimbic system but examination of the mechanisms involved are
proving inconclusive. Nicotinic receptors play an important role but whether this is a
specific regulatory mechanism or simply one of many means of influencing
endogenous acetylcholine, which in turn regulates dopamine activity, is still uncertain.
In some cases both nicotinic and muscarinic receptor antagonised the effects of nicotine
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but in other cases, especially in behavioural paradigms, muscarinic antagonists were
ineffective (Ivanova & Greenshaw, 1997; Grottick et al., 2000; Sziraki et al., 2002;
Zhang et al., 2005).
Recent technological advances in gene replacement have meant huge leaps in
understanding about the function of the receptor subunit. Both ‘knock-out’ (KO) mice,
in which a receptor subunit is missing and ‘knock-in’ (KI) mice which have a single
hypersensitive subunit have been studied in comparison to wild-type litter mates. Mice
without the  subunit have been found to lack all high affinity binding sites for
nicotine in the VTA and SN. Using patch clamp recording to measure electrical activity
it has been shown that the dopamine neurons of these mice do not respond to nicotine,
meaning there was no increase in levels of dopamine in the NAcc, as there was in wild
type mice. There was also reduced induction of Fos related antigens (FRAs) in the
NAcc compared to wild-type mice, indicating that there was less activation of second
messenger systems. In terms of behavioural output,  null mice showed a 50% drop in
locomotor activity in habituated environments compared with their own behaviour in a
novel environment and with the behaviour of wild-type mice. The  null mice, after
normal responding to cocaine during IVSA training using a nose poke apparatus,
showed no response to nicotine acting as if it were saline (Picciotto et al., 1998)
demonstrating the specificity of the  subunit for responding solely for nicotine and
not simply all reinforcing behaviour. Similar results have been found by Maskos et al.,
(2005) who found that mice lacking the subunit did not acquire nicotine self
administration in a Y-maze. However when the subunit was reinstated, using a
lentiviral vector to selectively insert DNA into the VTA, the mice acquired self
administration in a similar fashion to wild type mice. This suggests that the  subunit
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is necessary and sufficient for re-establishing sensitivity to nicotine. This reduction in
reinforcement behaviour due to the missing  subunit corresponds with the lack of
response to nicotine in striatal dopamine neurons, an area believed to participate in
mediation of reinforcement behaviour (Picciotto et al., 1998). Mice missing the 
subunit on the other hand have increased basal dopamine levels and showed no
differences in locomotor activity to wild type litter mates. These results would suggest
that the  subunit regulates tonic control of dopamine release (Marubio et al., 2003).
While KO mice may be used to test for the necessity of individual subunits, KI mice are
used in studies of sufficiency of specific receptor subunits for dopamine mechanisms
and behavioural phenotypes. The  KI mice have an  subunit that is hypersensitive
to nicotine, meaning that it is activated by extremely small doses that are sub-threshold
for other subunits. Activation of the  subunit was shown to be adequate to increase
action potential frequency of dopamine neurons in the VTA, and consequently
increased dopamine release in the striatum. The small doses used in this experiment had
no effect on wild-type mice. CPP has been induced in KI mice with a 50 fold lower
dose than was needed in the wild-type mice. Both nicotine induced tolerance to
hypothermia and sensitized motor activity were found in KI but not wild-type mice.
This indicated that the  subunit was sufficient for reward, tolerance and sensitization
(Tapper et al., 2004).
The results of these different types of study are conflicting. KO studies suggest that the
subunit was critical in reinforcement while KI studies indicate that the  subunit
was sufficient for reinforcement. However, results of studies using genetically modified
mice should be interpreted with caution as it is impossible to account for developmental
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compensatory changes that may occur due to the lack of or hypersensitivity of a single
subunit. For example, although cocaine increases dopamine by blocking dopamine
transporter (DAT), KO mice that do not have dopamine transporters were still able to
learn to self administer cocaine (Rocha et al., 1998). It is possible that developmental
changes allow another transporter, such as the noradrenaline transporter, to substitute
for the function for the deficient transporter.
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Chapter 4: The LDTg/PPTg and reinforcement
4.0 Introduction
Projections from the LDTg and PPTg make up a significant proportion of the excitatory
input to midbrain dopamine neurons and there is evidence that this is a critical pathway
responsible for modulating reinforcement. This section will examine the evidence for
LDTg and PPTg regulation of midbrain and terminal field dopamine activity and the
mechanism by which this occurs by looking at how electrical and chemical stimulation
of the LDTg and PPTg neurons affect striatal dopamine. It will also explore whether
these regulatory inputs, i.e. inputs that control activity in downstream regions, from the
LDTg and PPTg to the midbrain affect behaviour thought to depend on the mesolimbic
system, with a special emphasis on nicotine reinforcement.
4.1 The LDTg and PPTg regulate midbrain activity
The LDTg and PPTg are thought to regulate midbrain activity through the cholinergic
and glutamatergic projections from the LDTg and PPTg to the VTA and SNc
respectively (Lavoie & Parent, 1994a; Oakman et al., 1995; Charara et al., 1996;
Oakman et al., 1999). Stimulation of the PPTg results in burst firing in dopamine
neurons of both the SNc and VTA (Lokwan et al., 1999; Floresco et al., 2003), while
inactivation of the PPTg by anaesthetic microinjection suppressed the response of
dopamine neurons to conditioned sensory stimuli (Pan & Hyland, 2005). This
implicates the PPTg in relaying the information needed to respond to a rewarding
stimuli. PPTg projections to the SNc were showed to be both glutamatergic and
cholinergic because some SNc activity could be abolished by glutamatergic antagonists
and the remaining activity was suppressed by a broad spectrum cholinergic antagonist
62
(Futami et al., 1995).
The LDTg was also found to regulate activity in the midbrain. NMDA receptor
stimulation in the VTA increased the firing rate of dopamine neurons with or without a
functional LDTg input. However, when the LDTg was inactivated by an infusion of
GABAA & GABAB agonists, almost no “burst” firing occurred in the VTA dopamine
neurons (Lodge & Grace, 2006). Since burst firing is thought to facilitate
neurotransmitter release and thus convey important motivational information (Overton
& Clark, 1997), the input from the LDTg and PPTg may play an essential role in
regulating reinforcement.
Microinjections of neostigmine, a cholinesterase inhibitor that prevents the breakdown
of acetylcholine, into the PPTg or LDTg increased dopamine efflux in the striatum.
When the LDTg or PPTg was lesioned, dopamine efflux in the striatum was attenuated
relative to non-lesioned animals (Blaha & Winn, 1993; Blaha et al., 1996). This
indicates that the LDTg and PPTg regulate dopamine activity through the release of
endogenous ACh in the midbrain, which excites the surrounding dopamine neurons.
Injections of nicotine into the SNc or VTA also resulted in increased dopamine efflux
in the terminal fields, but when the PPTg was lesioned dopamine efflux in the striatum
was enhanced (Blaha & Winn, 1993). The fact that the PPTg lesion resulted in
enhanced dopamine efflux after intra-nigral nicotine suggests that postsynaptic
nicotinic receptors have become supersensitive, in response to the loss of cholinergic
inputs (brought about by the PPTg lesion).
In order to elucidate the mechanisms by which dopamine activity is increased,
experiments have also been done on the interaction of the LDTg and PPTg with the
mesolimbic dopamine pathways. Brief electrical stimulation in either the LDTg or the
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PPTg resulted in a triphasic pattern of dopamine efflux in the NAcc or striatum
respectively. Using chronoamperometry, Forster & Blaha, (2000; 2003) found an initial
sharp peak in the dopamine specific signal, followed by a brief inhibitory phase. The
dopamine signal then recovered and was elevated for approximately 35min. In order to
determine the type and location of receptor that mediated these changes in dopamine
efflux, specific receptor antagonists were microinjected into either the LDTg/PPTg or
SNc/VTA to block the effects of each region individually. The initial excitatory effect
was blocked by injections of both mecamylamine and kynurenate in the VTA or SNc
indicating that the initial phase was mediated by both nAChRs and ionotropic
glutamate receptors (iGluR) in the dopaminergic midbrain. The second inhibitory phase
was blocked by a muscarinic antagonist in the LDTg or PPTg. The final facilitated
phase was blocked by a muscarinic antagonist in the VTA or SNc. These data indicate
that, through the midbrain, the LDTg and PPTg are able to regulate dopamine efflux in
the NAcc and striatum, exploiting receptors in both the midbrain and LDTg/PPTg.
4.2 The LDTg/PPTg regulate reinforcement
Locomotor activity and reinforcement behaviour are both closely associated with the
mesolimbic dopamine system (Corrigall et al., 1994; Panagis et al., 1996; Louis &
Clarke, 1998; Ikemoto & Wise, 2002). If the LDTg and PPTg are able to regulate burst
firing in the midbrain and the subsequent dopamine release in the NAcc and striatum,
then it should also regulate behaviour that depends on this system. The evidence
demonstrates that the midbrain dopamine neurons rely on input from the LDTg and
PPTg and that disruption of this pathway affects normal functioning.
It would be expected therefore that normal locomotor behaviour would be disrupted by
lesions in the LDTg and PPTg. However, it has been shown that lesions that
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encompassed the entire PPTg had no effect on spontaneous locomotor behaviour. The
drawback to this evidence is that the PPTg can in fact be divided into 2 regions that
project to different sites (Lavoie & Parent, 1994b; Alderson et al., 2007), and it is
possible that each subregion regulates motor activity in a different manner. Indeed,
when lesions were made that included only the posterior or anterior parts of the PPTg,
the results were very different. While lesions in the anterior PPTg had a significant
effect on spontaneous locomotion, posterior PPTg lesions had no effect on locomotion
compared with control animals (Alderson et al., 2007). Despite being more similar to
the pPPTg in projection sites, the LDTg did have an effect on spontaneous locomotion.
This is possibly due to the fact that that pPPTg projections make up a small proportion
of the total excitatory input to the midbrain from the LDTg and pPPTg (Oakman et al.,
1995) so that under normal conditions the LDTg is still able to regulate dopamine, and
hence behaviour, even without the input from the pPPTg.
Some of the behavioural effects of drugs are thought to be mediated through the
mesolimbic dopamine system. The LDTg and PPTg, through their regulatory effects on
the midbrain, can also have an effect on drug induced behaviour. In control animals
with no lesions, d-amphetamine incrementally increased the locomotor response with
each additional dose. However, when the regulatory input from the posterior and
anterior PPTg was removed, animals were slow to sensitize to d-amphetamine despite
the fact that locomotor activity was normal when rats were given saline (Alderson et
al., 2003b). High doses of nicotine can have an initial depressant effect on activity.
When control animals were tested in a day-on-day-off procedure over 7 days, nicotine
initially resulted in a net reduction in activity over a 1h period compared with animals
given saline. By day 7 the neural system had sensitized so that animals showed
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increased activity in response to nicotine, compared with animals given saline. After
pPPTg or LDTg lesions, the initial depressant effect of nicotine disappeared, but lesions
of the aPPTg had no effect on nicotine induced activity. The indicates that while the
aPPTg projections to the SNc have some control over spontaneous locomotion, it is
projections from the LDTg and pPPTg to the VTA that control the response to nicotine.
The site of action of nicotine is still unclear, it is possible that lesions in the LDTg and
PPTg removed the receptors at which nicotine acts. LDTg cholinergic neurons have
been shown to express both α7 and β2 mRNA, while non-cholinergic neurons express
α4 mRNA (Azam et al., 2003). The high concentration of  in the cholinergic neurons
of the LDTg and PPTg and the fact that they are less prone to desensitization than other
receptor subtypes all point to the fact that this receptor subtype could be critical in
determining the response to nicotine. While the integrated effects of nicotine on nAChR
subtypes in the LDTg is still to be determined, it is possible that the loss of these
receptors would affect locomotor activity. Alternatively, it is possible that nicotine acts
directly on nAChRs on VTA dopamine neurons. Both dopaminergic and non-
dopaminergic neurons in the midbrain have nAChRs containing the α4 and β2 subunits
(Azam et al., 2002). The loss of cholinergic and glutamatergic input could simply
dysregulate dopamine neurons which could account for the change in nicotine induced
locomotor activity after LDTg or pPPTg lesions.
Studies investigating the role of the cholinergic input from the LDTg and PPTg to the
midbrain on responding for a reinforcer have had mixed results. When animals
responded on a PR schedule for a natural reward such as food, PPTg lesions had no
effect when the requirements of the schedule were low, but as the schedule became
increasingly demanding the break point decreased. As animals were capable of this task
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it suggests that there was no deficit in the ability to perceive the value of the reward.
This corresponds with results which showed that PPTg lesions had no effect on CPP for
low concentrations of sucrose (Alderson et al., 2001a). The fact that PPTg lesions
caused the number of inappropriate responses for food to increase as the requirements
increased and the task became more difficult, suggests that the PPTg was required to
control motor output. In fact, CPP experiments showed that PPTg lesions affect
responding only when motivational excitement was high, such as in deprived
conditions or when the concentration of sucrose increases (Alderson et al., 2001a).
Because these lesions were the entire length of the PPTg it is impossible to know if was
the projections from the anterior or posterior PPTg that regulated CPP behaviour.
IVSA is a model of addiction with more validity to human behaviour compared with
CPP or ICSS because the animal is expected to respond for the drug. If the LDTg and
PPTg do regulate reinforcement it would be expected that IVSA of different drugs of
abuse would be disrupted by PPTg lesions. IVSA of both heroin and d-amphetamine
were found to be normal after PPTg lesions when the lesion was made after operant
training had already occurred. If operant training occurred before the lesion was made
then IVSA on both a fixed and progressive ratio was disrupted (Olmstead et al., 1998;
Alderson et al., 2004a). This suggests that the PPTg is involved in the acquisition of the
operant response, rather than reward perception. Interestingly, despite pre-lesion
training, IVSA of d-amphetamine was still impaired on a progressive ratio schedule
(Alderson et al., 2004a). It is possible that while pre-training reduced the need for
dopamine regulation in the fixed ratio schedule, continuous dopamine regulation was
needed on the progressive ratio schedule. When untrained rats were primed with a non-
contingent dose of d-amphetamine prior to testing, performance on both schedules was
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comparable to control animals, highlighting the relationship between the PPTg and
dopamine regulation in the midbrain in reinforcement learning. Studies have also
determined with more accuracy the system involved in regulating IVSA. After lesions
of the PPTg, heroin IVSA was only impaired in a subset of animals while the remaining
animals showed a relatively normal performance (Olmstead et al., 1998). However,
when the location of the lesions was examined, it was discovered that impaired animals
were more likely to have lesions contained in the pPPTg rather than the aPPTg. The
pPPTg sends projections to both the VTA and SNc, while the projections from the
aPPTg mostly terminate in the SNc (Oakman et al., 1995). The fact that heroin IVSA
was more impaired by pPPTg lesions implicates the VTA and the mesolimbic system in
reinforcement.
4.3 The LDTg and PPTg regulate nicotine reinforcement
The LDTg and PPTg involvement in the reinforcement of drugs of abuse has been
demonstrated in a number of paradigms including CPP and IVSA (Alderson et al.,
2001a; Alderson et al., 2004a). The fact that the projections from the LDTg and PPTg
to the dopaminergic midbrain are in some part cholinergic, as well as the strong
presence of nAChRs in these regions, makes it likely that responding for nicotine will
be particularly affected by lesions in the PPTg. Corrigall et al., (1994) found that
nicotinic antagonist pre-treatment of the VTA decreased IVSA responding, lesions of
the PPTg failed to have any effect suggesting that nicotine was acting directly on
nicotine receptors in the VTA rather than influencing endogenous ACh. However, these
lesions were non selective and confined to the dorsal part of the PPTg. As the dorsal
region of the PPTg has a similar pattern of connectivity to the LDTg, it is possible that
the LDTg compensated for the damage in the PPTg. These results were inconsistent
Figure 4: Projections from the LDTg and PPTg to the dopaminergic midbrain (by
permission of Prof. Philip Winn)
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with more recent results suggesting that nicotine IVSA was sensitive both to
microinjection of a nicotinic antagonist in the PPTg and to lesions of the PPTg when
the lesion was selective for cholinergic neurons (Lanca et al., 2000a). However, the
cholinergic lesions, made with ethylcholine mustard aziridinium ion (AF64A), were not
successfully replicated by this lab and others; an area of cavitation was produced
suggesting that the toxin was not selectively cholinergic and the size of the lesion
seemed to increase with time suggesting a progressive effect of the toxin (H.L.
Alderson, personal comunication; Rodriguez et al., 1998). The lesion made by Lanca et
al., (2000a) attempted to span the entire PPTg from the superior cerebellar peduncle
(scp) to the SNc and to do this effectively more than one injection site is needed due to
the long rostro-caudal ararngement of the PPTg. However, only one injection was made
at the most central point of the PPTg. It is likely then that the lesion affected part, but
not all of both the posterior and anterior PPTg thus some projections to both the VTA
and SNc would have been destroyed. This could also explain the differing results
between Lanca et al., (2000a) and Corrigall et al., (1994) as the earlier study used an
excitotoxic lesion that was mostly contained within the dorsal more posterior region of
the PPTg and the later study used a selective cholinergic lesion targeted at the centre of
the PPTg. However, nicotine clearly has some effect that is mediated by some part of
the PPTg.
In order to determine more specifically the regional contributions to mechanisms
involved in nicotine IVSA, Alderson et al., (2006) made distinct lesions in either the
posterior or anterior regions of the PPTg and tested the effects on nicotine IVSA. It was
found that while lesions in the aPPTg had no effect on responding compared with
controls, lesions in the pPPTg resulted in increased responding for nicotine. This was
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not due to an increase in general responding, as there was no increase in responding for
food or on the inactive lever. There was also no shift in the dose response curve so it
would seem that the change in behaviour was due to enhanced stimulus control over
behaviour rather than a change in the perception of reward value. (Alderson et al.,
2004b) This increased activity after the projection from the PPTg to the midbrain was
removed was thought to be due to lesion induced receptor supersensitivity. This is
consistent with previous finding suggesting that nicotine induced dopamine efflux in
the striatum is enhanced after PPTg lesion (Blaha & Winn, 1993).
The mechanism by which the LDTg and PPTg controls reinforcement is still unknown
but some research has looked at the receptor types recruited by nicotine in the self
administration paradigm. So far research has been restricted to the PPTg and not the
LDTg, but little effort has been made to discriminate between the posterior and anterior
regions of the PPTg when studying the mechanisms of IVSA. Corrigall et al., (2001)
investigated GABAergic mechanisms in the PPTg; rats that were trained to self-
administer nicotine were pre-treated with micro-infusions of either a GABAA or a
GABAB agonist into the PPTg. They found that both GABA agonists decreased
responding for nicotine on an FR schedule but had no effect on responding for cocaine.
GABA mechanisms were also not involved when responding was on a PR schedule.
Micro-injections of muscarinic or μ-opioid receptor agonists into the PPTg were shown
to influence self-administration of both nicotine and cocaine on fixed and progressive
ratio schedules (Corrigall et al., 2002). This indicates that while muscarinic and μ-
opioid receptors in the PPTg may be involved in controlling responding, GABA
mechanisms are specific to nicotine and possibly even to the schedule of reinforcement.
This could be for a number of reasons: it is possible that GABAergic mechanisms were
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only recruited during FR paradigm as higher doses of drug were being used, or it could
be due to the different cognitive requirements of the different schedules (Corrigall et
al., 2001). Unlike the fixed contingencies of the FR schedule, under a PR schedule the
animal must continue to learn the new stimulus reward contingencies throughout the
session. These results are difficult to reconcile with results suggesting that whole PPTg
lesions have no effect on nicotine self-administration; it is possible that even though the
microinjections of the drugs were made in the middle region of the PPTg, the amount
of drug used allowed diffusion towards the pPPTg which when lesioned does affect
responding. Although Alderson et al., (2006) reported an increase in responding after
pPPTg lesions, this was due to the resulting post-synaptic supersensitization which
would not occur after infusions of GABA agonists. GABA neurons in the PPTg may
potentially influence local cholinergic and Glutamatergic neurons or alternatively may
play a more direct role in control of responding by projecting to the VTA and
influencing responding there. Although the effects of GABA give an impression of
specificity, muscarinic and μ-opioid receptors seem to have the more general effect of
reducing cholinergic output from the PPTg and hence reducing responding for nicotine.
The projections from the LDTg and PPTg to the midbrain do seem to be important as a
number of receptor types in the PPTg have been shown to be involved in the
mechanism of nicotine IVSA (Table 2).
4.4 Summary
Electrical and chemical stimulation of neurons in the LDTg and PPTg increased burst
firing in the midbrain and resulted in enhanced efflux of dopamine in the striatal region
mediated by both acetylcholine and ionotropic glutamate receptors in the midbrain
(Blaha & Winn, 1993; Blaha et al., 1996; Floresco et al., 2003; Forster & Blaha, 2003).
Table 2: Summary of the effects of LDTg and PPTg lesions on nicotine reinforcement
Author Date Lesion / Drug Region Effect
Nicotine antagonist VTA ↓ IVSA nicotine
Corrigall et al., 1994
Lesion dorsal PPTg no effect IVSA nicotine
Nicotine antagonist ↓ IVSA nicotine
Lanca et al., 2000a
Cholinergic lesion
PPTg
↓ IVSA nicotine
↓ (FR) IVSA nicotine
no effect IVSA cocaineCorrigall et al., 2001 GABA agonist PPTg
no effect (PR) IVSA nicotine
Corrigall et al., 2002
Muscarinic / Mu-
opioid receptor
agonist
PPTg ↓ (FR&PR) IVSA nicotine/cocaine
Lesion anterior PPTg no effect IVSA nicotine
Alderson et al., 2006
Lesion posterior PPTg ↑ IVSA nicotine
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The PPTg was shown to regulate both endogenous and nicotine induced changes in
striatal dopamine release, albeit using different mechanisms (Forster & Blaha, 2003).
PPTg lesions enhanced dopamine efflux, possibly because post-synaptic nicotinic
receptors were rendered super sensitive by the loss of input from the PPTg. Similarly,
pPPTg lesions enhanced self administration of nicotine in pre-trained animals, despite
having no effect on responding for food or amphetamine (Alderson et al., 2004a;
Alderson et al., 2006). This evidence implicates the PPTg in learning about
reinforcement due to the role as a source of excitatory inputs to the midbrain dopamine
neurons. Finally, the receptor mechanism of nicotine IVSA also seems to differ from
other drugs. While muscarinic and μ-opioid receptor antagonists reduce responding for
both nicotine and cocaine on a FR or PR schedule, GABA antagonists only affected
nicotine on an FR schedule, but have no effect on responding for cocaine (Corrigall et
al., 2001; Corrigall et al., 2002). These data suggest that while the LDTg and PPTg is
involved dopamine regulation in the midbrain, there is an additional mechanism that
affects only nicotine.
4.5 Outline of current research
As outlined in the last two chapters the midbrain dopamine neurons and the cholinergic
neurons of the mesopontine tegmentum play a key role in regulating the reinforcement
process associated with abused drugs. However, research by Lanca et al,. (2000b)
suggests that the effects of nicotine in the LDTg and PPTg may not be regulated by the
cholinergic neurons as only non-cholinergic neurons appear to be activated. However
very little research could be found that supported this claim.
The aim of experiment 1 was to replicate the results found by Lanca et al., (2000b) who
showed that Fos expression after acute systemic nicotine did not co-localise with
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NADPH-d labelling in the LDTg and PPTg. We attempted to extend this study by also
examining Fos expression in the dopaminergic midbrain regions. Experiment 2 was
carried out in order to compare the effects of chronic and acute systemic nicotine on
Fos expression in all four regions: the LDTg, PPTg, SNc and VTA. Experiments 3 and
4 were intended to further explore the mechanisms of nicotine induced activity by
looking at d-amphetamine induced Fos expression and the changes in nicotine induced
Fos activity after pre-treatment with haloperidol to block D2 autoreceptors in the
dopaminergic midbrain. A further two experiments were also carried out in an attempt
to explore new methods of visualising GABA neurons and to find a novel method of
producing a GABA specific lesion in the VTA.
Fos expression was used as a correlate of neural activity in the cholinergic regions of
the mesopontine tegmentum and dopaminergic midbrain. Fos is the protein product of
the immediate early gene (IEG), c-fos, which has been extensively used as a marker for
postsynaptic activity . It is has been used in the past to determine the primary targets of
abused drugs (Kiba & Jayaraman, 1994; Pich et al., 1997). When the drug activates a
receptor on the cell membrane, the second messenger cascade is stimulated. G-proteins
attached to the receptor, activate adenylyl cyclase which in turn converts adenosine
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). As the drug cannot
pass though the cell membrane, the purpose of cAMP is to transfer the effects of the
drug from the cell membrane to the cell nucleus. cAMP is then able to activate several
pathways: it can regulate levels of intracellular Ca2+ via ion channels on the cell
membrane and it can activate a protein kinase. A cAMP response element (CREB)
protein is then activated by the protein kinase, which allows for the transcription of a
diverse range of genes involved in an array of cell functions. IEG, c-fos, is in itself a
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transcription factor which can further influence gene expression. In this way the
induction of Fos, the protein product of c-fos gene transcription, participates in the
initiation of plastic changes in the nervous system associated with physiological events
such as activity dependent synaptic plasticity (Jomphe et al., 2003). Transcription
factor proteins such as Fos can be used to map patterns of activity in the brain as once a
cell has been activated the protein remains in the cell. It is thought to peak at one hr and
disappear by 3-4 hr, however this depends on the primary targets of the drug (Herdegen
& Leah, 1998). Immunohistochemistry, using antibodies to visualise proteins in the
tissue, or in situ hybridisation, using complementary RNA strands to visualise RNA
sequences in tissue, can be used to stain for the Fos protein or the c-fos RNA
respectively. It has been successfully used in studying neuronal activation induced by
nicotine (Pang et al., 1993; Kiba & Jayaraman, 1994; Mathieu-Kia et al., 1998; Lanca
et al., 2000b). One caveat when using Fos expression to measure neuronal activation is
that a number of stimuli can increase expression including sensory stimulation and
stress so every care must be taken to reduce extraneous stimuli.
Some of the data in this thesis was collected from an experiment carried out as part of
my undergraduate project. However, this is the first time the data have been
quantitatively analysed.
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4.6 General Methods
4.6.0 Animals
Drug naïve adult male Lister Hooded rats (Harlan Olac Ltd, UK) weighing 270-520g
were housed in pairs in cages at 20-22 °C, under a 12 h light/dark cycle, and provided
with food and water ad libitum. Testing was carried out during the light phase. In all
experiments compliance was incurred with national [Animals (Scientific Procedures)
Act, 1986] and international [European Communities Council Directive of 24
November 1986 (86/609/EEC)] legislation governing the maintenance of laboratory
animals and their use in scientific experiments. All efforts were made to minimize the
number of animals used and their suffering.
4.6.1 Anaesthesia
Rats were anaesthetized by placing animals in a small gas chamber. The chamber was
flooded with oxygen to habituate the animal, and then the concentration of isofluorane
was gradually increased over a 10 min period until anaesthesia was achieved, as judged
by loss of the righting reflex. The animal remained in the chamber for a further 3 min to
ensure total anaesthesia. Surgical anaesthesia was determined by loss of the righting
reflex, loss of hindlimb withdrawal reflex and absence of a blink reflex. The animal
was then placed in a stereotaxic frame (David Kopf, Ca, USA) and fitted with a
stereotaxic gas mask. Each animal was given carprofen analgesia (‘Rimadyl’, Pfizer,
Sandwich, UK; 0.05 ml) subcutaneously prior to starting surgical procedures.
4.6.2 Experimental Procedures
Fos induction without locomotor activity
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Rats were handled daily for at least 2 weeks prior to experimentation in order to
minimize stress or anxiety. The animals were habituated to both the transportation
cages and handling procedures for 2 days, and on the third day a saline injection
(subcutaneous; s.c. or intraperitoneal i.p. as required by the study) was introduced to the
procedure. Animals were taken one at a time to an ‘injection’ room, and after an
injection they were transferred to a dark holding room. Because Fos expression can be
generated by a wide variety of sensory stimuli, rats were kept in this carefully
controlled environment, minimizing visual and auditory stimuli for 1 h post injections,
prior to sacrifice. On the test day, animals were divided into pairs based on home-cage
mates. One of each pair received a saline control injection, while the other received one
of four possible doses of nicotine (dissolved in saline). Nicotine doses are reported as
that of the salt, nicotine hydrogen tartrate, not in terms of the free base. This matched
pair design meant that each animal in the experimental group could be compared to an
animal that had experienced the same conditions, providing a baseline with which to
compare levels of neural activity. All injections were done by an experienced
technician.
Fos induction with locomotor activity
Animals were handled for 1 week to minimise stress and anxiety. Animals were then
habituated to the locomotor boxes (SmartFrame cage rack system using MotorMonitor
software, Hamilton-Kinder, Ca. USA; cages were 24.13cm wide x 45.72cm long) and
handling procedures for 5 days to reduce the effects of novelty on locomotion. Saline
injections were given on days 3-5 to habituate animals to the procedure. After a 2 day
break, animals were tested with nicotine injections for 5 days. Animals were tested so
that 1 of each drug dose was included in each group The animal given saline acted as a
Figure 5: SmartFrame cage rack system for measuring locomotor activity
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control for the 3 doses of nicotine. Using this matched group paradigm reduced the
number of controls that were needed for this experiment. (A small group of drug naïve
animals were later tested with 1.0mg/kg nicotine using the matched pair procedure).
Visual and auditory stimuli were kept to a minimum during testing to prevent excess
Fos expression. Locomotor activity was measured for 1 h, after which animals were
perfused.
4.6.3 Histological analysis
Immunohistochemistry
Rats were humanely euthanized ( by an experienced technician) with an i.p. injection of
sodium pentobarbital (‘Dolethal’, Univet Ltd, Bicester, Oxon, UK; 200 mg/ml) and
transcardially perfused with phosphate buffered saline followed by at least 300ml of
4% paraformaldyhyde in 0.1M phosphate buffer. Brains were removed and stored in a
20% sucrose solution overnight. Brains were then cut into 30m coronal sections on a
freezing microtome, with 1:4 sections being taken for subsequent staining and analysis
by quantification. Using sections this thin reduced overlapping of neurons, making it
easier to distinguish double labelling from overlapping neurons.
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Table 3: Immunohistochemistry procedure: single and double labelling
Sections were initially washed in phosphate buffer solution (PBS) to remove traces of
antifreeze, used for storage of tissue. They were then immersed in blocking solution
(79.9% PBS, 20% NS, 0.1% Triton X-100) for 45 min to reduce background staining.
The normal serum (NS) used was always raised in a species not associated with any of
the primary or secondary antibodies to prevent cross reaction. Sections were incubated
overnight in an antibody diluting solution (ADS; 98.9% PBS, 1% NS, 0.1% Triton)
containing one primary antibody for single labelling or two primary antibodies for
double labelling. All incubations were carried out at room temperature on a flat bed
shaker. Tissue was then processed using the Vectastain avidin-biotin complex (ABC)
kit: a biotinylated secondary antibody at 1:200 for 90 min and then ABC at 1:50 for 60
min. Staining was then revealed using 3,3-diaminobenzidine tetrahydrochloride (DAB;
Sigma, UK) chromagen (3-10 min). When double labelling was required the second
Time Double Labelling Single Labelling
1. >45 min Blocking Solution Blocking Solution
2. Overnight Primary Antibodies (1 & 2) Primary Antibody (1)
3. 1.5 hr IgG (1) IgG (1)
4. 1hr ABC (1) ABC (1)
5. <10 min DAB (1) DAB (1)
6. 1 hr IgG (2) -
7. 1 hr PAP (2) -
8. <10 min Vector SG (2) -
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primary antibody was processed using the peroxidase-anti-peroxidase (PAP) method to
prevent cross reaction. Sections were incubated in immunoglobin (IgG) secondary
antibody (1:200) for 60 min, then PAP (1:200) for a further 60 min and staining was
revealed using Vector SG substrate kit (3-10 min). The intensity of colour was carefully
controlled for in order that double labelled neurons would be clearly visible Sections
were washed in PBS for 15 min between each stage. In order to determine the
specificity of the antibodies, control experiments where antibodies were omitted were
performed. This ensured against nonspecifc staining. Sections were mounted on
gelatine subbed slides and coverslipped. Sections were analysed using a light
microscope.
Cresyl Fast Violet Stain
Cresyl Fast Violet Stain, a regressive Nissl stain, was used in conjection with Neuronal
nuclei (NeuN) immunohistochemistry to highlight the location of lesions. While NeuN
only stained the intact nuclei of neurons, Cresyl violet stained both neurons and glia
which gave a clear indication as to where neurons had been lesioned. Brains were
processed for NeuN using the standard immunohistochemical procedure as described
above. Slides were then allowed to dry and placed in a gas chamber containing
paraformaldehyde. Slides were placed in xylene and then rehydrated in a sequence of
baths containing 100% ETOH, 50% ETOH and finally rinsed in running water. They
were then placed in cresyl violet for 2 min. The slides were once again placed under
running water until it ran clear and dehydrated following the opposite sequence to
rehydration. Slides were then coverslipped from xylene.
4.6.4 Cell Quantification
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Numbers of cholinergic and dopaminergic cells as well as changes in Fos expression
were quantified by cell counting within specific nuclei. Ensuring a constant level of
illumination through the microscope (Leitz “Diaplan” fitted with a Sony DXC-3000P
video camera connected to a high resolution colour monitor), sections were counted in
the LDTg, PPTg as well as the VTA and SNc. Although blind counting would have
been desirable this was impossible due to the obvious differences between the control
and nicotine conditions. This was especially true in the MT, where nicotine induced
substantial Fos expression but saline had no effect. Because of this, the MT could be
used to determine whether or not the animal received nicotine, ensuring that no mix-up
occurred between the experimental and control conditions. One pair of animals was
dropped from analysis because no Fos expression was found in the MT of either
animal, indicating neither had received saline. Cell counts were taken from consecutive
stained sections with one in four sections being stained. Sections were cut at 30m,
ensuring that consecutive sections were at least 90m apart. Cells in the PPTg are
thought to be no more than 50μm on the long axis (Takakusaki et al., 1996), meaning if
sections are 90μm apart there will be no double counting of cells. This method of
sampling is simply an estimation of the changes in cell counts rather than a
determination of the total number of neurons in each region. Counts were taken from a
minimum of eight sections for each structure. The amount of neuronal activity was
counted in one of two ways. The boundaries of the LDTg and PPTg are not clearly
labelled by brain derived nitric oxide synthase (bNOS) as they also contain large
numbers of putative GABAergic and glutamatergic neurons so samples were taken by
estimating the centre of the structure under x16 magnification and projecting this image
onto a 19’’ screen. All Fos positive nuclei within this boundary were counted. The
VTA and SNc, on the other hand were clearly labelled by TH so all Fos positive nuclei
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within the borders of TH staining were counted. The VTA is made up of a number of
areas including the PBP, the PN and IF nuclei. Because they are all strongly labelled
with TH, the borders between the subdivisions of the VTA are not clearly defined so
they were all counted together. Cells were counted by superimposing a 2’’ square grid
upon the image and counting all the cells within the sampled area. bNOS and TH
labelling was quantified to ensure that the differences in double labelling was not
simply due to changes in the neurons labelled. Neurons labelled with bNOS were large
easily distinguishable neurons and so all were counted within the same boundaries used
for Fos quantification. TH neurons, on the other hand, are small, numerous and very
closely packed so a smaller sample was used when counting TH than was used for
counting Fos. TH in the SNc and VTA was counted together as the intensity of staining
made the border between the two regions indistinct.
4.6.5 Statistics
Cell Quantification
In order to analyze the differences between cell counts, data were collapsed to include
totals from the left and right sides of the brain. Because of the differing baseline rates of
Fos induction as well as unavoidable differences in staining intensity, final analysis was
done using the average percent difference from the saline treated control animal to the
matched nicotine treated animal for each dose of nicotine for both cell labelling (bNOS
and TH) and Fos expression. Double labelling was analysed as the percent of Fos
expression that were also labelled by a cell marker (i.e. the number of double labelled
neurons was divided by the total amount of Fos expression in each region).
The results of bNOS, Fos and double labelling were analyzed using the SPSS statistics
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program to run a 2-way between subjects analysis of variance (ANOVA). The TH
counts were analysed using a 1-way between subjects ANOVA. Cholinergic and
dopaminergic regions were analyzed separately. The independent within subject
variable was brain regions, while the independent between subject variable was drug
dose. The dependent variables were the percent difference in cell marker, Fos or double
labelling. Intra-rater reliability was analysed by correlating a first and second count on
selected animals.
Locomotor Activity
Locomotor activity was analyzed using a 2-way mixed ANOVA. Drug dose was the
between subjects independent variable and session (day) was the within subjects
independent variable. The dependent variable was the total number of beam breaks over
a 1 hr period. The correlation between Fos activity and locomotor activity at each 10
min interval time bin was also measured.
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Chapter 5: Fos expression in the mesopontine tegmentum and midbrain after
acute nicotine
5.0 Introduction
Acute systemic nicotine was found preferentially to activate non-cholinergic neurons,
as measured by Fos expression in the LDTg and PPTg (Lanca et al., 2000b). Further
examination of the evidence also revealed that acute nicotine failed to induce Fos
expression in the dopamine neurons of the VTA and SNc. Pang et al., (1993) found
very few neurons that expressed Fos in the VTA and none at all in the SNc, while
Mathieu-Kia et al., (1998) found large amounts of Fos expression in VTA terminal
fields, the NAcc, CeA, lateral habenula (LHb) and cortex, but again none in the VTA.
The aim of this experiment was to attempt to replicate and verify these results using a
slightly different methodology that was intended to clarify both the extent of nicotine
induced activity and double labelling within the mesopontine tegmentum and midbrain
simultaneously.
Lanca et al., (2000b) assessed the effects of two doses of nicotine (0.3 and 1.0 mg/kg)
and a saline control on Fos expression after survival times of 30, 60 or 120 min post-
injection, in order to determine the extent and timing of nicotinic activation in the
LDTg and PPTg as well as the type of cell activated. In the PPTg, nicotine induced a
dose dependent increase in the amount of Fos labelled neurons at the 30 min survival
time. By 60 min there was no difference between the two doses of nicotine; both 0.3
and 1.0,g/kg doses of nicotine resulted in three times as much Fos expression as the
saline control. In the LDTg, the baseline level of Fos expression was twice that of the
PPTg. At the 30 min survival time both the 0.3 and 1.0mg/kg doses of nicotine doubled
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the amount of Fos expression, but at 60 min the 1.0mg/kg dose of nicotine showed
more Fos expression than both saline and 0.3mg/kg nicotine. By 120 min there was
little difference between nicotine and saline induced Fos expression in either region,
indicating a return to baseline levels. In summary, when the data were collapsed over
all three survival times, nicotine induced Fos activity over and above baseline levels in
both the PPTg and LDTg, but the difference between the doses was only significant in
the LDTg. The 60 min survival time resulted in the most activity overall. Sections were
also labelled with Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-
d) in order to examine the degree to which nicotine activated cholinergic neurons.
Cholinergic neurons in the mesopontine tegmentum have been shown to be unique in
containing NADPH-d and as such it can be utilized as a reliable and selective cell
marker (Vincent et al., 1983). Double labelling of Fos and NADPH-d amounted to
approximately 5% of NADPH-d labelled neurons, meaning that the majority of
activated neurons in the PPTg and LDTg were presumed non-cholinergic. Considering
the fact that the LDTg and PPTg have such a large number of concentrated cholinergic
neurons all containing several types of nAChR (Azam et al., 2003), it seems
implausible that nicotine would result in Fos expression occurring in less than 5% of
the cholinergic cells.
Typically the behavioural and neurophysiological effects of nicotine exhibit an
‘inverted-U’ shaped dose response curve. Acute nicotine can have a strong depressant
effect on locomotor activity at higher doses. Fos, as a general metabolic marker, can be
induced by any sensory or motor activity in the brain (Kiba & Jayaraman, 1994;
Pagliusi et al., 1996), including that associated with locomotion. The mesolimbic
dopamine system has been loosely associated with nicotine induced locomotor activity
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(Louis & Clarke, 1998) and is one of the areas in which Fos expression will be
analysed. There is a trend for higher doses of nicotine to depress activity and lower
doses to stimulate activity. However, pilot experiments found no significant difference
in locomotor activity after 0.1, 0.4, or 0.8mg/kg nicotine compared with saline (Porter,
2004). In order to account for changes in Fos expression caused by locomotor activity,
a range of doses of nicotine, 0.1, 0.4 and 0.8mg/kg, will be used in the following
experiment as well as a saline control. A further factor that can affect nicotine’s
locomotor depressant effect is the novelty of the environment (Clarke & Kumar, 1983)
so rats will be habituated to the transport cages for three days prior to experimentation.
The following experiment is a replication of the study by Lanca et al., (2000b) using a
matched pair design so that nicotine induced activity could be analysed using percent
difference rather than absolute differences. This means that changes in baseline Fos
expression due to environmental factors are taken into account. It also allows for the
fact that the intensity of staining varies with each batch of sections. In order to subtract
out the differences in staining that could occur from the analysis, rats were processed in
pairs. This experiment also attempted a clearer method of labelling cholinergic neurons
such that double labelling could be clearly visualised. While NADPHd histochemistry
is a reliable marker for cholinergic neurons in the mesopontine tegmentum, it does
result in very dark staining due to the formation of an insoluble precipitate from
nitroblue tetrazolium. This could mean that double labelling of Fos and NADPH-d,
indicating activation of cholinergic neurons, would simply be very difficult to detect.
Dark staining may be one possible explanation for the lack of Fos expression found in
cholinergic neurons in the LDTg and PPTg by Lanca et al., (2000b). In order to label
the cholinergic neurons more clearly, the following study will use a multiple antigen
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labelling protocol so the intensity of the staining can be more carefully controlled. An
antibody against bNOS, also a selective marker for cholinergic neurons in the
mesopontine tegmentum, will be visualised using the Vector SG enzyme substrate
(Vectorlabs), a light grey colour that will contrast clearly with the brown DAB enzyme
substrate that will be used to stain for Fos expression. This should result in more exact
quantification of double labelling and easier discrimination between truly double
labelled neurons and cases where there is simply overlap of a Fos labelled neuron with
a bNOS labelled neuron.
The proposed experiment goes beyond the previous study by Lanca et al., (2000b) to
describe more accurately a wider group of targets. Two new regions will also be added
to the study. The LDTg and PPTg send a large number of excitatory projections to the
SNc and VTA which are thought to regulate dopamine activity. This modulatory role
suggests the LDTg and PPTg are involved in reinforcement; and because of the partly
cholinergic nature of this region it is of particular importance to understanding nicotine
reinforcement. Simultaneous examination of nicotine induced Fos activity in the LDTg,
PPTg, SNc and VTA will lead to a better understanding of the interactions between
nicotine and the interrelated neural systems in the effects of acute systemic nicotine and
the mediation of nicotine addiction.
It was hypothesized that the reinforcing effects of nicotine are reliant on the input from
the mesopontine tegmentum to midbrain dopamine neurons. Two questions followed
from this: (1) To what extent did nicotine induce activity in the LDTg, PPTg, and in the
VTA and SNc as downstream targets; and (2) What was the neurochemical
composition of the neurons activated by nicotine in the mesopontine tegmentum and
midbrain areas – were the cholinergic neurons of mesopontine tegmentum and the
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dopaminergic neurons of the VTA/SNc activated or not? These questions were
examined using standard immunohistological techniques: (1) Nicotine induced
neuronal activation was analyzed by quantification of Fos immunoreactivity in LDTg,
PPTg, VTA and SNc. (2) The nature of activated neurons was measured by double
labelling sections with bNOS, in the LDTg and PPTg, and TH in the VTA and SN.
5.1 Methods
5.1.0 Animals
46 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 280-460g
were used in this experiment. 1 pair of animals in the 0.4mg/kg group were dropped
from analysis because the lack of any Fos expression in the MT which suggested that
the experimental animal did not receive a full dose of nicotine (see General Methods).
Nicotine n Control N
Group 1 0 mg/kg 4 Sal 4
Group 2 0.1 mg/kg 6 Sal 6
Group 3 0.4 mg/kg 9 Sal 9
Group 4 0.8 mg/kg 4 Sal 4
Total 23 Total 23
5.1.1 Experimental procedure
Experimental procedure used was ‘Fos induction without locomotor activity’ as
described in General Methods.
5.1.2 Histological Analysis
Histological analysis was performed as described in the General Methods. Sections
were double labelled for either Fos (1:8000, made in rabbit, Oncogene Science, PC38)
and bNOS (1:1000, made in mouse, Sigma) or Fos and TH (1:25,000, made in mouse,
Chemicon). The secondary antibody to Fos was anti-rabbit IgG (Vectastain,
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Vectorlabs) and the secondary antibody to bNOS and TH was anti-mouse IgG
(Sternburgers Monoclonals, USA); the PAP was also anti-mouse (Sternburgers
Monoclonals, USA).
5.1.3 Quantification & Statistics
Cell Quantification and subsequent statistical analysis was performed as described in
the General Methods.
5.2 Results
Reliability of quantification was tested by correlating a small sample of recounted
sections with the original counts. This test of intra-rater reliability demonstrated a
highly significant relationship between the counts taken at different times (r =0.92, DF
= 6, p<0.001).
5.2.0 LDTg and PPTg
bNOS
The largest percent difference in bNOS labelled neurons was in control animals, while
the animals that received nicotine showed almost no difference at all. This large
difference was probably due to damaged sections because a full and accurate count of
bNOS labelling could not be carried out. However the difference was less than 20% in
all cases. Figure 8 illustrated these relatively small changes as well as the similarities
between the LDTg and PPTg. Within subjects analysis showed no effect of region (F1,18
= 0.01, ns) and no interaction between region and dose (F3,18 = 0.77, ns). Between
subjects analysis showed no effect of dose (F3,18 = 1.91, ns) on the expression of bNOS
in the mesopontine tegmentum.
Figure 6:   Laterodorsal tegmental nucleus
CDouble labelling of bNOS (black) and Fos 
expression (brown) in the LDTg after 
saline (A),  0.4mg/kg nicotine (B),  0.4mg/kg 
haloperidol followed by 0.4mg/kg nicotine (C). 
Fos induction after 0.4mg/kg nicotine is not 
significantly greater than after saline.  Activity
is almost exclusively non-cholinergic.
Pre-treatment with haloperidol inhibits Fos 
expression in the LDTg.
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Figure 7:   Pedunculopontine tegmental nucleus
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Double labelling of bNOS (black) and Fos 
expression (brown) in the PPTg after 
saline (A),  0.4mg/kg nicotine (B),  0.4mg/kg 
haloperidol followed by 0.4mg/kg nicotine (C). 
Fos induction after 0.4mg/kg nicotine is not 
significantly greater than after saline.  Activity
is almost exclusively non-cholinergic.
Pre-treatment with haloperidol inhibits Fos 
expression in the PPTg.
Figure 8: bNOS labelling in the LDTg and PPTg after acute nicotine
Mean and standard error of the percent difference in bNOS labelled neurons from the saline
treated control animal to the matched nicotine treated animal for each dose of acute nicotine.
Nicotine had no significant effect on bNOS labelling in the LDTg or PPTg.
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Figure 9: Fos expression in the LDTg & PPTg after acute nicotine
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of acute nicotine.
Nicotine had no significant effect on Fos expression in the LDTg or PPTg.
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Figure 10: Double labelling of bNOS and Fos in the LDTg and PPTg after acute
nicotine
Mean and standard error of percent of Fos labelled neurons that are also labelled by bNOS in
the LDTg and PPTg for each dose of acute nicotine. Nicotine had no significant effect on
double labelling in the LDTg or PPTg.
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Total Fos
Acute nicotine induced different patterns of Fos expression in the LDTg and PPTg.
There was a dose response curve pattern in the LDTg (Figure 9); the largest increase in
nicotine induced Fos activity was after 0.4mg/kg nicotine (Figure 6). In the PPTg
(Figure 9), nicotine induced a similar amount of Fos activity regardless of the dose
compared with control animals, although Fos was increased over saline (Figure 7). The
high variance, showed by the error bars in Figure 9, was indicative of the large
individual differences seen in response to nicotine, as well as differences in the strength
of staining and tissue fixation. Within subjects analysis showed a significant effect of
region (F1,18 = 4.61, p<0.05) on nicotine induced activity but no interaction between
region and dose (F3,18 = 2.01, ns). Between subjects analysis showed no effect of dose
(F3,18 = 1.91, ns) on Fos expression in the LDTg and PPTg. These data indicated that
nicotine had a greater overall effect in the PPTg than in the LDTg, but that the dose of
nicotine had no significant impact on Fos expression in either region.
Double labelling of bNOS and Fos
The results in Figure 10 showed that almost no cholinergic neurons were activated by
acute nicotine. Within subjects analysis showed no effect of region (F1,18 = 0.30, ns)
and no interaction between region and dose (F3,18 = 0.34, ns). Between subjects analysis
showed no effect of dose (F3,18 = 0.61, ns) on double labelling. These data suggested
that the majority of activated neurons in the LDTg and PPTg were non-cholinergic
(Figure 6 & 7).
5.2.1 SNc and VTA
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TH
Dose of nicotine had a small effect on TH labelling in the VTA and SNc, but this was
not a significant (Figure 13). One-way between subjects ANOVA showed no effect of
nicotine dose (F3,6 = 0.72, ns) on the expression of TH in the midbrain.
Total Fos
The baseline level of Fos expression was higher in the VTA (Figure 12) than in the SNc
(Figure 11; data not shown). However, the pattern of nicotine induced activation of Fos
was the same in both the SNc and the VTA: a typical inverted-U shaped curve (Figure
14). The largest percent increase was after 0.4mg/kg nicotine. While 0.1 and 0.8mg/kg
nicotine had a smaller effect on Fos expression than 0.4mg/kg, both were still greater
than baseline levels. Within subjects analysis showed no significant effect of region
(F1,18 = 0.002, ns) on nicotine induced activity and no interaction between region and
dose (F3,18 = 0.09, ns). Between subjects analysis showed a significant effect of dose
(F3,18 = 6.28, p<0.005) on Fos expression in the midbrain. Post-hoc tests (Bonferroni t-
test) showed that the 0.4mg/kg dose of nicotine increased nicotine induced activity
significantly more than either saline (p<0.01) or 0.1mg/kg nicotine (p<0.05). These
data showed that 0.4mg/kg nicotine had a significant impact on neural activity, as
measured by Fos expression, compared with lower doses.
Double labelling of TH and Fos
The results showed that less that 2.5% of the activity in the SNc induced by nicotine
was also labelled with TH. In the VTA approximately 7-15% of the Fos expression
induced by nicotine was in TH containing neurons. As can be seen in Figure 15, there
was little difference between saline and the two lower doses of nicotine, 0.1 and
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Figure 11:   Substantia nigra pars compacta
C
BA
Double labelling of TH (black) and Fos 
expression (brown) in the SNc after 
saline (A),  0.4mg/kg nicotine (B),  0.4mg/kg 
haloperidol followed by 0.4mg/kg nicotine (C). 
Fos induction after 0.4mg/kg nicotine is 
significantly greater than after saline.  Activity
is almost exclusively non-dopaminergic.
Pre-treatment with haloperidol inhibits Fos 
expression in the SNc.
Figure 12:   Ventral tegmental area
C
BA
Key:   
Scale bars = 100µm 
Red arrows = Fos
Black arrows =  TH
Curved arrows = Double 
labelling
Double labelling of TH (black) and Fos 
expression (brown) in the VTA after 
saline (A),  0.4mg/kg nicotine (B),  0.4mg/kg 
haloperidol followed by 0.4mg/kg nicotine (C). 
Fos induction after 0.4mg/kg nicotine is 
significantly greater than after saline.  Activity
is almost exclusively non-dopaminergic.
Pre-treatment with haloperidol inhibits Fos 
expression in the VTA.
Figure 13: TH labelling in the SNc and VTA after acute nicotine.
Mean and standard error of the percent difference in TH labelling from the saline treated
control animal to the matched nicotine treated animal for each dose of acute nicotine.
Nicotine had no significant effect on TH labelling.
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Figure 14: Fos expression in the SNc and VTA after acute nicotine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of acute nicotine. Fos
expression in the SNc and VTA together was significantly increased after 0.4mg/kg nicotine
compared with either saline or 0.1mg/kg nicotine.
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Figure 15: Double labelling of TH and Fos in the SNc and VTA after acute nicotine.
Mean and standard error of percent of Fos labelled neurons that are also labelled by TH in the
SNc and VTA for each dose of acute nicotine. 0.8mg/kg nicotine induces significantly more
double labelling in the SNc and VTA together than either saline of 0.4mg/kg nicotine.
Significantly more double labelling of Fos and TH occurs in the VTA than in the SNc.
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0.4mg/kg. However, after 0.8mg/kg nicotine the amount of Fos activity that occurred in
TH containing neurons increased to 15%. An example of double labelling of Fos
expression and TH was given in Figure 12. However, it must be noted that the data
were expressed as a percentage of the total Fos expression that occurred in dopamine
neurons and as such did not give an indication of the total number of dopamine neurons
that were activated. Within subjects analysis showed a significant effect of midbrain
region (F1,18 = 153.1, p<0.001) on nicotine induced activity but no interaction between
region and dose (F3,18 = 2.86, ns). Between subjects analysis showed a significant effect
of nicotine dose (F3,18 = 6.47, p<0.005). Post-hoc tests (Bonferroni t-test) showed that
the 0.8mg/kg dose of nicotine increased double labelling significantly more than either
saline (p<0.005) or 0.4mg/kg nicotine (p<0.05). Although the majority of Fos
expression in the midbrain was in neurons not labelled with TH, 0.8mg/kg nicotine
significantly increased the number of double labelled neurons in the VTA over both
saline and 0.4mg/kg nicotine.
4.3 Discussion
The aim of this experiment was to examine the extent of neural activity in the
LDTg/PPTg and SNc/VTA that resulted from acute systemic nicotine, as well as the
type of neuron that was activated. Results from the LDTg and PPTg showed that acute
nicotine did not significantly affect the number of bNOS labelled neurons in either the
LDTg or PPTg. The large differences that occurred in the control group were probably
due to damaged sections in some groups. Overall acute nicotine induced significantly
more Fos expression, indicating putative neural activity, in the PPTg relative to the
LDTg, but the change in the dose of nicotine did not have a significant effect on the
induction of Fos expression. There was almost no double labelling in either the PPTg or
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LDTg which suggested that only non-cholinergic neurons were activated by acute
nicotine.
In the midbrain the number of TH labelled neurons did not change after acute systemic
nicotine. The pattern of Fos expression was almost identical in both the SNc and VTA;
activity occurred in a typical inverted U-shaped curve. 0.4mg/kg nicotine was the most
effective dose; it significantly increased activity above both saline and 0.1mg/kg
nicotine. Double labelling of Fos and TH was minimal in the SNc, but some double
labelling occurred in the VTA. The highest dose, 0.8mg/kg nicotine, was the only dose
that increased the amount of activity in TH containing neurons above baseline levels.
However, the majority of activity was in neurons not labelled for TH. Although up to
15% of the activated neurons contained TH, this represents less than 5% of the total TH
labelled population.
The present results confirmed some findings from Lanca et al., (2000b) but not all. In
the PPTg, both Lanca et al., (2000b) and this experiment found no difference in Fos
expression between doses of acute nicotine, but that all three doses increased Fos
activity equally over saline. Results from the LDTg differed slightly: Lanca et al.,
(2000b) found a positive linear relationship between nicotine dose and neural activity
where the largest increase occurred after 1.0mg/kg, whereas this study found an
inverted-U shaped curve pattern of activity where 0.4mg/kg had the largest impact. Fos
expression was not induced by 0.8mg/kg nicotine over levels induced by saline. Most
importantly this study confirmed the lack of cholinergic activity in the LDTg and PPTg
found by Lanca et al., (2000b) after any dose of nicotine tested.
Fos expression in TH containing and unlabelled neurons was also examined in the SNc
and VTA. In contrast to previous studies that reported very little Fos expression in the
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VTA and SNc (Pang et al., 1993; Mathieu-Kia et al., 1998), this study found nicotine
induced Fos expression in both areas. One methodological factor which could have
influenced this basic difference in results was sacrifice time. In this study rats were left
for 1 hr post injection, while Mathieu-Kia et al., (1998) used a 90min sacrifice time and
Pang et al., (1993) used a 2hr and a 4hr sacrifice time. This may account for the lack of
Fos expression as a number of studies have found maximal expression at 60 min (Sharp
et al., 1993; Hughes & Dragunow, 1995; Lanca et al., 2000b). It is possible that
different sacrifice times must be used to visualise second messenger activity in different
parts of the brain depending on the time taken to activate various regions. Nuclei that
are activated by fast sensory relays may show Fos expression earlier than parts of the
brain that rely on slower inputs from more widespread areas.
It is possible that the scarcity of double labelling of Fos expression and TH in the
dopaminergic midbrain area is due to methodological difficulties. However, the
noradrenergic LC neurons show densely packed Fos that is double labelled with TH
(Figure 16). This nucleus of the brain is activated by stress or anxiety (Ceccatelli et al.,
1989), so double labelling in this area is not unexpected. The LC is thought to be
activated by nicotine via the local release of glutamate in a similar manner to activation
in the VTA (Erhardt et al., 2000), thus it is possible for neurons activated in this
manner to show Fos expression.
The small number of putative dopamine neurons that were activated, regardless of
group, were almost always confined to a the ventral regions of the VTA, the IF and the
PN. However, due to the difficulty in defining the borders of the VTA subdivisions as
all were stained equally by TH, all the regions were counted together. It is possible that
the different subregions of the VTA showed different patterns of connectivity and this
Figure 16:   Locus coeruleus
Double labelling of TH (black) and Fos expression 
(brown) in the locus coeruleus (LC). Double 
labelling in these TH containing neurons indicates 
that there are no methodological issues preventing 
Fos expression in dopamine neurons of the VTA.
Scale Bar = 50µm
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resulted in localised regions of Fos expression. For example, Cornwall et al., (1990)
found that injections of anterograde tracer in the LDTg labelled the ventral regions of
the VTA such as the IF and the PN more often than the dorsal regions. As the LDTg is
a source of excitatory input into the VTA, this could explain why only dopamine
neurons in the ventral VTA show Fos expression. It is also true that more dorsal
injections of retrograde tracer in the NAcc label more ventral regions of the VTA (Brog
et al., 1993), again suggesting that there may be distinct functional differences that can
be mapped by the pattern of connections in the mesolimbic system.
The LDTg/PPTg and SNc/VTA are thought to be involved in the regulation of nicotine
reinforcement (Corrigall et al., 1994; Alderson et al., 2006), however the type of
neuron involved and the mechanism by which nicotine works is less clear (Nisell et al.,
1994; Lanca et al., 2000b; Corrigall et al., 2001; Corrigall et al., 2002). A number of
studies have showed that sub-regions within the PPTg are involved in nicotine induced
locomotion and nicotine self-administration (Alderson et al., 2003a; Alderson et al.,
2005), one study has even reported that selective cholinergic lesions of the PPTg
reduced IVSA of nicotine (Lanca et al., 2000a). The lack of bNOS, presumed
cholinergic, co-localisation with Fos expression after acute nicotine is surprising
considering the function that the largely cholinergic LDTg and PPTg are considered to
play in reinforcement mechanisms. However, the present experiments along with
results from Lanca et al., (2000b) suggest that it is not cholinergic neurons that are
activated by nicotine.
Acute nicotine is known to elevate dopamine levels in the VTA (Rahman et al., 2003)
as well as increase the rate of firing and percentage of action potentials that are fired in
bursts (Yin & French, 2000; Erhardt et al., 2002; Schilstrom et al., 2004). As well as
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receiving excitatory cholinergic input from the mesopontine tegmentum, dopamine
neurons in the VTA and SNc also contain intrinsic nAChRs (Azam et al., 2002;
Omelchenko & Sesack, 2006). Considering this, the lack of double labelling of Fos
with TH after acute nicotine is unexpected.
It could be that the lack of Fos activation in TH containing neurons that was found in
this experiment was due to GABA mediated inhibition. A rapid increase in firing of
GABA neurons has been found after acute nicotine (Yin & French, 2000). The large
increases in Fos expression in non-dopamine neurons may reflect this increase in firing
which results in inhibition of dopamine neurons. Nicotine is thought to become
addictive with repeated exposure due to sensitization, or enhanced responding of the
mesolimbic dopamine system. During this process GABAergic neurons were thought to
be desensitized when repeated stimulation by nicotine led to a temporary refractory
period. A second experiment was proposed to examine the possibility that sensitization
caused by repeated exposure to nicotine would result in desensitization of GABAergic
neurons in the SNc and VTA and thus increase dopamine release. This increase in
metabolic activity in dopamine neurons would lead to increased Fos expression.
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Chapter 6: Fos expression in the mesopontine tegmentum and midbrain after
chronic nicotine administration
6.0 Introduction
After acute nicotine (0.35mg/kg), Mathieu-Kia et al., (1998) consistently found
increased Fos expression in a number of visuo-motor structures such as the SC and MT,
as well as in the NAcc, part of the terminal field of the VTA. Nonetheless they found
no activity in any cell type in the VTA or SNc. In contrast to these data, Experiment 1,
“Fos expression after acute nicotine administration” showed that 0.4mg/kg acute
nicotine significantly increased Fos expression in both the SNc and VTA. However the
majority of the activity was in non-dopaminergic neurons. Experiment 1 also confirmed
results from Lanca et al., (2000b) who showed that nicotine induced Fos expression in
the LDTg and PPTg occurs almost exclusively in non-cholinergic neurons.
The aim of this experiment was to determine if there was an increase in the activity of
cholinergic neurons in the mesopontine tegmentum and dopaminergic activity in the
midbrain in response to a final challenge of nicotine following sensitization of the
mesolimbic system by repeated exposure to nicotine. Sensitization is the enhanced
effect that a drug has after repeated administration. The initiation of sensitization is
thought to be regulated by mechanisms in the dopaminergic midbrain but the continued
expression of sensitization is thought to be mediated by the NAcc (Kalivas, 1995). The
repeated administration of psychostimulant drugs results in enhanced dopamine release
in the NAcc, which in turn augments the behaviours associated with the NAcc;
psychomotor effects and incentive motivation (Robinson & Berridge, 2003).
Both locomotor activity and dopamine efflux in the NAcc have been examined after
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chronic nicotine. Sensitization to nicotine can occur in as little as 5 days and results in
an increase in dopamine efflux in the NAcc but not in the dorsal lateral striatum,
indicating the sensitivity of the mesolimbic system to nicotine (Benwell & Balfour,
1992; Nisell et al., 1994; Panagis et al., 1996; Benwell & Balfour, 1997). Locomotor
activity has also been found to be increased by repeated doses of nicotine (Balfour et
al., 1996; Alderson et al., 2005). This increase in NAcc dopamine efflux after nicotine
sensitization is thought to be due to mechanisms located in the VTA and the LDTg
(Nisell et al., 1994; Panagis et al., 1996; Schilstrom et al., 1998; Forster & Blaha,
2000). Fos expression is thought to occur following metabolic activity in the cell.
Therefore it seems reasonable to assume that sensitization to nicotine will increase Fos
expression in the LDTg and VTA.
When Mathieu-Kia et al., (1998) examined the effects of repeated nicotine in the
midbrain, repeated injections over 15 days produced Fos expression in visuo-motor
areas as well as the NAcc, but compared with acute nicotine additionally recruited
activity in the cingulate cortex as well as both the core and ventral shell of the NAcc.
Despite this there was still no activity found in the VTA, which is a major source of
excitatory projections to the NAcc. However, the inconsistencies found in the results
after acute nicotine between Mathieu-Kia et al., (1998) and Experiment 1 justify a re-
examination of Fos expression after chronic nicotine.
While Mathieu-Kia et al., (1998) looked at numerous regions of the brain including
visuo-motor structures, various thalamic nuclei and the terminal fields of VTA neurons,
they only used one dose of nicotine. The effect of different doses of systemic chronic
nicotine on patterns of Fos expression appears to have only been previously examined
in the NAcc and striatum. Despite Pang et al., (1993) reporting that doses of nicotine
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larger than 0.4mg/kg did not change the patterns of Fos immunoreactivity, Experiment
1 found that while 0.8mg/kg nicotine had no effect on Fos activity in the PPTg
compared with 0.1 and 0.4mg/kg nicotine, the LDTg, VTA and SNc all showed a
decrease in the amount of Fos expression at 0.8mg/kg nicotine.
The design of this experiment improved upon the methods of Experiment 1 by testing
all doses of nicotine in each session (except for 0.8mg/kg nicotine which was tested in a
separate session). This means that differences in Fos expression due to different
environmental circumstances can be ruled out, and also prevents differences in the
intensity of staining masking the true effects of nicotine. This also allowed us to use
fewer animals as one animal could be used as a control for all three doses of nicotine
tested. Locomotor activity after nicotine administration was measured in addition to
Fos expression. Because both locomotor activity and neurobiological sensitization are
thought to be mediated, at least partly, by the mesolimbic system, locomotor activity
can be used as a behavioural measure of the degree to which sensitisation of the neural
system has occurred. Panagis et al., (1996) found that a dose of nicotine that
significantly enhanced locomotor activity also significantly enhanced Fos expression in
the NAcc, while doses that had no effect on locomotion also had no effect on Fos
expression.
It was hypothesized that sensitization of midbrain dopamine neurons by repeated
nicotine would lead to increased dopamine efflux and electrophysiological activity in
the mesolimbic system. Two questions followed from this: (1) to what extent did
repeated nicotine stimulate locomotor activity and (2) what was the extent and type of
neuron activated by chronic nicotine in the dopaminergic midbrain, and the cholinergic
mesopontine tegmentum as a source of excitatory input to the midbrain? These
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questions were examined by measuring locomotor activity induced by 5 doses of
nicotine over 5 days of testing, with nicotine or saline given every day, and by
quantification and identification of activated neurons, by means of Fos expression, in
the mesopontine tegmentum and midbrain.
6.1 Methods
6.1.0 Animals
42 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 270-470g
were used for locomotor testing and 30 of these were further processed in order to
analyse Fos expression.
Nicotine n (Locomotor) n (Fos expression)
Group 1 0 mg/kg 11 9
Group 2 0.1 mg/kg 8 6
Group 3 0.4 mg/kg 8 6
Group 4 0.8 mg/kg 8 6
Group 5 1.0 mg/kg 3 3
Total 42 30
6.1.1 Experimental procedure
Experimental procedure used was ‘Fos induction with locomotor activity’ as described
in General Methods.
6.1.2 Histological Analysis
Histological analysis was performed as described in the General Methods. Sections
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were double labelled for either Fos (1:8000, made in rabbit, Oncogene Science, PC38)
and bNOS (1:1000, made in mouse, Sigma) or Fos and TH (1:25,000, made in mouse,
Chemicon). Secondary antibody was either anti-rabbit (Vectastain) or anti-mouse
(Sternburgers Monoclonals, USA); and the PAP was also anti-mouse (Sternburgers
Monoclonals, USA).
6.1.3 Quantification & Statistics
Cell Quantification and subsequent statistical analysis was performed as described in
the General Methods.
6.2 Results
6.2.0 Locomotor Activity
Animals were habituated to the testing environment for five days prior to the
experiment starting. Locomotor activity measurements, which commenced immediately
after injections were given, were recorded for one hr. On the first day of testing, the
three higher doses of nicotine, 0.4, 0.8 and 1.0mg/kg nicotine, suppressed activity. As
shown in Figure 17, 5 days of passive subcutaneous nicotine led to a dose-dependent
increased locomotor activity after both the 0.4 and 0.8mg/kg doses. While the 1.0mg/kg
dose of nicotine increased locomotor activity, by day 5 it was not greater than
locomotor activity after saline. A repeated measures day x dose ANOVA on the
number of beam breaks revealed a significant main effect of day (F4,116 = 30.64,
p<0.001), as well as an effect of nicotine dose (F4,29 = 3.22, p<0.05). There was also a
significant day x dose interaction (F16,116 = 8.39, p<0.001).
Further analysis of the simple effects of each dose of nicotine on locomotor activity
over time revealed that saline (F4,32 = 1.10, ns) and 0.1mg/kg nicotine (F4,24 = 1.56, ns)
Figure 17: Locomotor Activity over five days of chronic nicotine.
Mean and standard error of beam breaks made in a 1hr period over 5 days of subcutaneous nicotine.
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Table 4: Relationship between Fos expression and locomotor activity on day 5
1-10 min 11-20 min 21-30 min 31-40 min 41-50 min 51-60 min
LDTg
r = 0.26,
DF = 22,
ns
r = 0.66,
DF = 22,
p<0.001
r = 0.72,
DF = 22,
p<0.001
r = 0.20,
DF = 22,
ns
r = 0.15,
DF = 22,
ns
r = 0.17,
DF = 22,
ns
PPTg
r = 0.26,
DF = 22,
ns
r = 0.55,
DF = 22,
p<0.005
r = 0.56,
DF = 22,
p<0.005
r = 0.22,
DF = 22,
ns
r = -0.02,
DF = 22,
ns
r = 0.10,
DF = 22,
ns
SNc
r = 0.28,
DF = 22,
ns
r = 0.63,
DF = 22,
p<0.005
r = 0.53,
DF = 22,
p<0.01
r = 0.53,
DF = 22,
p<0.01
r = 0.39,
DF = 22,
p<0.05
r = 0.39,
DF = 22,
p<0.05
VTA
r = 0.28,
DF = 22,
ns
r = 0.76,
DF = 22,
p<0.001
r = 0.61,
DF = 22,
p<0.005
r = 0.38,
DF = 22,
p<0.05
r = 0.26,
DF = 22,
ns
r = 0.43,
DF = 22,
p<0.05
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had no effect of locomotor activity, but the 0.4 (F4,28 = 38.51, p<0.001) and 0.8mg/kg
(F4,28 = 40.22, p<0.001) doses of nicotine changed activity significantly over the 5 days.
1.0mg/kg nicotine had no effect on locomotor activity over 5 days (F4,4 = 47.6, ns).
Pairwise comparisons (after Bonferroni correction) reveal that after both 0.4 and
0.8mgkg nicotine, locomotor activity was significantly lower on day 1 than every other
day (p<0.001). On days 4 and 5, 0.4mg/kg nicotine had caused activity to rise
significantly from both day 1 (p<0.001) and day 2 (p<0.005), as had 0.8mg/kg nicotine
(day 1, p<0.001; day 2, p<0.005).
Further analysis looking at the simple effects of nicotine dose on each individual day
revealed that nicotine had a significant effect on locomotion on days 1 (F4,37 = 9.98,
p<0.001), day 3 (F4,37= 3.19, p<0.05), day 4 (F4,35 = 3.70, p<0.05) and day 5 (F4,37 =
8.53, p<0.001) but not on day 2 (F4,31 = 2.37, ns). Post-hoc tests revealed that on day 1
the 0.4, 0.8 and 1.0mg/kg doses of nicotine resulted in significant suppression of
locomotor activity in comparison with saline (0.4, p<0.001; 0.8, p<0.001; 1.0,
p<0.005). 0.8 and 1.0mg/kg nicotine also induced significantly less locomotor activity
than 0.1mg/kg nicotine (0.8, p<0.05; 1.0, p<0.05). On day 3, locomotor activity after
0.4 and 0.8mg/kg nicotine had increased so it was not significantly different from saline
induced activity. 1.0mg/kg nicotine induced significantly less locomotor activity than
0.8mg/kg nicotine (p<0.05) but not less that saline. On day 4 there was no significant
differences in locomotor activity between doses of nicotine after Bonferroni correction.
On day 5, both 0.4 and 0.8mg/kg nicotine induced significantly more locomotor activity
than saline (0.4, p<0.005; 0.8, p<0.001), while 0.8mg/kg nicotine additionally increased
locomotor activity above 0.1mg/kg nicotine (p<0.05). 1.0mg/kg nicotine had increased
locomotor activity so it was not significantly different from saline, but it was
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significantly below levels of locomotion induced by 0.4 or 0.8mg/kg nicotine (0.4,
p<0.05; 0.8, p<0.01).
In summary, both 0.4 and 0.8mg/kg nicotine suppressed activity on day 1, but by day 5
behavioural sensitization meant that both these doses of nicotine resulted in greatly
enhanced locomotor activity. 1.0mg/kg nicotine increased locomotor activity but
behavioural sensitization did not occur.
In order to determine whether or not there was a relationship between brain activity,
measured by Fos expression, and locomotor activity, a Pearson’s correlation was
performed comparing Fos expression with locomotor activity on day 5. Locomotor
activity was broken down into six time bins of 10min each. A significant positive
relationship was found between Fos expression in the LDTg and PPTg and locomotor
activity in the time bins recorded between 10 and 30 min after the injection time. A
significant positive relationship was also found between Fos expression in the SNc and
locomotor activity in all time bins recorded after 10min from the injection time; and
between Fos expression in the VTA and locomotor activity in time bins recorded
between 10 and 40 min, as well as 50-60 min from the injection time (Table 4). These
results indicate that Fos expression measured 1hr after nicotine injections correlates
most strongly with locomotor activity recorded between 10 and 30 min after the
injection time. It also indicates that Fos activity in all four brain regions examined may
be involved in nicotine induced locomotor activity.
5.2.1 LDTg and PPTg
bNOS
As Figure 20 shows, nicotine did have some effect on the number of bNOS labelled
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neurons in the LDTg and PPTg. Within subjects analysis showed an effect of region
(F1,22 = 5.71, p<0.05) on bNOS labelling such that there was a greater difference in the
LDTg than in the PPTg. However there was no interaction between region and dose
(F4,22 = 0.48, ns). Between subjects analysis showed no effect of dose (F4,22 = 2.23, ns)
on the number of bNOS labelled neurons.
Total Fos
Figure 18 and 19 showed bNOS and Fos expression in the LDTg and PPTg. Figure 21
illustrates that the effects of chronic nicotine on the LDTg and PPTg are almost
identical. Nicotine resulted in a dose-dependent increase in Fos expression so that the
largest increase in Fos expression was after 0.8mg/kg nicotine. 1.0mg/kg nicotine did
not result in any effect on Fos expression. Within subjects analysis revealed no effect of
region (F1,22 = 0.002, ns) and no interaction effects (F4,22 = 0.12, ns). Between subjects
analysis showed that there is a significant effect of dose (F4,22 = 5.48, p<0.005). Post-
hoc Bonferroni tests revealed that 0.8mg/kg nicotine induced significantly more Fos
expression than both saline (p<0.01) and 0.1mg/kg nicotine (p<0.05). 0.1, 0.4 and
1.0mg/kg nicotine did not differ significantly from saline induced Fos expression.
Double labelling of bNOS and Fos
Figure 22 shows that less than 2% of cholinergic neurons were activated by nicotine,
regardless of the dose used. Within subjects analysis revealed no main effect of region
(F1,22 = 2.99, ns) and no interaction (F4,22 = 0.41, ns). Between subjects analysis showed
no effect of dose (F4,22 = 1.26, ns) on the amount of double labelling, as indicated by
double labelling of bNOS and Fos, in the LDTg and PPTg.
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Figure 18:   Laterodorsal tegmental nucleus
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Figure 19:   Pedunculopontine tegmental nucleus
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Figure 20: bNOS labelling in the LDTg and PPTg after chronic nicotine.
Mean and standard error of the percent difference in bNOS labelled neurons from the saline
treated control animal to the matched nicotine treated animal for each dose of chronic
nicotine. Nicotine had no significant effect on bNOS labelling in the LDTg or PPTg.
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Figure 21: Fos expression in the LDTg and PPTg after chronic nicotine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of chronic nicotine.
Nicotine had no significant effect on Fos expression in the LDTg or PPTg.
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Figure 22: Double labelling of bNOS and Fos in the LDTg and PPTg after chronic
nicotine
Mean and standard error of percent of Fos labelled neurons that are also labelled by bNOS in
the LDTg and PPTg after each dose of chronic nicotine. Nicotine had no significant effect on
double labelling in the LDTg or PPTg.
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6.2.2 SNc and VTA
TH
As can be seen in Figure 25, the amount of TH labelling in the SNc and VTA together
was not affected by the dose of nicotine. One way between subjects ANOVA showed
no significant effect of dose (F4,13 = 0.40, ns) on the number of TH labelled neurons in
the midbrain.
Total Fos
Figure 23 and 24 showed TH and Fos expression in the SNc and VTA. The results in
Figure 26 showed that nicotine had a dose dependent effect on Fos expression in the
dopaminergic midbrain but this effect was larger in the VTA than the SNc. Within
subjects analysis showed a significant main effect of region (F1,22 = 20.36, p<0.001) and
a significant interaction between the effects of region and dose (F4,22 = 4.30, p<0.05).
Between subjects analysis revealed no significant effect of dose alone (F4,22 = 2.34, ns).
Further analysis of the effect of dose in each region revealed that the effects of nicotine
were significant in the VTA (F4,22 = 4.83, p<0.005), but not the SNc (F4,22 = 0.67, ns).
Post-hoc Bonferroni tests revealed that 0.8mg/kg nicotine induced a significantly larger
amount of Fos activity than saline (p<0.01). Fos expression after 0.1, 0.4 and 1.0mg/kg
nicotine was not significantly difference from saline. Further analysis of the effects of
region at each of the 4 doses of nicotine revealed that there was a significant effect of
region after 0.4 (p<0.01) and 0.8mg.kg nicotine (p<0.005). There was no difference
between the VTA and SNc at saline, 0.1 or 1.0mg/kg nicotine.
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Figure 23:   Substantia nigra pars compacta
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Figure 24:   Ventral tegmental area
Figure 25: TH labelling in the SNc and VTA after chronic nicotine.
Mean and standard error of the percent difference in TH labelling from the saline treated
control animal to the matched nicotine treated animal for each dose of chronic nicotine.
Nicotine had no significant effect on TH labelling.
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Figure 26: Fos expression in the SNc and VTA after chronic nicotine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of chronic nicotine. Fos
expression in the SNc and VTA together was significantly increased after 0.4mg/kg nicotine
compared with either saline or 0.1mg/kg nicotine.
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Figure 27: Double labelling of TH and Fos in the SNc and VTA after chronic
nicotine.
Mean and standard error of percent of Fos labelled neurons that are also TH labelled after
each dose of chronic nicotine. 0.8mg/kg nicotine induces significantly more double labelling
in the SNc and VTA together than either saline of 0.4mg/kg nicotine. Significantly more
double labelling of Fos and TH occurs in the VTA than in the SNc.
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Figure 27 shows that the majority of double labelling of Fos activity and TH labelling
in the dopaminergic midbrain occurred in the VTA not the SNc. Almost no double
labelling of TH and Fos was found in the SNc (Figure 23). In the VTA (Figure 24),
double labelling was not only found to increase with dose of nicotine, but the location
of double labelled neurons after 0.4 (Figure 24C) and 0.8mg/kg (Figure 24D) nicotine
spread in both a dorsal and ventral direction, compared with double labelled neurons
found after saline (Figure 24A) or 0.1mg/kg nicotine (Figure 24B). In both regions the
0.4, 0.8 and 1.0mg/kg doses of nicotine induced more activity than saline or 0.1mg/kg.
Within subjects analysis revealed a significant main effect of region (F1,25 = 229.39,
p<0.001), indicating that all doses of nicotine had a significantly larger effect in the
VTA. There was no interaction between region and dose of nicotine (F4,25 = 2.15, ns).
Between subjects analysis revealed that there was also a significant effect of nicotine
dose on Fos activity in TH labelled neurons (F4,25 = 4.64, p<0.01). Post-hoc Bonferroni
tests show that the 0.8mg/kg dose of nicotine induced significantly more Fos activity in
TH containing neurons than either saline (p<0.01) or 0.1mg/kg nicotine (p<0.01).
Double labelling of TH and Fos after 0.1, 0.4 or 1.0mg/kg nicotine was not
significantly from that after saline.
5.3 Discussion
The aim of this experiment was to determine the dose of nicotine that would result in
sensitization after 5 days and subsequently if sensitization would increase cholinergic
and dopaminergic activity in the cholinergic region of the mesopontine tegmentum and
the dopaminergic midbrain, compared with animals that did not sensitize to nicotine.
Locomotor activity was tested after repeated exposure to one of four doses of nicotine
or a control saline group. 0.1mg/kg nicotine was found not to have any effect on
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locomotion over the 5 days of testing compared with saline. 1.0mg/kg nicotine initially
depressed locomotor activity on day 1 but recovered to normal baseline levels by day 5
but did not enhance locomotor activity. This indicates that sensitization did not occur
after 0.1 or 1.0mg/kg nicotine. 0.4 and 0.8mg/kg nicotine had a similar effect on
locomotor activity: activity was initially depressed on day 1, but had returned to the
normal baseline level, shown by saline controls, by day 2. On day 5 locomotion of both
the 0.4 and 0.8mg/kg groups was significantly greater that saline or 0.1mg/kg nicotine.
This increased locomotor response to the same dose of nicotine on each subsequent day
was thought to be the result of increased sensitivity of dopamine neurons in the
mesolimbic system. Fos expression in all four regions measured was found to correlate
with locomotor activity between 10 and 30 min after injections.
A significant effect of region was found on bNOS labelling, suggesting that nicotine
had a greater effect on bNOS labelling in the LDTg than in the PPTg. It is possible that
some sections were damaged during processing resulting in an inaccurate count.
Overall, the dose of nicotine had no effect on bNOS labelling. TH labelling in the
midbrain was unaffected by nicotine dose.
Although both the 0.4 and 0.8mg/kg nicotine groups showed locomotor sensitization,
only the 0.8mg/kg induced significantly more neural activity, measured by Fos
expression, than doses that did not result in sensitization: saline, 0.1 and 1.0mg/kg
nicotine. Both the LDTg and PPTg saw a dose response pattern in Fos activity, with
0.8mg/kg nicotine inducing significantly more activity than saline or 0.1mg/kg nicotine
in both regions. Fos expression after 1.0mg/kg nicotine was similar to baseline levels,
as measured by Fos expression after saline. There was almost no activity in cholinergic
neurons, indicated by the lack of bNOS and Fos double labelling.
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In the midbrain significantly more Fos activity was found in the VTA than in the SNc.
The VTA saw a significant increase in activity at 0.8mg/kg compared with saline. 0.4
and 1.0mg/kg nicotine showed an increase in Fos expression compared with saline
controls, but this was not significant. In the SNc, there was an equal increase in Fos
activity at 0.4, 0.8 and 1.0mg/kg nicotine compared with saline or 0.1mg/kg nicotine,
but it was not a significant increase. While there was almost no activity in TH positive
neurons in the SNc, approximately 20% of the total Fos activity after 0.8mg/kg nicotine
occurred in TH positive neurons, a significant increase over saline and 0.1mg/kg
nicotine. Both 0.4 and 1.0mg/kg nicotine increased double labelling over saline induced
double labelling but this was not significant. Although it was not quantified the double
labelling that occurred in the VTA after saline and 0.1mg/kg nicotine seemed to be
restricted to the IF. After 0.4 or 0.8mg/kg nicotine, double labelling seemed to spread to
the PN and PBP. It is possible that increasing doses of nicotine not only increase
dopamine activity, but recruit different populations of neurons within the VTA. This
may be functionally significant as different regions of dopamine neurons in the VTA
are thought to project to different regions of the brain.
In summary, both 0.4 and 0.8mg/kg nicotine resulted in significantly increased
locomotor activity after 5 days compared with saline controls, but only the 0.8mg/kg
nicotine induced significantly more Fos expression in the LDTg/PPTg or SNc/VTA
than saline controls. Both the 0.4mg/kg nicotine, which did show behavioural
sensitization, and 1.0mg/kg nicotine, which failed to sensitize in the 5 days of testing,
did not significantly increase Fos expression in any of the regions measured. Fos
expression was not induced by nicotine in the cholinergic neurons of the LDTg and
PPTg. Double labelling of Fos expression and TH labelled neurons did increase after
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0.8mg/kg nicotine, but the overall level of Fos expression in these presumed
dopaminergic neurons was low.
These results confirm previous findings of enhanced locomotor activity due to nicotine
sensitization (Benwell & Balfour, 1992; Alderson et al., 2005). It has been found
previously that a dose of nicotine injected intra-tegmentally that increased locomotion,
also resulted in a significant increase in NAcc activity, while a dose that had no effect
on locomotor activity also failed to stimulate Fos activity (Panagis et al., 1996). This is
similar to the present results as both the 0.1 and 1.0mg/kg nicotine failed to result in
behavioural sensitization, and also failed to increase Fos activity above baseline in any
of the regions examined. Both the 0.4 and 0.8mg/kg doses of nicotine, which
significantly increased locomotor activity after 5 days, increased Fos expression above
baseline levels but this was only significant after 0.8mg/kg nicotine. It is likely that the
mesolimbic system is slower to sensitize to the lower dose of 0.4mg/kg nicotine. Many
of the studies that have found sensitization after 0.35 or 0.4mg/kg nicotine have used a
procedure that lasted 7-14 days and involved giving multiple injections per day, rather
than the 1 injection per day over 5 days as used here (Mathieu-Kia et al., 1998; Shim et
al., 2001). This may also be true for the 1.0mg/kg dose of nicotine as although
locomotor activity failed to reach even baseline levels, it did increase somewhat over
the 5 days of testing.
This is the first time that Fos expression has been examined in the cholinergic regions
of the mesopontine tegmentum following chronic nicotine. The increase in Fos
expression with the increasing doses of nicotine and subsequent increases in locomotor
activity is consistent with the fact that the LDTg is thought to regulate VTA activity
and the resulting behavioural changes (Blaha et al., 1996; Forster et al., 2002). Lesions
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in both the pPPTg and the LDTg have been shown to blunt the locomotor response to
nicotine so that there was no difference in behaviour regardless of whether animals had
been given saline or nicotine (Alderson et al., 2003a; Alderson et al., 2005). This
suggests that the LDTg and pPPTg are critical in modulating sensitization to nicotine. It
is possible that the Fos expression seen after chronic nicotine reflects activity in the
neurons that regulate nicotine-induced locomotor activity. It has been hypothesized that
the regulatory effect of the LDTg and PPTg on midbrain dopamine neurons originates
from cholinergic neurons. The increased Fos expression in non-cholinergic neurons
after chronic nicotine indicates that it may by the glutamate projections that regulate
nicotine induced changes in dopamine neuron activity. This is consistent with evidence
that burst firing is dependent on EAA projections, which originate at least in part in the
mesopontine tegmentum (Lodge & Grace, 2006). Indeed, nicotine is able to increase
glutamate levels in the VTA by activation of a7 nAChRs (Schilstrom et al., 2000c).
This suggests that nicotine activates dopamine neurons via pre-synaptic mechanisms
either in local glutamatergic neurons or glutamatergic projections from the LDTg and
PPTg
There is a direct relationship between the mesolimbic dopamine system and drugs of
abuse, and therefore substantial research into the effects of chronic nicotine
administration on midbrain regions has been carried out. Despite this, Fos activity has
never previously been reported in the VTA or SNc after chronic nicotine. Not only did
Mathieu-Kia et al ., (1998) find no Fos expression in TH positive neurons, they
reported a complete absence of any activity, as measured by Fos expression, in the
VTA and SNc. This is surprising given that the VTA is the source of the excitatory
projections that are thought to sensitize in response to chronic nicotine (Nisell et al.,
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1994; Panagis et al., 1996). It is also inconsistent with the results found in this
experiment. Not only did the VTA contain widespread Fos expression in control
animals (389.2 ± 53.3), but activity was significantly increased in the VTA of animals
given nicotine, to approximately 567.8 (± 73.1) after 0.4mg/kg nicotine and to 663 (±
72.6) after 0.8mg/kg nicotine. However, given that there was approximately 2500-3000
dopamine neurons in the sample region that Fos was counted, only a minority of
dopamine neurons were activated.
Results from this experiment are consistent with previous results suggesting that the
mesolimbic system sensitizes to nicotine much more readily than the nigrostriatal
system. Significantly more nicotine induced activity was found in the VTA compared
with the SNc. Mathieu-Kia et al., (1998) found significant increases in activity in both
the core and shell of the NAcc, but no changes in striatal activity. Benwell & Balfour,
(1997) also found that nicotine pre-treatment increased dopamine release in the NAcc.
It is possible that the increased sensitivity of the NAcc to nicotine is the result of the
increased activity, visualised by the difference in Fos expression, in the VTA compared
with the SNc.
Despite the robust increases in dopamine release found in the NAcc (Benwell &
Balfour, 1992) as well as in the VTA (Rahman et al., 2003) after chronic nicotine, the
majority of Fos activity found in this experiment was in non-dopamine neurons.
Considering that locomotor activity is thought to depend on the activation of dopamine
neurons in the midbrain, the lack of activity is surprising. This leads to two possible
conclusions: firstly that locomotor activity in fact depends on non-dopaminergic
activity, or secondly that Fos expression is unable to measure the full magnitude of
dopamine activity in the midbrain. However, this second explanation is unlikely given
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that a number of dopamine neurons did show Fos expression, especially in the VTA.
5.4 Comparison of Fos expression after acute or chronic nicotine
The aim of these experiments was to determine the pattern of activation that occurs in
the SNc/VTA and the LDTg/PPTg after acute or chronic systemic nicotine. Double
labelling of Fos expression and antibodies selective for neurochemicals in specific
neuronal populations allowed not only the localisation of neural activity but also
identification of the type of cell activated. By comparing activation after acute and
chronic nicotine, the changes that occur from the initial dose of nicotine to the
sensitization of the system were catalogued for the first time in both the cholinergic
regions of the mesopontine tegmentum and the dopaminergic midbrain. After rats were
given acute nicotine, the pattern of total Fos expression was in most regions a dose
response curve in the shape of an inverted U, with the largest increase in activity
occurring after 0.4mg/kg nicotine, with 0.8mg/kg nicotine resulting in a much lesser
increase. The only exception to this was in the PPTg, where nicotine induced activity
was the same regardless of nicotine dose. In the LDTg and PPTg, this increase in
activity was almost entirely non-cholinergic as less than 1% of activated neurons were
also labelled with bNOS. In the midbrain only 20% of Fos activity was labelled with
TH, although there was a significant increase in Fos expression in TH positive neurons
after 0.8mg/kg nicotine.
After chronic nicotine, the pattern of Fos activity was also a dose-response curve in an
inverted U shape. However, the dose that showed the greatest increase in activity
changed from 0.4 to 0.8mg/kg nicotine. In the LDTg, PPTg and VTA only 0.8mg/kg
nicotine induced significantly more activity than was induced in saline control animals,
while in the SNc there was no significant increase in activity after any dose of nicotine.
111
In the LDTg and PPTg, once again activity was almost entirely non-cholinergic, while
in the SNc and VTA, although the majority of activated neurons were non-
dopaminergic, there was a significant increase in dopamine activity after 0.8mg/kg
nicotine. While Fos induction in the LDTg and PPTg as well as the SNc and VTA has
previously been examined after nicotine administration (Pang et al., 1993; Mathieu-Kia
et al., 1998; Lanca et al., 2000b), this is the first time this has been verified by looking
at multiple regions within the same animal. It is also the first time this has been
demonstrated using the matched pair design. This means that baseline Fos induction, as
well as Fos not specific to nicotine, can be subtracted out.
In the mesopontine tegmentum the amount of activity in cholinergic neurons did not
change after chronic nicotine compared with one acute dose of nicotine, however the
pattern of activity in non-cholinergic neurons did change. After one dose of nicotine
0.4mg/kg was most effective at increasing activity while after five doses of nicotine it
was the 0.8mg/kg dose of nicotine that significantly increased activity. The same was
true of activation of non-dopaminergic neurons in the midbrain, all doses of chronic
nicotine reduced activity compared with acute nicotine except 0.8mg/kg which was
most effective at increasing activity. While the largest increase in the mesopontine
tegmentum was approximately 40% regardless of whether nicotine was given acutely or
chronically, in the midbrain the largest increases after acute nicotine were greater
(94%) than those after chronic nicotine (71%).
To summarise, chronic injections reduced nicotine induced activity compared with an
acute injection at both the 0.1 and 0.4mg/kg doses. The most striking difference
between acute and chronic nicotine was the increase in activity found after 0.8mg/kg.
After acute nicotine there was always a smaller increase in activity after 0.8mg/kg than
112
after 0.4mg/kg, but after chronic nicotine the increase seen after 0.8mg/kg nicotine was
always greater than that found after 0.4mg/kg nicotine. The amount of double labelling
seen in both the LDTg and PPTg was similar regardless of whether animals had been
treated with acute or chronic nicotine as neither had any effect on cholinergic activity,
measured by Fos/bNOS double labelling. In the midbrain, chronic nicotine resulted in
an increase in dopaminergic activity by approximately 5% at every dose except
0.1mg/kg despite the fact that at doses lower than 0.4mg/kg total nicotine induced
activity is actually decreased by chronic nicotine. After 0.8mg/kg both total nicotine
induced Fos activity and double labelling were increased. This indicated that dopamine
neurons could play a more significant role in the response to chronic nicotine than to
acute nicotine. However since this increase also occurred in animals treated with saline
this seemed unlikely. It is possible that the location of activated dopamine neurons was
important in determining sensitization to nicotine. After acute nicotine the majority of
double labelling was found in the IF. This was similar to results found after chronic
saline or 0.1mg/kg nicotine. Only after 0.4 or 0.8mg/kg was double labelling found
throughout the VTA, in the IF as well as the PN and PBP subregions.
As well as the pattern of activated neurons, the type of locomotor behaviour elicited by
acute and chronic nicotine was very different. Locomotor activity was not measured in
the animals given acute nicotine, however it was measured in a pilot group of animals
in order to test the effects of saline and the 3 doses of nicotine on locomotor activity
before Fos was measured. Both the 0.4 and 0.8mg/kg doses of nicotine showed a
reduction in locomotor activity compared with saline and 0.1mg/kg nicotine although it
was not a significant amount. This was consistent with other studies carried out in this
lab (Alderson et al., 2005). When locomotor activity was tested during the chronic
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nicotine procedure, a similar depressant effect of nicotine was found after the first few
doses. Despite the reduction in locomotor activity after acute nicotine there was an
increase in the amount of neural activity, compared with the saline controls. Locomotor
activity was tested each day during the chronic nicotine procedure. Animals gradually
sensitized over the 5 days so that by day 4, both the 0.4 and 0.8mg/kg doses of nicotine
induced significantly more locomotion than either saline or 0.1mg/kg nicotine. It was
possible that the increasing amount of Fos expression with increasing dose of nicotine
after chronic injection was simply due to increased locomotor activity after each dose,
however the 0.4mg/kg dose of acute nicotine, which depressed locomotor activity, also
showed large increases in neural activity in the midbrain. The fact that Fos expression
was only significantly increased after 0.8mg/kg while locomotor activity was
significantly increased after both the 0.4 and 0.8mg/kg doses of nicotine also made it
unlikely that the increased Fos expression simply corresponded to increased locomotor
activity. It may be that the high doses of acute nicotine which depressed locomotor
activity showed increased activity in inhibitory neurons while the high doses of chronic
nicotine which showed sensitized locomotor activity induced activity in excitatory
neurons but this is impossible to determine without further experiments.
Although there was a big change found in the pattern of activity after chronic nicotine
compared with acute nicotine the identity of the neurons activated has yet to be
determined. The remaining neurons, non-cholinergic neurons in the mesopontine
tegmentum and non-dopaminergic neurons in the midbrain, are likely to be both
GABAergic and glutamatergic. Both GABAergic and glutamatergic neurons have been
found interdigitated with the cholinergic neurons of the mesopontine tegmentum and
the dopaminergic neurons of the midbrain (Ford et al., 1995; Yamaguchi et al., 2007),
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so it is possible that the Fos expression in these regions reflects activity in one or both
of these populations.
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Chapter 7: Fos expression in the mesopontine tegmentum and midbrain after d-
amphetamine administration
7.0 Introduction
In Experiment 2 “Fos expression after chronic nicotine administration”, Fos expression
in the LDTg, PPTg, SNc and VTA was found to be significantly increased after
0.8mg/kg nicotine compared with saline controls. Both 0.4 and 0.8mg/kg nicotine had a
large impact on locomotor activity and by day 5 activity was significantly greater than
both saline controls and initial activity on day 1. Changes in activity in dopamine
neurons in the midbrain have been associated with psychostimulant induced changes in
locomotor activity (Panagis et al., 1996; Louis & Clarke, 1998) so it is possible that the
changes in Fos expression simply reflect the increase in locomotor activity. The aim of
this experiment was to determine whether stimulating locomotion with an acute dose of
d-amphetamine was sufficient to increase levels of Fos expression in the mesopontine
tegmentum and midbrain.
When given acutely d-amphetamine is a powerful stimulant. Typically, researchers
looking at the effects of d-amphetamine on locomotor activity or reinforcement use a
dose of 1.5mg/kg (Robbins & Iversen, 1973; Forster et al., 2002; Miller et al., 2002;
Alderson et al., 2003b). However, d-amphetamine doses as low as 0.125mg/kg and as
high as 10mg/kg have been shown to increase locomotor activity over and above saline
(Grilly & Loveland, 2001). A number of studies have systematically evaluated the
dose-response relationship of d-amphetamine. Simpson, (1974) used 4 doses of d-
amphetamine from 0.1mg/kg to 1.0mg/kg and found that while 0.5 and 1.0mg/kg
increased locomotion, the smaller doses, 0.1 and 0.25mg/kg, had little effect.
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Considerable variability between animals in the total amount of activity stimulated by
d-amphetamine was also observed. Similarly, Holtzman, (1974) found that 0.1mg/kg to
10mg/kg d-amphetamine increased locomotor activity above saline, but that 3.0mg/kg
had the greatest effect. However, the activity levels reported were based on 6
observations of each animal so the results can not be equated with drug naïve animals.
Winn et al., (1982) also examined the effect of graded doses of d-amphetamine ranging
from 0.125-4.0mg/kg on locomotion, and found that all doses significantly increased
locomotor activity over saline controls.
The locomotor effects of d-amphetamine are thought to be due to changes in dopamine
release in the mesolimbic system. 1.5mg/kg d-amphetamine has been shown to increase
dopamine efflux in the NAcc and dorsal striatum by over 500% (Forster et al., 2002;
Miller et al., 2002). Direct injections of d-amphetamine into the NAcc also results in
increased locomotion indicating the NAcc as a possible site of action for d-
amphetamine (Druhan et al., 1993). Lesions in the NAcc, but not the striatum have
been shown to abolish the hyper-locomotor response to d-amphetamine (Kelly et al.,
1975). The cholinergic region of the mesopontine tegmentum has also been implicated
in the sensitization of d-amphetamine. A single dose of d-amphetamine was enough to
activate number of neurons in the LDTg and PPTg that were also retrogradely labelled
from the VTA (Colussi-Mas et al., 2007). Lesions in both the LDTg and PPTg have
been found to result in increased NAcc and striatal dopamine efflux (Forster et al.,
2002; Miller et al., 2002), but have also been shown to attenuate behavioural
sensitization to d-amphetamine (Alderson et al., 2003b; Nelson et al., 2007). These data
implicate the mesopontine tegmentum-VTA-NAcc pathway in the sensitization of d-
amphetamine.
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The type of equipment used to measure locomotor behaviour has been updated since
the early 1980’s. For example, the equipment used by Winn et al., (1982) measured
locomotor activity with 6 microswitches activated by pressure on floor panels. The
modern equipment used in this experiment used 22 infrared beams to monitor
behaviour which allows for much more detailed analysis of activity. A pilot study of the
dose-response relationship of d-amphetamine was undertaken using a range of doses
from 0.14-0.6mg/kg. Results showed that the 0.14, 0.25 and 0.60mg/kg doses had little
effect on locomotor activity in these test circumstances, while both the 0.4 and
0.5mg/kg doses increased locomotor activity by approximately 40 and 85%
respectively. Why the highest dose of d-amphetamine failed to stimulate activity is
unknown, but only a small sample of animals were used. Because a dose was required
that produced a similar increase in locomotion to nicotine sensitized animals, three
doses were chosen close to the 0.4mg/kg dose of d-amphetamine.
It was hypothesized that stimulation of midbrain dopamine neurons by acute d-
amphetamine would lead to increased Fos expression. Two questions followed from
this: (1) to what extent did a low dose of d-amphetamine stimulate locomotor activity
and (2) what was the extent and type of activity incurred by d-amphetamine in the
LDTg, PPTg, SNc, and VTA. In order to test this hypothesis animals were given an
acute dose of 0.35, 0.40 or 0.45mg/kg d-amphetamine.
7.1 Methods
7.1.0 Animals
12 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 350-450g
were used in this experiment.
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d-amphetamine N
Group 1 0 mg/kg 3
Group 2 0.35 mg/kg 3
Group 3 0.40 mg/kg 3
Group 4 0.45 mg/kg 3
Total 12
7.1.1 Experimental procedure
Experimental procedure used was ‘Fos induction with locomotor activity’ as described
in General Methods.
7.1.2 Histological Analysis
Histological analysis was performed as described in the General Methods. Sections
were double labelled for either Fos (1:8000, made in rabbit, Oncogene Science, PC38)
and bNOS (1:1000, made in mouse, Sigma) or Fos and TH (1:25,000, made in mouse,
Chemicon). Secondary antibody was either anti-rabbit (Vectastain) or anti-mouse
(Sternburgers Monoclonals, USA); and the PAP was also anti-mouse (Sternburgers
Monoclonals, USA).
7.1.3 Quantification & Statistics
Cell Quantification and subsequent statistical analysis was performed as described in
the General Methods.
7.2 Results
7.2.0 Locomotor Activity
Locomotor activity did not change significantly during a week of habituation to the
locomotor testing chambers (F5,55 = 0.61, ns) so the data were combined to provide a
Figure 28: Locomotor Activity during habituation to d-amphetamine.
Locomotor Activity during habituation to d-amphetamine: Mean and standard error of beam
breaks made in a 1hr period over 6 days. Saline injections were given on days 3-6. There was
no significant effect of habituation.
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Figure 29: Locomotor Activity after average habituation or d-amphetamine.
Locomotor Activity after average habituation or d-amphetamine: Mean and standard error of
beam breaks made in a 1hr period for habituation and drug at each dose of d-amphetamine.
There was a significant effect of day but not dose of d-amphetamine.
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baseline with which to compare any changes in activity due to drug administration
(Figure 28). As seen in Figure 29 the levels of locomotor activity were increased in all
groups including the saline control group after drug administration. D-amphetamine
increased the levels of locomotion above that of the saline group so that activity after
0.45mg/kg d-amphetamine was almost double that found after saline. This was not a
statistically significant increase, possibly due to the high variability in response to the
drug. A repeated measured day x dose ANOVA on the number of beam breaks revealed
a significant main effect of day (F1,8 = 20.85, p<0.005), but no effect of d-amphetamine
dose (F3,8 = 1.71, ns). There was no significant day x dose interaction (F3,8 = 1.33, ns).
This overall effect of day indicated that, compared with habituation, locomotor activity
on the day of drug treatment was increased regardless of the dose of d-amphetamine.
7.2.1 LDTg and PPTg
bNOS
The number of bNOS labelled neurons in the LDTg and PPTg seemed to be reduced by
d-amphetamine (Figure 31). However, this was probably due to the fact that animals in
the 0.4mg/kg d-amphetamine group had several damaged sections (which may have
occurred during sectioning or during the staining of the sections) that led to a drop in
the number of bNOS labelled neurons counted. Within subjects analysis showed no
effect of region (F1,8 = 0.41, ns) and no interaction between region and dose (F3,8 = 0.26,
ns). Between subjects analysis showed no effect of dose (F3,8 = 3.86, ns) on the number
of bNOS labelled neurons.
Total Fos
The effects of d-amphetamine had a similar inhibitory effect on Fos expression in the
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Figure 31: bNOS labelling in the LDTg and PPTg after acute d-amphetamine.
Mean and standard error of the percent difference in bNOS labelled neurons from the saline
treated control animal to the matched nicotine treated animal for each dose of d-
amphetamine. D-amphetamine had no significant effect on bNOS labelling in the LDTg or
PPTg
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Figure 32: Fos expression in the LDTg and PPTg after acute d-amphetamine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of d-amphetamine. D-
amphetamine had no significant effect on Fos expression in the LDTg or PPTg.
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Figure 33: Double labelling of bNOS and Fos in the LDTg and PPTg after acute d-
amphetamine.
Mean and standard error of percent of Fos labelled neurons that are also labelled by bNOS in
the LDTg and PPTg after each dose of d-amphetamine. D-amphetamine had no significant
effect on double labelling in the LDTg or PPTg.
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LDTg and PPTg at the two lower doses of 0.35 and 0.40mg/kg compared with the
effects of saline(Figure 30). Figure 32 demonstrated that at the higher dose of
0.45mg/kg d-amphetamine, the inhibitory effect was reduced in the LDTg and there
was an increase of Fos expression in the PPTg. Within subjects analysis revealed no
effect of region (F1,8 = 1.22, ns) and no interaction effects (F3,8 = 1.42, ns). Between
subjects analysis showed than there was also no significant effect of dose (F3,8 = 1.77,
ns).
Double labelling of bNOS and Fos
Figure 33 illustrated that less than 1% of cholinergic neurons were activated by d-
amphetamine, regardless of the dose used. Within subjects analysis revealed no main
effect of region (F1,8 = 1.64, ns) and no interaction effect (F3,8 = 1.01, ns). Between
subjects analysis showed no effect of dose (F3,8 = 0.89, ns) on the amount of double
labelling in the mesopontine tegmentum.
7.2.2 SNc and VTA
TH
Figure 35 demonstrated that d-amphetamine had no effect on TH expression in the
midbrain. The results of a one way ANOVA showed that d-amphetamine had no
significant effect on the number of TH labelled neurons in the midbrain (F3,4 = 0.99,
ns).
Total Fos
D-amphetamine had a dose dependent effect on Fos expression the midbrain. Although
the total amount of Fos expression was greater in the VTA (data not shown), the
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Figure 34:   Substantia nigra pars compacta & ventral tegmental area
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Figure 35: TH labelling in the SNc and VTA after acute d-amphetamine.
Mean and standard error of the percent difference in TH labelling from the saline treated
control animal to the matched nicotine treated animal for each dose of d-amphetamine. D-
amphetamine had no significant effect on TH labelling.
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Figure 36: Fos expression in the SNc and VTA after acute d-amphetamine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each dose of d-amphetamine. The
change in Fos expression was significantly greater in the SNc than the VTA. Overall
0.35mg/kg d-amphetamine significantly reduced Fos expression below control saline levels.
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Figure 37: Double labelling of TH and Fos in the SNc and VTA after acute d-
amphetamine.
Mean and standard error of percent of Fos labelled neurons that are also TH labelled after
each dose of d-amphetamine. There was significantly more double labelling in the VTA than
in the SNc. Dose of d-amphetamine had no effect on double labelling of TH and Fos.
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percent difference from saline to d-amphetamine was larger in the SNc than in the
VTA. As illustrated in Figure 36, the smallest dose of d-amphetamine had the largest
effect. Fos expression was inhibited in both the SNc and VTA (Figure 34). As the dose
of d-amphetamine increased the number of cells expressing Fos increased but was not
increased over and above the levels induced by saline. Within subjects analysis showed
a significant main effect of region (F1,8 = 13.78, p<0.01) which indicated that d-
amphetamine had a greater effect on Fos expression in the SNc than in the VTA. There
was no significant interaction between the effects of region and dose (F3,8 = 1.67, ns).
Between subjects analysis revealed a significant effect of dose alone (F3,8 = 4.57,
p<0.05). Post-hoc Bonferroni tests revealed that 0.35mg/kg d-amphetamine induced
significantly less activity than saline (p<0.05).
Double labelling of TH and Fos
D-amphetamine induced very little Fos expression in TH labelled neurons in the SNc,
but there was some Fos expression in TH labelled neurons in the VTA. However, as
seen in Figure 37, the dose of d-amphetamine did not change the level of Fos
expression. Within subjects analysis revealed a significant main effect of region (F1,8 =
94.98, p<0.001), indicating that all doses of d-amphetamine had a significantly larger
effect in the VTA than in the SNc. There was no interaction effect (F3,8 = 0.12, ns).
Between subjects analysis revealed that there was no significant effect of dose (F3,8 =
0.065, ns).
7.3 Discussion
The aim of this experiment was to determine if Fos expression in the LDTg, PPTg, SNc
and VTA were the result of increased locomotor activity. Animals were given acute
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systemic d-amphetamine at a very low dose to stimulate the low levels of locomotor
activity equivalent to those found after behavioural sensitization to nicotine. It was
hypothesized that if Fos expression after chronic nicotine was due to increased
locomotor activity then acute d-amphetamine might result in similar increases in Fos
expression.
The low doses of d-amphetamine used in this experiment were found to be sufficient to
increase locomotor activity. The intention was to find a dose of d-amphetamine that
increased locomotion by 35-50% as was found after 5 days of sensitization to nicotine.
This was successful as the three doses of d-amphetamine, 0.35, 0.40 and 0.45, were
found to increase locomotor activity by 50, 39 and 85% respectively. Although this was
not a significant increase in activity compared with saline control animals, this was
probably due to the fact that only 3 animals were used per group resulting in low
statistical power.
Results from the LDTg and PPTg suggested that bNOS expression was not
significantly altered by acute d-amphetamine although all three doses resulted in
slightly reduced bNOS labelling. This slight reduction was probably due either to
damage to sections preventing an accurate count, or a change in the strength of staining
for bNOS which could be due to a number of factors during the immunohistochemical
procedure. D-amphetamine had no significant effect on the total amount of Fos
expression in the LDTg and PPTg, but again there was a slight reduction in labelled
neurons which, considering the similar effect after bNOS labelled neurons could be due
to damaged sections preventing an accurate count. There was no effect of d-
amphetamine on the number of cholinergic neurons that expressed Fos. Almost all
neural activity, as measured by Fos, occurred in non-bNOS labelled neurons.
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There was no effect of d-amphetamine on TH labelling in the midbrain. In both the SNc
and VTA the total amount of Fos expression was inhibited by acute d-amphetamine,
although this did lessen slightly as the dose increased. The amount of Fos expressed in
dopaminergic neurons was greater in the VTA than in the SNc, but the dose of d-
amphetamine had no effect on double labelling of Fos and TH. The majority of Fos
expression occurred in non-TH labelled neurons.
A previous experiment that examined neural activity after d-amphetamine consistently
found increased levels of Fos expression throughout the brain, including the NAcc and
LDTg/PPTg (Colussi-Mas et al., 2007). D-amphetamine has also been shown to
increase both dopamine release and Fos expression in the NAcc and to a lesser extent in
the dorsal striatum (Di Chiara & Imperato, 1988; Graybiel et al., 1990; Johansson et al.,
1994). However, these experiments used much larger doses of d-amphetamine ranging
from 1.0 to 5.0mg/kg. It is possible that the inhibitory effect of d-amphetamine on Fos
expression found in this experiment may to be restricted to very low doses.
The inhibition of activity in the SNc and VTA is thought to be due to the fact that acute
d-amphetamine increases dopamine efflux in the NAcc and striatum. Acute stimulation
in the NAcc by d-amphetamine is thought to activate a feedback loop to the midbrain,
inhibiting these neurons from further activity (Bunney et al., 1973). When the tail of the
caudate nucleus was lesioned, even a potentially lethal dose of d-amphetamine failed to
depress activity in the SNc (Bunney & Achajanian, 1976). It is this regulatory
mechanism that may be inhibiting Fos expression in the midbrain after acute d-
amphetamine.
Despite the small increases in locomotion that occurred after acute administration of d-
amphetamine the total amount of Fos expression in the SNc and VTA was significantly
124
reduced. Chronic nicotine, on the other hand resulted in a significant increase in Fos
expression in both the LDTg/PPTg and the SNc/VTA after similar increased levels of
locomotor activity to that found after acute d-amphetamine. This indicated that the
increased Fos expression found after sensitization to nicotine was unlikely to be
attributable to the locomotor activating effects of the drug.
The different effects of nicotine and d-amphetamine are unlikely to be due to different
modes of action within the brain as pre-treatment with a dose of nicotine that results in
behavioural sensitization also results in enhanced locomotor activity in response to d-
amphetamine, but not to cocaine (Birrell & Balfour, 1998). This suggests that the
locomotor stimulant effects of both nicotine and d-amphetamine depend upon the same
neural system. Both nicotine and d-amphetamine have been shown to enhance
dopamine efflux in the NAcc (Benwell & Balfour, 1992; Fu et al., 2000; Forster et al.,
2002; Miller et al., 2002) suggesting the NAcc is an important site of action for both
drugs.
If the increased Fos expression after chronic nicotine was the result of increased motor
activity, then it would be expected that a similar increase would be seen after the
increases in locomotor activity induced by d-amphetamine. However, in contrast to
results found after chronic nicotine, d-amphetamine inhibited Fos expression in all four
regions examined: the LDTg, PPTg, SNc and VTA. D-amphetamine was showed to
simultaneously increase locomotor activity and suppress Fos expression in the midbrain
indicating that activation of Fos in neurons in the SNc and VTA was not necessary for
motor activity to occur.
125
Chapter 8: Nicotine induced Fos expression after pre-treatment with haloperidol
8.0 Introduction
In Experiment 1: “Fos expression after acute nicotine administration”, it was found that
the majority of activated neurons in the SNc and VTA after nicotine stimulation were
not TH-containing neurons. This is surprising considering that a number of studies have
shown increased dopamine release in the SNc and VTA, and in terminal regions, as a
result of nicotinic stimulation (Nomikos et al., 2000; Yin & French, 2000; Erhardt et
al., 2002; Rahman et al., 2003; Schilstrom et al., 2004). Additionally, various
experiments, using both in vitro and in vivo methodologies, have found Fos in
dopamine neurons (Maloney et al., 2002; Jomphe et al., 2003). This implies both that
that these neurons do express the c-fos gene and that activity is occurring in these
neurons. A possible explanation for the lack of Fos expression found in dopamine
neurons in the midbrain is that acute nicotine activates an inhibitory mechanism. Two
mechanisms are known to regulate dopamine activity in the midbrain: dopamine
autoreceptors and GABAergic feedback pathways from the striatum (Cragg &
Greenfield, 1997; Cobb & Abercrombie, 2002).
The aim of this experiment was to determine if autoreceptor control was the inhibitory
mechanism preventing Fos expression in dopamine neurons after acute nicotine
stimulation. Autoreceptors are receptors that are sensitive only to the neurotransmitter
released by the neuron on which they sit. Dopamine autoreceptors, thought to be D2-
like (Mercuri et al., 1997), are normally activated by increased dopamine levels in the
extracellular space. G-protein coupled receptors decrease presynaptic Ca2+ entry into
the cell which forestalls activation of the second messenger systems, thus preventing
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Fos expression. This serves as a negative feedback mechanism to prevent the build up
of extracellular dopamine. The timescale of this response is thought to be less than
600ms and maximal between 150 and 300ms (Benoit-Marand et al., 2001). There are
two types of dopamine autoreceptor: presynaptic autoreceptors inhibit the synthesis and
release of dopamine, and somatodendritic autoreceptors which reduce cell firing. The
consequence of both is reduced dopamine release in terminal areas.
Hunt and McGregor (2002) showed that electrical stimulation of the mfb, at a
frequency that supports responding also results in significant increase in Fos expression
in the NAcc and striatum. While a D1 antagonist reduced Fos expression in these
regions, a D2 antagonist increased Fos expression compared with animals receiving no
drug. They also found increases in the VTA but these just failed to reach significance.
Benoit-Marand et al., (2001) also using electrical stimulation of the mfb, showed that
dopamine D2 antagonist, haloperidol almost entirely blocked dopamine autoinhibition
in the dorsal striatum.
Consistent with this evidence showing increased activity in mesolimbic terminal
regions in response to dopamine D2 antagonism, haloperidol also has the effect of
disinhibiting dopamine neurons in the VTA, the source of mesolimbic dopamine
projections (Jomphe et al., 2003). They demonstrated that haloperidol induced Fos
expression in a primary culture of VTA neurons. However it is possible that induction
of Fos expression in the VTA due to D2 antagonism only occurs in cultured neurons
due either to upregulation of receptors or to absent regulatory inputs. However, studies
looking at Fos expression in the midbrain of both rats and monkeys in vivo have
identified D2 antagonist induced Fos expression in dopamine neurons in the VTA, but
not in the SNc (Wirtshafter & Asin, 1995, 1999).
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Electrophysiological studies looking at the interaction of autoreceptors and drug
stimulation have shown that acute cocaine inhibits dopamine release in midbrain
dopamine neurons by stimulation of local autoreceptors (Einhorn et al., 1988). In
contrast, when the system became sensitized to cocaine, D2 dopamine autoreceptors
became sub-sensitive resulting in both an increase in the number of active neurons and
a significantly higher firing rate (Henry et al., 1989). Although there is no cross
sensitization between nicotine and cocaine (Schenk et al., 1991) a common neural
substrate for both has been proposed based on overlapping activation maps of Fos
related antigens in the core and shell of the NAcc, the medial PFC and in the medial
caudate-putamen (Pich et al., 1997). It is possible that acute nicotine similarly inhibits
dopamine neurons in such a way as to prevent stimulation of second messenger
cascades and that this is under the control of autoreceptors.
Balfour and colleagues (1998) have reported a similar response of autoreceptors on the
effects of sensitization to nicotine: while the dopamine D2 antagonist, Raclopride,
increases NAcc dopamine after saline pre-treatment, the effect is abolished if animals
have been pre-treated with nicotine, as receptors become subsensitive. In the striatum, a
region which shows no sensitization to nicotine, there is no difference between the
nicotine and saline pre-treated groups, indicating no change in autoreceptor sensitivity.
The existing evidence suggests that a) sensitization to nicotine and the associated
increase in dopamine activity is related in part to the attenuation of autoreceptor control
in the mesolimbic but not nigrostriatal systems; and b) a D2 autoreceptor antagonist
induces Fos expression, a measure of neural activity, in midbrain dopamine neurons in
vitro and in vivo. From these conclusions it was hypothesised that haloperidol would
block D2 autoreceptor control of dopamine neurons in the VTA, but not the SNc,
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resulting in increased Fos expression in these dopamine neurons in response to acute
nicotine. In populations where activity was not under the control of D2 receptors, for
example the non-dopaminergic populations of the midbrain and in the LDTg and PPTg,
haloperidol was not expected to have any effect.
8.1 Methods
8.1.0 Animals
12 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 320-520g
were used.
Drug n
Group 0.4mg/kg haloperidol + saline 6
Group 0.4mg/kg haloperidol + 0.4mg/kg nicotine 6
Total 12
8.1.1 Experimental procedure
Experimental procedure used was largely the same as described in General Methods:
‘Fos induction without locomotor activity’. A single injection of haloperidol (Sigma,
UK; dissolved in lactic acid, then diluted to 0.4mg/kg) was given subcutaneously in the
flank 30min before injection of nicotine or saline.
8.1.2 Histological Analysis
Histological analysis was performed as described in the General Methods. Sections
were double labelled for either Fos (1:8000, made in rabbit, Oncogene Science, PC38)
and bNOS (1:1000, made in mouse, Sigma) or Fos and TH (1:25,000, made in mouse,
Chemicon). The secondary antibody to Fos was anti-rabbit IgG (Vectastain) and the
secondary antibody to bNOS and TH was anti-mouse IgG (Sternburgers Monoclonals,
USA); the PAP was also anti-mouse (Sternburgers Monoclonals, USA).
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8.1.3 Quantification & Statistics
Cell Quantification was performed as described in the General Methods. The results
from this experiment were compared to results from Experiment 1: ‘Acute Nicotine’.
Analysis was done using planned comparisons to compare changes total Fos expression
after haloperidol pretreatment of nicotine with the increases in total Fos expression
after saline and after 0.4mg/kg acute nicotine alone. Changes in double labeling of Fos
and bNOS or TH were also analyzed using planned comparisons: comparing saline
with haloperidol/saline and haloperidol/nicotine as well as 0.4mg/kg acute nicotine with
haloperidol/saline and haloperidol/nicotine. Haloperidol pretreatment of saline was
included as a group in the analysis of double labeling in order to take into account the
effects of haloperidol alone.
8.2 Results
8.2.0 Mesopontine Tegmentum
Total Fos
In both the LDTg and PPTg pre-treatment with haloperidol negated the effects of
nicotine on Fos expression. Figure 38 showed that when nicotine administration was
preceded by haloperidol the level of Fos expression was reduced back to the baseline
levels found after saline. The high variance was probably due to individual differences
in response to both nicotine and haloperidol, as well as differences in staining and
fixation of the tissue. Planned comparisons showed that haloperidol pre-treatment
followed by nicotine were not significantly different from either saline or nicotine
alone(Figure 6 & 7).
Figure 38: Fos expression in the LDTg and PPTg after haloperidol pre-treatment
and acute nicotine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each drug group. Haloperidol pre-
treatment of 0.4mg/kg nicotine had no significant effect on Fos expression in the LDTg or
PPTg.
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Figure 39: Double labelling of bNOS and Fos in the LDTg and PPTg after
haloperidol pre-treatment and acute nicotine.
Mean and standard error of percent of Fos labelled neurons that are also labelled by bNOS in
the LDTg and PPTg. Haloperidol pre-treatment of 0.4mg/kg nicotine had no significant effect
on double labelling in the LDTg or PPTg.
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Double labelling of bNOS and Fos
Figure 39 illustrates that Fos activity was almost entirely non-cholinergic. Planned
comparisons showed that co-expression of Fos and bNOS in the LDTg and PPTg was
not significantly affected by haloperidol pre-treatment of saline or haloperidol pre-
treatment of acute nicotine, compared with saline or nicotine alone.
8.2.1 Midbrain dopamine Area
Total Fos
In the midbrain, as seen in Figure 40, haloperidol pre-treatment of acute nicotine
administration had a different effect in the SNc and VTA. In the SNc, pre-treatment
with haloperidol negated the effect of nicotine and reduced nicotine induced Fos
expression to baseline levels. Planned comparisons showed no difference between
saline and haloperidol pre-treatment of nicotine, but showed significantly less activity
after haloperidol pre-treatment of nicotine than after nicotine alone (independent
samples t-test; p<0.05). In the VTA there was a different pattern of activity; haloperidol
pre-treatment resulted in less nicotine induced Fos expression than after nicotine alone,
but more than after the saline treatment. However, planned comparisons showed that
activity after haloperidol pre-treatment of acute nicotine was not significantly different
from either saline or nicotine alone (Figure 11 & 12).
Double labelling of TH and Fos
Figure 41 shows that the overall level of co-expression of Fos and TH was greater in
the VTA than in the SNc in all groups. Haloperidol had a large effect on double
labelling in the VTA, but nicotine had no additional effect. In contrast, haloperidol had
Figure 40: Fos expression in the SNc and VTA after haloperidol pre-treatment and
acute nicotine.
Mean and standard error of the percent difference in Fos expression from the saline treated
control animal to the matched nicotine treated animal for each drug group. Haloperidol pre-
treatment of 0.4mg/kg nicotine significantly reduced Fos expression in the SNc but had a
much smaller effect on Fos expression in the VTA.
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Figure 41: Double labelling of TH and Fos in the SNc and VTA after haloperidol
pre-treatment and acute nicotine.
Mean and standard error of percent of Fos labelled neurons that are also TH labelled.
Haloperidol alone had a significant effect on double labelling in both the SNc and VTA
compared with saline and nicotine alone. However, haloperidol pre-treatment of 0.4mg/kg
nicotine had a significant effect on double labelling in the SNc, compared with haloperidol
alone, but there was no significant change in the VTA (see pg 128 for explanation of groups).
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no effect in the SNc before saline, but did potentiate the effect of nicotine.
In the SNc both haloperidol pre-treatment of saline and of nicotine had significantly
more activity than saline alone (Independent samples t-test: hal/saline p<0.01;
hal/nicotine p<0.01) but only haloperidol pre-treatment of nicotine had more double
labelling that after nicotine alone (p<0.05). There was significantly more double
labelling after haloperidol pre-treatment of nicotine than after haloperidol pre-treatment
of saline (p<0.05) which suggested that there was more nicotine induced activity in
dopaminergic neurons of the SNc when autoreceptors are blocked.
In the VTA, activity was significantly greater after haloperidol pre-treatment of
nicotine than either of the non-haloperidol conditions (saline p<0.005; nicotine
p<0.001), but activity was also significantly greater than saline (p<0.001) or nicotine
(p<0.001) after haloperidol and saline. When compared to the increases in activity after
haloperidol and saline, there was no additional effect of nicotine on the percent of
activity that is dopaminergic.
8.3 Discussion
The aim of this experiment was to test whether the lack of dopamine activity, measured
by Fos expression, in the SNc and VTA after acute nicotine stimulation was due to
inhibition from local autoreceptors. It was hypothesised that pre-treatment with
dopamine D2 antagonist, haloperidol, would block dopamine autoreceptors and thus
increase nicotine induced activity in mesolimbic but not nigrostriatal dopamine
neurons. No effect was expected in the non-dopaminergic neurons of the midbrain or in
the LDTg and PPTg as activity was not under the control of dopamine D2 receptors.
Although there was a small decrease in the total amount of Fos expression in the LDTg
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and PPTg, as expected, no significant changes were found in either cholinergic or non-
cholinergic neurons. In the VTA, pre-treatment with haloperidol resulted in a 50%
decrease in non-dopaminergic Fos expression, compared with nicotine alone. Fos
activity in TH labelled neurons was found to be increased over saline alone and
nicotine alone by blocking autoreceptors, but contrary to the hypothesis, nicotine had
no additional effect. In the SNc, the effect of nicotine on non-TH labelled activity, as
measured by Fos expression, was completely blocked by haloperidol. Blocking
autoreceptors again increased Fos expression in TH labelled neurons, but unexpectedly
nicotine did have an additional effect, increasing activity over all other conditions.
These results confirm previous findings as haloperidol alone increased Fos expression
in the VTA but not in the SNc (Wirtshafter & Asin, 1995, 1999). Unexpectedly, there
seems to be a greater sensitivity of dopamine neurons to the interaction of haloperidol
and nicotine in the SNc, part of the nigrostriatal system, than in the VTA, the source of
mesolimbic and mesocortical projections. In the SNc, haloperidol completely
counteracted the effects of nicotine on non-dopaminergic activity, but increased the
effects of nicotine in dopamine neurons. In the VTA, haloperidol only partially
counteracted the effects of nicotine. While haloperidol alone increased Fos expression
in dopamine neurons, nicotine was not able to increase Fos expression in dopaminergic
neurons. Thus, disabling autoreceptors did not lead to a nicotine induced increase in
VTA dopamine activity.
This could be explained by the fact that that the increase in Fos expression found by
Jomphe et al., (2003) after application of haloperidol to primary culture neurons was
thought not to be dependent on D2 receptor mechanisms. A second, more selective D2
receptor antagonist, sulpiride, did not have the same effect on Fos expression as
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haloperidol. Even when D2 receptors were saturated with sulpiride, haloperidol still
induced Fos expression in the VTA dopamine neurons. Fos induction was shown to
require the presence of Ca2+ and activation of sodium channels as well as activation of
calmodulin dependent kinase (CaMK). These finding suggest that haloperidol increases
Fos expression through a D2 independent increase in Ca2+ (Jomphe et al., 2003). Cragg
& Greenfield (1997) found similar results when investigating the VTA. They found that
despite strong autoreceptor control of dopamine terminal regions, D2 autoinhibition
played no part in regulating dopamine release in the VTA. In contrast, they did find
enhanced dopamine release after sulpiride in the SNc. One explanation for haloperidol
induced Fos expression is that the increased activity in dopamine neurons is due to an
increased glutamatergic drive to the midbrain. While systemic injection of haloperidol
increased dopamine in the SNc, intranigral injections had no effect, indicating that the
effects of haloperidol were not local. Glutamatergic input to the midbrain originates in
the STN, PFC and the PPTg. Both CNQX and CPP, glutamate antagonists, blocked the
ability of haloperidol to increase dopamine in the SNc (Cobb & Abercrombie, 2002).
This could explain why systemic haloperidol pre-treatment failed to result in nicotine
induced Fos expression in a substantial number of dopamine neurons.
The hypothesis, based on theories of autoreceptor control of sensitization, predicted that
the greater effect would be in the mesolimbic system as sensitization to nicotine,
thought to related to autoreceptor control, occurs in the mesolimbic but not nigrostriatal
system (Balfour et al., 1998). However, it seems that autoreceptors had a greater
control over dopamine neurons in the SNc than in the VTA. Although blocking
autoreceptors had little effect on dopamine efflux in the midbrain, in the CPu and NAcc
dopamine efflux was increased to 250% of control animals (Cragg & Greenfield, 1997).
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Sensitization to nicotine also results in greater Fos expression in dopamine terminal
regions than in the midbrain (Mathieu-Kia et al., 1998; Shim et al., 2001). It is possible
that sensitization to nicotine occurs due to attenuation of autoreceptor control in
dopamine terminal regions rather than in the midbrain.
One of the problems in speculating about local drug mechanisms after systemic drug
application is that systems outside of the midbrain that project back to the midbrain
could be affected. One such major feedback system in the brain is the basal ganglia,
widely thought to act as an interface between the limbic and motor systems in the brain
(Smith et al., 1998). The model of basal ganglia circuitry contains two pathways, one of
which, the indirect pathway, has been suggested to preferentially express the D2
receptor subtype (Bolam et al., 2000). Consequently when working with haloperidol, a
D2 antagonist, it is important to take this system into consideration. Haloperidol has
been shown to increase activation in the striatum (Cragg & Greenfield, 1997; Benoit-
Marand et al., 2001), which decreases activation in the GP resulting in disinhibition of
the GABA neurons of the SNr. Although it was not quantified, there was a noticeable
increase in the amount of Fos induced by the haloperidol nicotine interaction in the
medial SNr (Figure 42). It is possible that haloperidol induced disinhibition of the
GABA containing SNr neurons reversed the effects of haloperidol on the midbrain
dopamine neurons, resulting in lower Fos expression than would have been expected
after autoreceptor inhibition. Indeed, SNr stimulation has been found to have inhibitory
effects in both the SNc and VTA (Tepper et al., 1995; Paladini et al., 1999; Saitoh et
al., 2004).
Despite the fact that blocking autoreceptors increases Fos expression both in vitro and
in vivo (Wirtshafter & Asin, 1995, 1999; Jomphe et al., 2003), this is not the
Figure 42:  Substantia nigra pars reticulata
Fos expression in the SNr is enhanced after 0.4mg/kg haloperidol pretreatment followed by 0.4mg/kg 
nicotine (A) compared with haloperidol alone (B).
Scale bar = 100µm
A B
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mechanism blocking Fos expression after acute nicotine administration. Considering
the robust increases in dopamine release and in percentage of burst firing found after
acute nicotine (Erhardt et al., 2002; Rahman et al., 2003), it seems likely that there is
another inhibitory mechanism at work in both the VTA and SNc preventing Fos
expression. Cobb and Abercrombie (2002) observed that both GABAA antagonist,
bicuculline, and haloperidol stimulated an increase in nigral dopamine efflux but that
the two drug effects were additive, indicating that there are a number of mechanisms
that are causing the inhibition of Fos induction in the midbrain dopamine areas after
acute nicotine.
136
Chapter 9: Discussion of Fos experiments
9.0 Fos expression after acute or chronic nicotine
Experiment 1 looked at Fos expression in the LDTg and PPTg and the dopaminergic
midbrain after acute systemic nicotine administration. Experiment 1 confirmed
previous findings (Lanca et al., 2000b) that acute systemic nicotine administration did
not activate the cholinergic neurons in the mesopontine tegmentum. In the LDTg and
PPTg, Fos was primarily induced in putative GABAergic and glutamatergic
populations. Contrary to previous reports (Pang et al., 1993; Mathieu-Kia et al., 1998),
Fos expression was induced by acute nicotine in the VTA and SNc. While there was
some activity in dopaminergic neurons, the majority of Fos was found in what are
thought to be GABAerigc and glutamatergic neurons. In all regions except the PPTg,
acute nicotine produced a dose-response curve, in the typical inverted U-shape, with the
largest effect at 0.4mg/kg, while in the PPTg nicotine had a similar effect at all doses
tested.
Experiment 2 measured both locomotor behaviour and Fos expression in the
LDTg/PPTg and SNc/VTA after chronic nicotine. This was the first time Fos
expression was examined in the LDTg and PPTg after chronic nicotine administration.
Behavioural sensitization was found after 0.4 and 0.8mg/kg nicotine, but not after the
highest dose – 1.0mg/kg nicotine. However, only the 0.8mg/kg dose of nicotine
increased Fos expression in the LDTg and PPTg above levels induced by saline. In the
dopaminergic midbrain, chronic nicotine had a much stronger effect in the VTA than in
the SNc, particularly after 0.8mg/kg nicotine. In the VTA, only 0.8mg/kg significantly
increased Fos expression above the baseline level. There was no effect of nicotine in
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the SNc. Again, Experiment 2 refuted previous results that showed a lack of Fos
expression in dopaminergic midbrain areas after chronic nicotine; the majority of Fos
expression found was in non-dopaminergic neurons.
The increased Fos expression with dose of nicotine could be due to two things. Firstly it
could be that low levels of nicotine do activate neurons but it was too weak to detect
using immunohistochemistry and increasing doses are simply increasing Fos expression
to a level that can be detected. Or alternatively it could be that higher doses of nicotine
are recruiting an increasing number of neurons. With the current results it is impossible
to discriminate between these two theories.
The biggest difference between Fos expression after acute or chronic nicotine was after
0.8mg/kg nicotine. After acute 0.8mg/kg nicotine locomotor activity was inhibited,
while Fos expression was comparable to control animals with nicotine apparently
having no effect. Chronic treatment of 0.8mg/kg nicotine enhanced both locomotor
activity and Fos expression in both the LDTg/PPTg and SNc/VTA. Rahman et al.,
(2003) found that chronic nicotine was less effective at stimulating dopamine release
compared with acute nicotine, which could correspond with the decrease in overall Fos
expression found after 0.1 and 0.4mg/kg chronic nicotine in this experiment, compared
with acute nicotine. This decrease in activity after prolonged exposure to nicotine is
thought to be due to the loss of responsiveness or desensitization of the nicotine
receptors in the dopaminergic midbrain (Pidoplichko et al., 1997). Nearly all dopamine
neurons in the VTA and SNc contain the  subunit subtype (Klink et al., 2001; Azam
et al., 2002), which was easily desensitized by a 1mM ‘puff’ of nicotine (Wooltorton et
al., 2003), whereas less than half contain the less easily sensitized  subunit (Klink et
al., 2001; Azam et al., 2002). This suggests that while acute nicotine may activate
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several different types of nAChR, after desensitization by repeated nicotine injection,
chronic nicotine may be more effective at activating receptors containing  subunit.
Depending on the location of different receptor subtypes in the dopaminergic midbrain
region, this may result in a different type of activation after chronic compared with
acute nicotine.
9.0.0 LDTg and PPTg
The effects of abused drugs are thought to be mediated through the dopaminergic
mesolimbic system. The dopamine neurons in the midbrain are dependent on glutamate
input in order to function in a manner that can relay motivationally relevant
information. Glutamatergic input from the LDTg and PPTg is essential to maintain
burst firing in these neurons (Lodge & Grace, 2006). The LDTg and PPTg are also
considered to play an important role in reinforcement mechanisms. A number of studies
have shown that sub-regions within the LDTg and PPTg are involved in different
processes relating to nicotine induced locomotion and nicotine self-administration
(Alderson et al., 2003a; Alderson et al., 2006). One study has even reported that
selective cholinergic lesions of the PPTg reduced IVSA of nicotine (Lanca et al.,
2000a). However experiments 1 and 2 as well as data from Lanca et al., (2000b)
suggest that cholinergic neurons are not activated by acute or chronic nicotine.
The prominence of the cholinergic neurons within the mesopontine tegmentum as well
as the action of nicotine on cholinergic receptors has made cholinergic neurons in this
region the focus of research on nicotinic mechanisms in the brainstem. However, much
of the research used excitotoxic lesions in the LDTg and PPTg to determine the
contributions of this region which results in non-specific lesions. It is entirely possible
that the effects on locomotor activity and IVSA found by Alderson and colleagues
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(2005; 2007) is in fact due to non-cholinergic mechanisms. Results found by Lanca et
al., (2000a) suggesting that selective cholinergic lesions reduced nicotine IVSA could
not be replicated by other labs as the toxin (ethylcholine mustard aziridinium ion;
AF64A) was found to produce large non-selective lesions (H.L. Alderson, personal
communication; Rodriguez et al., 1998). Corrigall et al., (2001) have demonstrated that
GABAergic mechanisms within the LDTg and PPTg are essential in nicotine IVSA.
This is consistent with the fact that nicotine activates Fos expression in non-cholinergic
neurons.
This lack of cholinergic co-localisation with Fos expression after either acute or chronic
nicotine is surprising. It is not the case that cholinergic neurons simply do not contain
the gene for the Fos protein. Double labelling of cholinergic neurons and Fos has been
demonstrated after cholinergically induced paradoxical sleep, deprivation or recovery
of paradoxical sleep and after noxious peripheral stimulation (Shiromani et al., 1996;
Maloney et al., 1999; Kayalioglu & Balkan, 2004). The lack of Fos expression in
cholinergic neurons is also surprising due to the fact that over 80% of the cholinergic
neurons in the LDTg and PPTg contain  mRNA (Azam et al., 2003). Since  is
thought to have the highest permeability to Ca2+ (Dajas-Bailador & Wonnacott, 2004)
and Ca2+ entry into a cell is directly related to Fos induction (Jomphe et al., 2003), it is
surprising that there is not more Fos expression in cholinergic neurons. However, an
specific antagonist has been found to have no effect on nicotine induced locomotion
or on nicotine IVSA, while an  antagonist is able to suppress locomotor activity
and responding for nicotine. Similarly an specific agonist was able to increase
locomotor activity in a similar fashion to nicotine in both non-tolerant animals and
animals sensitized to nicotine, while an specific agonist had no effect at all (Grottick
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et al., 2000). Considering that fewer than 10% of cholinergic neurons in the LDTg and
PPTg contain mRNA (Azam et al., 2003), it is probable that the effect of the
specific agonist is mediated by the non-cholinergic neurons rather than
cholinergic neurons. Although no studies have looked at the effects of specific nAChR
subtypes in the LDTg and PPTg on nicotine reinforcement, microinjections of a non-
specific nAChR antagonist into the PPTg has been found to attenuate nicotine enhanced
IVSA (Lanca et al., 2000a).
Although it is surprising that a largely cholinergic population of neurons is not
activated by nicotine, intracranial self-stimulation, an animal model of reward has also
been found to activate only non-cholinergic neurons. Nakahara et al., (2001) found that
even in control animals activated neurons were more likely to be GABAergic. After
ICSS, co-localisation of Fos and GABA represented 55% of all activated neurons in the
PPTg and 44% of activated neurons in the LDTg. Despite the lack of Fos expression in
cholinergic neurons, Nakahara et al., (2001) found a significant increase in ACh efflux
in the VTA indicating that activation of Fos in the cholinergic neurons of the LDTg and
PPTg has little relation to subsequent ACh release. It is possible that nicotine also
activates neurons in the dorsal raphe nucleus (DRN) and LC (Figure 16), and that these
neurons suppress activation in cholinergic neurons in the LDTg and PPTg (Williams &
Reiner, 1993; Mihailescu et al., 2001). However, this is unlikely as stimulation of the
LDTg and PPTg can result in ACh release in the VTA when cholinergic neurons are
Fos negative (Nakahara et al., 2001).
9.0.1 SNc and VTA
The midbrain dopamine projections, especially the mesolimbic projections from the
VTA to the NAcc play a large role in the way an animal responds to an addictive
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substance. Previous experiments looking at the effects of nicotine on midbrain
dopamine neurons have found increased somatodendritic release of dopamine in the
VTA after acute and chronic systemic nicotine (Rahman et al., 2003), as well as much
larger increases in firing rate in dopamine neurons than in not non-dopamine neurons
(Yin & French, 2000). This is difficult to assimilate with the results found in this
experiment suggesting that the majority of activity, measured by Fos expression, in the
SNc and VTA was non-dopaminergic.
The fact that regions downstream of the SNc and VTA are activated (Pang et al., 1993;
Mathieu-Kia et al., 1998) and the role of this pathway as part of the reinforcement
circuit makes it very surprising that it is almost exclusively non-dopaminergic neurons
that have been activated by nicotine. A number of studies have found increased
dopamine release in the NAcc and striatum as well as increased Fos expression after
acute and chronic nicotine. This induction of Fos in the NAcc and striatum is thought to
be dependent in part on NMDA stimulation as well as dopamine D1 receptors, but is
also thought to mediated by nAChRs in the VTA (Kiba & Jayaraman, 1994; Schilstrom
et al., 2000a). These nAChRs could be located on GABAerigc or glutamatergic
neurons. mRNA for and  nAChR subunits has been found to co-localise with
GAD mRNA in the SNc and VTA (Azam et al., 2002).
A number of other experimental procedures thought to increase dopamine activity have
also failed to find Fos expression in dopamine neurons of the SNc and VTA. Induction
of Fos expression by ether anaesthesia, was found only in non-dopaminergic neurons
(Ishida et al., 2001; Shehab & Julyan, 2002), while Hunt and McGregor, (1998)
estimated that fewer than 5% of neurons activated in the VTA after ICSS were actually
dopaminergic. This is inconsistent with studies showing that nicotine facilitates the
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rewarding effect of ICSS (Ivanova & Greenshaw, 1997; Panagis et al., 2000), a
paradigm that is thought to increase dopamine activity in the mesolimbic system.
Dopamine neurons in the VTA and SNc do express the immediate early gene, c-fos, as
it has been induced in the VTA dopamine neurons during paradoxical sleep deprivation
and recovery (Maloney et al., 2002). Jomphe et al., (2003) have also found Fos
expression induced by D2 receptor antagonist, haloperidol, in a preparation of VTA
dopamine neurons in primary culture. This is also consistent with the fact that Fos
expression was found in some dopamine neurons in the VTA, especially the IF.
The VTA is often though of as a single entity despite the characterisation of the
different subdivisions, including the PBP, PN and IF. However, the organisation of the
VTA may be more complex than previously thought as regional differences have been
found in the reinforcing effects of several drugs of abuse including nicotine. One
difficulty in interpreting the data from studies of the VTA is the lack of a clear
description of the boundaries of the posterior versus the anterior VTA. Results from
studies using ICSA or microinjections are difficult to interpret due to the fact that
placements of cannulae into the VTA differ widely from lab to lab. Ikemoto and
colleagues (Ikemoto et al., 1997b; Ikemoto et al., 2006) have made the most thorough
examination of reinforcement mechanisms in the VTA; they describe the posterior
VTA as the region dorsal to the IPN and medial to the SN, while the anterior VTA is
dorsal to the MN and just medial to the SN.
While animals learned to lever press for nicotine into the posterior VTA, injections into
the anterior VTA and SN had no effect (Ikemoto et al., 2006). Although it was not
quantified in experiments 1 & 2, observation suggested that there was a regional
difference in double labelling of TH and Fos expression in the VTA. It appeared that
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0.8mg/kg nicotine in particular had a strong effect on Fos expression in dopamine
neurons in the posterior region of the VTA. However, because TH labelled neurons
were not fully quantified it is impossible to determine the percentage of dopamine
neurons showing Fos expression.
Dorsal-ventral differences in the projection system from the VTA to the NAcc have
also been previously described. Phillipson, (1979b) suggested that the PN sends
projections to the septum and NAcc, while the PBP sends fibres to the anterior
olfactory nucleus, the olfactory tubercle and the amygdala. Sensitization to nicotine is
thought to be due to enhanced responding in the mesolimbic projection to the NAcc,
therefore it is expected that Fos expression, indicating neural activity, would be greater
in the ventral regions of the VTA, rather than the dorsal regions. The regional
differences within the VTA were not quantified, but it appeared that double labelling of
TH and Fos expression was more numerous in the ventral regions, namely the IF and
PN, while much less double labelling was found in the more dorsal regions of the PBP.
It also appeared as if nicotine recruited dopamine neurons with a more dorsal-lateral
spread with each increasing dose. This may be due to the sensitization of neurons to
chronic nicotine resulting in a wider distribution of information from the VTA. The
VTA has been proposed as a structure capable of integration of information from a
diverse range of inputs (Geisler & Zahm, 2005). Presumably then it has the capability
to relay this information to structures involved in the relevant behavioural response.
The increasing spread of Fos expression in dopamine neurons with increasing dose of
nicotine could be a reflection of an increasingly motivationally relevant signal being
relayed to the appropriate target.
It is not possible to understand the LDTg and PPTg contribution to the regulation of
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midbrain dopamine neurons after administration of nicotine from the data in these
experiments. Although the pattern of activation is similar in both the LDTg and PPTg
and the SNc and VTA, the lack of temporal resolution of Fos expression means that
there is no indication of the causal relationship between the LDTg/PPTg and the
dopaminergic midbrain. It is possible that both regions are being activated by inputs
from nicotinic mechanisms elsewhere in the brain, or that the LDTg and PPTg are
activated by feedback from the VTA and SNc.
9.1 Fos expression after acute d-amphetamine
The aim of experiment 3 “Fos expression after acute d-amphetamine administration”
was to establish if the dose dependent increases in Fos expression found after chronic
nicotine were simply due to the increased locomotor activity found after each
subsequent dose of nicotine. The small doses of d-amphetamine used in this
experiment, 0.35-0.45mg/kg, were found to increase locomotor activity to a similar
degree to that found after 0.8mg/kg chronic nicotine. However, total Fos expression
was suppressed in both the LDTg and PPTg and the SNc and VTA although this was
only significant in the SNc and VTA. D-amphetamine had no effect on dopamine
activity in the midbrain, with 10% of Fos expression being found in dopamine neurons
regardless of whether rats received saline or drug. These data suggest that the robust
increases in Fos expression after chronic nicotine are not due to increases in locomotor
activity. This also suggests that locomotor activity may not be dependent on the
activation of dopamine neurons in the midbrain. However, this contrasts with results
suggesting that Fos expression in the dopaminergic midbrain, as well as in the LDTg
and PPTg, does correlate with locomotor activity.
The locomotor enhancing effect of nicotine is thought to depend on projections from
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the dopaminergic midbrain to the NAcc (Louis & Clarke, 1998). However, results from
these experiments suggest that Fos expression in the SNc and VTA is not the
consequence of increased locomotor activity. D-amphetamine inhibited Fos expression
in non-dopamine neurons and had no effect on dopamine neurons in the midbrain
despite increasing locomotion. Fos expression was greatly increased after a dose of
acute nicotine, that would normally inhibit locomotion, and after doses of chronic
nicotine, that enhanced locomotion, compared with animals treated with saline. Balfour
and colleagues (Shoaib et al., 1994; Balfour et al., 1996) have proposed that the
locomotor and dopamine enhancing effects of nicotine can be dissociated. Their
experiments show that while a glutamate antagonist has no effect on locomotor activity
after nicotine pre-treatment, it clearly inhibits dopamine release in the NAcc.
Surprisingly the glutamate antagonist also potentiates the effects of acute nicotine on
dopamine release such that it resembles the sensitized response to nicotine, while
having no effect on locomotor activity. These seemingly opposing effects suggest that
locomotor activity and dopamine efflux are mediated by separate neural systems. This
theory could explain how acute and chronic nicotine both increase Fos expression in the
SNc and VTA, while having opposite effects on locomotor activity.
9.2 Autoreceptor inhibition of dopamine activity in the midbrain
Assuming an optimum environment for inducing Fos expression, there are two possible
alternative explanations for the mechanism by which dopamine activity is suppressed
after systemic nicotine injections: autoreceptor inhibition or GABAergic inhibition. It is
possible that both D2 autoreceptors and GABAergic mechanisms play an important
regulatory role. Cobb & Abercrombie (2002) have shown that application of a GABAA
antagonist alone in the SNc significantly increased local dopamine efflux and that a
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further increase in extracellular dopamine was found after systemic haloperidol. The
fact that these effects are additive suggests that there are two independent mechanisms
exerting influence over the midbrain dopamine neurons. To further elucidate the effect
of the autoreceptors in the SNc and VTA on nicotine induced activity, we have
examined Fos expression in the LDTg and PPTg and SNc and VTA after systemic
haloperidol pre-treatment of rats given 0.4mg/kg nicotine.
The explanation that dopamine is being rapidly inhibited by local autoreceptors is
supported by the work of Cragg and Greenfield (1997). They provided evidence that
D2-like autoreceptors are one of several mechanisms that control neurotransmission in
the VTA and SNc. Autoreceptors are believed to work through decreasing presynaptic
entry of calcium into a cell (Sallette et al., 2004), and this would limit the activity of
Ca2+ dependent mechanisms, such as Fos expression. Fos expression can be artificially
induced by D2 receptor antagonist, haloperidol, in cultured VTA dopamine neurons
(Jomphe et al., 2003). However, cultured neurons cannot be directly compared with
similar neurons in vivo as there would not be feedback from other areas of the brain.
Experiment 4 “Fos expression after haloperidol pre-treatment and acute nicotine
administration” attempted to assess the mechanism responsible for the lack of Fos
expression in dopamine neurons in the midbrain. It was hypothesized that the lack of
Fos induction in dopamine populations, despite robust illustration of nicotine generated
increases in dopamine release (Rahman et al., 2003), may have been attributable to
dopamine autoreceptors. Autoreceptor inhibitory mechanisms were examined using
haloperidol. Blocking D2 autoreceptors reduced total Fos expression in the SNc
compared with nicotine alone, but had a smaller effect in the VTA. Haloperidol alone
increase Fos expression in dopamine neurons in the VTA but not the SNc. Blocking
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autoreceptors additionally increased nicotine induced Fos expression in the SNc but not
in the VTA. This suggests that while haloperidol did increase Fos expression in VTA
dopamine neurons, nicotine was not able to utilize the absence of inhibitory feedback to
have any additional effect on Fos expression in these neurons. This indicates that D2
autoreceptors are not wholly responsible for the lack of Fos expression in dopamine
neurons after acute nicotine administration. In the SNc, nicotine did have an effect on
Fos expression in dopamine neurons after autoreceptors were blocked.
Jomphe et al., (2003) have found that the Fos expression induced by D2 antagonist
haloperidol was not replicated by a second D2 antagonist, sulpiride, or by protein
kinase A (PKA) antagonist. This suggests that the mechanism does not directly involve
D2 receptors or the cAMP cascade, of which Fos expression is a part. However, it was
shown to be activity dependent and calcium dependent, requiring the activation of a
calmodulin dependent kinase (CaMK), and by the ability of tetrodoxin (TTX, a sodium
channel blocker), BAPTA (a membrane permeable Ca2+ chelator) and KN-93 (a
CaMK-II & IV inhibitor) to block Fos (Jomphe et al., 2003).
After haloperidol pre-treatment, there was a simultaneous decrease in nicotine induced
Fos expression in non-dopaminergic neurons and an increase in Fos expression in
dopaminergic neurons in the SNc. This may indicate a reduction in the inhibitory
influence of GABAergic interneurons in the SNc. In the VTA, on the other hand, there
was only a partial reduction in nicotine induced non-dopaminergic Fos expression, but
no increase in nicotine induced dopaminergic Fos expression above what was induced
by haloperidol. It is possible that as well as D2 receptors behaving as autoreceptors,
there are also D2 receptors on other neuron types within the SNc and VTA. Indeed D2
receptor peptides do not always co-localise with TH on dendrites in the midbrain
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(Sesack et al., 1994). However activity in non-dopamine neurons was also reduced. The
changes in Fos activity after haloperidol pre-treatment may also be due to the actions of
haloperidol elsewhere in the brain.
9.3 GABAergic inhibition of dopamine activity in the midbrain
A second explanation for reduced dopamine activity after nicotine is GABAergic
inhibition; either inhibition from local GABAergic interneurons or inhibitory
GABAergic feedback from the striatum. Fos expression induced by ether anaesthesia
has been found not to co-localise with TH but with parvalbumin containing GABAergic
neurons (Shehab & Julyan, 2002). Similarly, after ICSS there was no dopamine
activity, but Fos was found in both GABAergic and glutamatergic populations in the
VTA. (Ishida et al., 2001). This could be explained by the fact that VTA dopamine
neurons are tonically inhibited by GABA interneurons (Johnson & North, 1992a).
Stimulation of the GABAergic SNr had inhibitory effects on dopamine neurons in both
the VTA and SNc (Saitoh et al., 2004). Injections in the SN of a GABA agonist can
block Fos expression both in the SN, and in terminal areas (Shehab & Julyan, 2002). A
variant of Fos, FosB, has also been found to be selectively induced by forced cocaine
administration in a population of GABAergic neurons in the posterior tail of the VTA.
A number of studies have shown that dopamine function is modulated by GABA
receptors, but the subtype responsible remains elusive. Paladini et al., (1999) show that
GABAA but not GABAB antagonists can block the inhibition of dopamine firing rate
produced by electrical stimulation of the neostriatum, GP or SNr. Brebner et al., (1999)
on the other hand, show that systemic injections of a GABAB agonist can decrease
cocaine self administration on a PR schedule. This suggests that dopamine activity in
the midbrain is regulated by both local GABAergic mechanisms and by feedback from
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the striatum via the GP and SNr.
9.4 Alternative mechanisms of inhibition of midbrain dopamine neurons
The Fos expression found in dopamine neurons after paradoxical sleep deprivation and
recovery is believed to be associated with different firing patterns between being awake
and asleep. Normally dopamine neurons discharge in bursts of spikes but during PS
deprivation and recovery they are thought to discharge in a bursting pattern that is
associated with increased Ca2+ influx, thought to stimulate Fos expression (Maloney et
al., 2002). This difference between tonic activity and phasic burst firing in the VTA
could be crucial to understanding why dopamine neurons fail to show Fos expression
after acute or chronic nicotine. Nicotine has been found to have a profoundly different
effect on dopamine neurons depending on the underlying activity. Both nicotine and
nicotine receptor antagonist, mecamylamine, inhibit dopamine release when pre-
synaptic activity is low, during tonic activity, but during phasic activity nicotine acts to
facilitate dopamine release. This is relevant to reward seeking behaviour as phasic
activity occurs during the presentation of salient stimuli, such as lever pressing in an
IVSA paradigm (Zhang & Sulzer, 2004). It is possible that because nicotine is being
administered passively in this experiment the underlying activity is tonic. This would
result in dopamine neurons being actively suppressed so the second messenger system
would not be engaged.
Experiments by Balfour and colleagues (Balfour et al., 1996) showed that NMDA
receptor antagonist, D-CPPene, regulated the effects of acute and chronic nicotine
differently. After being pretreated with chronic nicotine, D-CPPene blocks the
sensitized response of NAcc dopamine neurons to a challenge dose of nicotine, but
after pre-treatment with saline, D-CPPene results in an apparent sensitized response to
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the acute challenge dose of nicotine. It is possible that part of the nicotinic effect on
dopamine efflux in the NAcc is though NMDA receptors. Balfour and colleagues
(1998) postulate that blocking NMDA receptors attenuates the sensitized response of
dopamine to nicotine, while blockade of NMDA receptors before acute nicotine
disinhibits the mesolimbic dopamine neurons, leading to increased dopamine efflux in
the NAcc. This suggests that the mechanism blocking Fos expression in dopamine
neurons is an inhibitory effect of the stimulation of NMDA receptors by acute nicotine.
The result of stimulation of NMDA receptors in the midbrain by chronic nicotine is the
facilitation of dopamine release. However, in experiment 2, Fos expression in
dopamine neurons is not facilitated by chronic nicotine compared with acute nicotine.
This fails to explain why the majority of Fos expression after chronic nicotine still
occurs in non-dopaminergic neurons in the midbrain.
Refuting the theory that the effect of glutamate released in response to acute nicotine is
to inhibit dopamine release in the NAcc is more recent research that has found that
direct infusion of an NMDA antagonist in the VTA attenuates both acute systemic
nicotine induced Fos expression and dopamine efflux in the NAcc (Schilstrom et al.,
1998). The opposing results from these experiments are difficult to reconcile. The only
difference in the methodology that could account for the opposing results is the fact that
a systemic injection of glutamate antagonist D-CPPene increased nicotine enhanced
dopamine, while the attenuation of nicotine enhanced dopamine was due to the direct
infusion of glutamate antagonist AP-5 into the VTA. This would suggest that enhancing
effects of blocking glutamate receptors occur outside the VTA. Alternatively the
difference could be due to the fact that each experiment found a different effect of
nicotine alone on the change in dopamine efflux in the NAcc. Both experiments
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actually found that glutamate antagonist pre-treatment followed by nicotine resulted in
an increase above the baseline level of dopamine efflux. However, Schilstrom et al.,
(1998) found that nicotine alone had a greater effect on NAcc dopamine efflux, while
Balfour et al., (1996) found that nicotine alone had no effect on NAcc dopamine efflux.
The inhibitory effects of a glutamate antagonist are substantiated by results of an
electrophysiological study as a glutamate antagonist reversed a nicotine facilitated
increase in firing rate and the percentage of spikes fired in bursts (Erhardt et al., 2002).
Burst firing of dopamine neurons in the midbrain depends on EAA afferents from
regions, including the LDTg, and has been associated with enhanced dopamine efflux
in the NAcc (Lodge & Grace, 2006).
9.5 Theories of addiction
9.5.0 Learning about reward
Reinforcement depends on the ability to learn associations between a stimulus and the
response. For example, animals that have been trained in operant responding for an
IVSA procedure are able to associate their own response on the lever with the delivery
of food. Drugs that are commonly abused seem to hijack this ability and either enhance
the reinforcement that the drug produces or simulate the reinforcement produced by a
natural reward such as food. The LDTg and PPTg are thought to be involved in the
formation of the association learning involved in reinforcement. When the PPTg was
lesioned prior to learning the association between lever and a food reward, subsequent
responding for d-amphetamine was reduced, but if that association was learned before
the lesion was made then there was no deficit in responding (Alderson et al., 2004a). In
order for learning to occur, activation in the regions of the brain relevant to learning
about a reward would need to be activated at the time of the initial exposure to the
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reinforcing stimulus. Fos expression is believed to occur in response to metabolic
activity in the neurons because it is part of the second messenger cascade. These
experiments show that Fos expression, presumably indicative of some sort of activity in
the cell, is induced specifically by nicotine in the LDTg and PPTg as well as the
dopaminergic regions of the midbrain. The fact that both regions show the same pattern
of activity after acute nicotine and chronic, a dose response curve with the greatest
induction of activity occurring at 0.4 or 0.8mg/kg nicotine, suggests that these regions
may be involved in the same process.
9.5.1 Reward Expectation
Reward expectation theories state that the activation of dopamine neurons in the
midbrain by rewarding stimuli is a reward prediction signal (Schultz, 1998). Initially
dopamine neurons respond to the presentation of the reward, but not to the presentation
of the predicting stimulus. After a number of trials the reward becomes predictable due
to the presentation of the stimulus and dopamine neurons no longer need to fire in
response to the reward and the response transfers to the predictive signal (Montague et
al., 1996). The midbrain dopamine neurons are ideal for this task as they are situated at
the centre of an integrative network of connections that span the entire brain. As a
major source of excitatory input to the midbrain dopamine neurons, the PPTg has come
under scrutiny as a source of reward prediction information during reinforcement. In a
task of conditioned motor performance in cats, the PPTg neurons fired at extremely
short latency in response to the stimulus, such that it may be one of the first structures
in the brain to respond to the presence of the stimulus. Some neurons also fired in
response to the reward but the pattern of activity was more sustained than after the
stimulus onset. Neurons were classified according to the length of the action potential
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spike as broad spikes are thought to be characteristic of cholinergic neurons. The
majority of brief spike, presumably non-cholinergic neurons, responded both to the
stimulus and the reward, while equal numbers of broad spike neurons to both stimulus
and reward or reward only (Dormont et al., 1998). This suggests that both cholinergic
and non-cholinergic neurons in the PPTg are involved in signalling stimulus and reward
information to the dopaminergic neurons in the midbrain. This does not correspond
with results found in this experiment suggesting that only non-cholinergic neurons are
involved in responding to nicotine. However, it may be that cholinergic neurons
regulate information about conditioned stimuli while non-cholinergic neurons respond
to unconditioned stimuli. Alternatively the non-cholinergic neurons may suppress the
cholinergic response prior to the stimulus being conditioned.
9.5.2 Incentive sensitization
At a neuropsychological level sensitization is thought to increase the incentive salience
attributed to drug related stimuli. Incentive salience is hypothesized to transform the
neural representation of otherwise neutral stimuli into salient incentives, able to grab
attention, making them more wanted (Robinson & Berridge, 2001). They have also
suggested that enhanced dopamine elicited by conditioned stimuli is experienced
subjectively as craving. As the system becomes progressively more sensitized the
cravings spiral out of control and this is when the dissociation of ‘wanting’ and ‘liking’
is seen, as only the system mediating ‘wanting’, the mesolimbic dopamine system is
sensitized. Substantial associations were found between cue-induced craving and the
cue-induced blood oxygen level dependent signal in the VTA and PPTg. These data
suggest that visual cues that are associated with smoking behaviour and cravings are
processed in some way in the VTA as well as the PPTg (Smolka et al., 2006). Cravings
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have been defined as the subjective feeling that occurs during attribution of incentive
salience to drug associated stimuli. It is possible that the regulation of this process
occurs in the VTA and PPTg. The Fos expression found in these regions may
correspond with the initiation of attribution of incentive salience to cues that would
predict nicotine administration. If a more defined pattern of Fos expression could be
identified in animals using models based on different stages in addiction and relapse, it
may be possible to compare these with results from human studies using functional
neuroimaging techniques. The results from Smolka et al., (2006) show that it is
possible to identify discrete regions of the brain that may be involved in addiction
associated behaviours.
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Chapter 10: GABA in the mesopontine tegmentum and midbrain
10.0 Introduction
The previous experiments have examined neural activity, using immediate early gene
Fos, in the LDTg, PPTg, SNc and VTA after acute and chronic systemic nicotine.
0.4mg/kg nicotine was found to increase activity in all four regions after both 1 and 5
days passive administration, while 0.8mg/kg nicotine was found only to increase
activity in these regions after 5 days. However, the large increases in the LDTg and
PPTg were found to be almost exclusively non-cholinergic. Despite well documented
increases in dopamine in both the VTA and in terminal regions (Nisell et al., 1994;
Sziraki et al., 2002; Rahman et al., 2003), the majority of activity in the SNc and VTA
was non-dopaminergic. D2 autoreceptors are known to modulate activity in the
mesolimbic system and their loss of control is thought to play a part in psychomotor
sensitization to cocaine and nicotine. However, the lack of increase in nicotine induced
neural activity after blocking autoreceptors, indicated that this was not a contributing
factor to the lack of Fos expression in dopamine neurons in the VTA seen after acute
and chronic nicotine.
Although dopamine is often thought of as the major neurotransmitter in the VTA and
SNc there are also substantial numbers of GABAergic and putative glutamergic
neurons (Johnson & North, 1992b; Steffensen et al., 1998; Maloney et al., 1999;
Ungless et al., 2004; Yamaguchi et al., 2007). Local GABAergic interneurons as well
as long loop feedback from the striatum are also a modulatory factor in midbrain
dopamine transmission. GABA neurons are known to interact with dopamine
transmission. This has been demonstrated both through direct experiments on
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GABA/dopamine interactions and also through experiments on the effects of
GABAergic drugs on dopamine mediated behaviours. It is also possible that the LDTg
and PPTg are involved in GABAergic interactions with dopamine either directly
through GABA projections to the dopaminergic midbrain, or alternatively through local
inhibitory effects on cholinergic regulatory projections to the midbrain.
GABA neurons in the VTA and SNc make up a substantial proportion of neurons and
are thought to play a modulatory role with regard to dopamine neurons. They tonically
inhibit dopamine release through both local GABAergic interneurons and long-loop
GABA feedback projections from the NAcc and VP. Indeed, morphine, a opioid
receptor agonist, is thought to be reinforcing through its ability to attenuate tonic
GABA inhibition in the midbrain and thus disinhibiting dopamine neurons (Churchill et
al., 1992; Klitenick et al., 1992). The effects of GABA have been directly tested by
activating or blocking GABA receptors in the midbrain. However, there are two types
of GABA receptor which, because of their opposing effects on dopamine, have been
hypothesised to be situated on different neuron types in the midbrain. GABAB receptors
are thought to be located on dopamine neurons, consequently a GABAB agonist would
act directly to inhibit dopamine neurons. GABAA receptors, on the other hand, are
thought to be located on GABAergic interneurons in the midbrain (Churchill et al.,
1992; Klitenick et al., 1992). This suggests that a GABAA agonist, like opioid
agonists, will inhibit the interneuron, thus releasing the dopamine neuron from tonic
inhibition. Indeed, a GABAB agonist, baclofen, has been shown to decrease axonal and
somatodendritic dopamine release when injected directly into the VTA (Yoshida et al.,
1993). Conversely, GABAA agonist, muscimol, increases extra-cellular dopamine
(Klitenick et al., 1992) consistent with the theory of disinhibition. What is difficult to
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explain within this framework is why GABAA antagonists have also been shown to
increase excitation of midbrain dopamine neurons (Johnson & North, 1992a). It has
been suggested that there are regional differences in the midbrain that contribute to
these seemingly opposite drug effects (Ikemoto et al., 1997a; Ikemoto et al., 1998).
GABAA agonists are thought to increase dopamine in the posterior VTA, at the level of
the IPN, and GABAA antagonists are thought to increase dopamine in the anterior VTA,
at the level of the MN. Whether this distinction is due to intrinsic differences in the
midbrain or topographical differences in the organisation of afferents has yet to be
determined. Johnson & North, (1992a) found that a GABAA antagonist increased
synaptic potentials in the dopaminergic midbrain region. When the methodology is
examined more closely it is found that, despite recording in vitro, they have extracted
neurons that lie between the MT and FR, at the level of the MN, in the anterior region
of the VTA. However, Klitenick et al., (1992), looking at the effects of a GABAA
agonist, found increased dopamine release in the posterior VTA. Therefore their
conflicting results showing that a GABAA agonist and antagonist both inhibited tonic
inhibition from interneurons could be due to regional differences.
The influence of GABA receptors on drug induced changes in midbrain dopamine
activity is less clear cut. Consistent with the fact that a GABAB agonist inhibits
dopamine are results showing that a GABAB antagonist facilitated nicotine induced
burst firing in dopamine neurons (Erhardt et al., 2002). However inconsistent with
these data are results from Sziraki et al., (2002) showing that nicotine and cocaine
induced dopamine release in the NAcc is inhibited by local injections of a GABAB
antagonist in the VTA. One explanation for this difference is that there could be
regional differences in GABAB receptor function, as has been found with GABAA
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receptors. Sziraki et al., (2002) used more anterior coordinates than Erhardt et al.,
(2002) in locating the VTA.
GABA/dopamine interactions in the SNc and VTA have also been examined by
looking at the effects of GABA receptors on dopamine mediated behaviour.
Locomotion and reinforcement paradigms such as ICSS, IVSA and ICSA are all
thought to be mediated by dopamine projections from the VTA to the NAcc. Micro-
injections in the posterior VTA of opioid receptor agonist, DAMGO, and GABAA
receptor agonist, muscimol, have both been found to increase locomotor behaviour
(Klitenick et al., 1992). This is presumably due to disinhibition of dopamine in the
VTA from the tonic control by local GABA interneurons. This indicates that
reinforcement is also influenced by GABAergic mechanisms. ICSS has been found to
increase Fos expression almost exclusively in non-dopamine neurons (Hunt &
McGregor, 1998). Ishida et al., (2001) found that 61- 88% of Fos expression after ICSS
was in GAD labelled neurons. However in both these studies only small sample regions
were counted in the anterior VTA so regional variations were not taken into account.
Regional variations in the GABAergic influences on midbrain dopamine have been
most extensively studied by Ikemoto and colleagues, (1997a; 1997b; 1998) using ICSA.
They have found that GABAA agonists are reinforcing when cannulae placement is in
the posterior VTA (Ikemoto et al., 1998). GABAA antagonists are reinforcing, and also
increase extracellular levels of dopamine in the NAcc when self administered into the
anterior VTA (Ikemoto et al., 1997a; Ikemoto et al., 1997b). This is consistent with the
regional differences in neuron type found by Olson & Nestler (2007). Topographical
mapping suggested that a greater number of GAD positive neurons were to be found in
the anterior VTA, while TH neurons were equally distributed throughout the VTA. It is
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also possible that there are regional differences in projections to the striatal region, as
retrograde labelling from the NAcc labels more neurons in the posterior VTA than in
the anterior VTA (Olson & Nestler 2007). The topographical differences in both
neurochemical identity of the cells and of projection site provide a possible explanation
for the regional differences in dopamine/GABA interactions in the midbrain.
Intravenous drug self administration, which of all the animal models is most akin to
human drug taking has been shown to induce ΔFosB, an indicator of long term 
plasticity, in GABAergic neurons of the posterior tail of the VTA for up to two weeks
(Perrotti et al., 2005). IVSA also reveals similar patterns of behaviour to ICSA in
response to GABAergic receptor drugs. However most of the research in this area has
been done on GABAB agonists as they have shown most therapeutic potential in clinical
trials. The highly specific GABAB agonist, CGP44532, shifts the dose-response curve
of cocaine on a PR schedule to the right, meaning that a higher dose of cocaine was
required to achieve the same level of responding (Brebner et al., 1999). GABAB
agonist, baclofen, was found to be more effective at reducing break-point when injected
into the VTA, rather than in the NAcc or striatum. These effects are specific to
responding for cocaine and not to the sedative effects of the drug, as responding for
food was not affected by manipulation of GABA. GABAB agonists have been found to
have a similar effect on the IVSA of nicotine, blocking responding in a similar fashion
to nicotine receptor antagonist, mecamylamene (Fattore et al., 2002). This indicates that
facilitating GABAergic inhibition of dopamine has the same effect as blocking
activation of dopamine through nAChRs. The effect was specific to nicotine at lower
doses in the fixed ratio schedule, and affected all responding in the progressive ratio
schedule. The fact that responding for food on the progressive ratio schedule was
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affected at all doses could be due to the higher demands of this task. The ability of a
GABAB agonist to block reinforcement by decreasing dopamine release confirms the
hypothesized location of GABAB on dopamine neurons.
The role of GABAergic mechanisms in the LDTg and PPTg has also been examined,
due to the ability of these regions to regulate midbrain dopamine transmission (Blaha &
Winn, 1993; Blaha et al., 1996) as well as reinforcement (Alderson et al., 2002;
Alderson et al., 2006; Nelson et al., 2007). Both the LDTg and PPTg are thought to
contain a large population of GABAergic neurons (Ford et al., 1995). One hr of ICSS
has been found to increase Fos in both the PPTg and LDTg. Despite concurrent
increases in ACh in the VTA, Fos expression was restricted to GABA and not
cholinergic neurons in the LDTg and PPTg (Nakahara et al., 2001). Bilateral micro-
injections of opioid agonist, DAMGO, in the PPTg have been found to increase
motor activity and levels of extra-cellular dopamine in the NAcc in a dose dependent
manner (Klitenick & Kalivas, 1994). This effect is thought to be mediated by
projections to the dopaminergic midbrain as blocking D2 dopamine receptors by
systemic injections of haloperidol abolishes the response to DAMGO. Micro-injections
of GABAB agonist, baclofen, into the PPTg also attenuated DAMGO induced
locomotor activity (Klitenick & Kalivas, 1994). However, these experiments can not
clarify if effects are due to local inhibition of excitatory projections to the VTA or
direct inhibitory projections to the VTA. Conversely, Corrigall et al., (2002) found that
intra-PPTg injections of DAMGO reduced responding for nicotine on a fixed ratio and
progressive ratio schedule. They also found that activating both GABAA and GABAB
receptors in the PPTg reduced nicotine self administration on a FR schedule but had no
effect on cocaine (Corrigall et al., 2001; Corrigall et al., 2002). A possible explanation
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for these opposing results is the differences in connectivity between the posterior and
anterior PPTg. The coordinates from Corrigall et al., (2001; 2002) are more posterior to
those used by Klitenick & Kalivas (1994). The posterior PPTg is thought to project
more strongly to the VTA while the anterior PPTg is thought to project more strongly
to the SNc. As the mesolimbic system is thought to be more involved in reinforcement
that the nigrostriatal, inhibiting GABA projections from the posterior PPTg, as
Corrigall & colleagues (2001; 2002) showed, is more likely to inhibit self
administration.
In summary, local GABAergic interneurons in the VTA are a source of tonic inhibition
on neighbouring dopamine neurons. By hyperpolarising these neurons, via opioid or
GABAA receptors, dopamine neurons are disinhibited resulting in increased firing rate
and release of dopamine. The behavioural manifestation of this is increased locomotor
activity or increased responding in a reinforcement paradigm. Stimulation of GABAB
receptors, on the other hand, lead to inhibition of dopamine, due to their location
directly on the dopamine neuron. However it is important to note that, due to
differences in either the location of the receptor or topographical differences in
afferents, there are regional differences in whether a GABAA receptor agonist or
antagonist will increase dopamine release. GABA projections from the LDTg and PPTg
are also an important regulatory factor in midbrain dopamine transmission as
reinforcement activates GABAergic neurons in the LDTg and PPTg; and activating
GABA neurons in the PPTg reduces reinforcement, possibly via mechanisms in the
VTA.
It is possible that a large proportion of Fos expression after acute and chronic nicotine
is in GABAergic neurons. This indicates that GABA neurons of the LDTg/PPTg and
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SNc/VTA may be important in nicotine mechanisms; and perhaps play a part in the
nicotine induced suppression of midbrain dopamine activity, as measured by Fos
expression. However, the following chapter is not intended to answer this question but
instead to develop the methods needed to test this hypothesis. The first experiment
examined the regional differences in glutamate decarboxylase (GAD) in order to find a
reliable marker for GABAergic neurons. Sections through the mesopontine tegmentum
and midbrain were examined using antibodies raised against three different isotopes of
GAD. The second experiment examined the possibilities of inducing a GABA specific
lesion in the VTA. The suggestion that the lack of dopaminergic activity after nicotine
is due to GABAergic inhibition could be tested by blocking the effects of local
interneurons in the VTA. However, there are many conflicting factors in this method
due to the heterogeneity of GABAergic connections and receptor subtypes in the
different parts of the VTA. Blocking local interneurons by way of a systemic drug
could also present problems as it may affect GABA mechanisms in any part of the
brain. A procedure has yet to be established to lesion GABA neurons in the VTA that
would result in maximum GABA loss while maintaining dopamine neurons.
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10.1 Visualisation of GABA neurons in the mesopontine tegmentum and
midbrain
10.1.0 Introduction
GABAergic neurons have been shown to play an important role in the modulation of
midbrain dopamine neuron activity, particularly in modulating the response to drugs of
abuse such as cocaine and nicotine. Previous studies by Jones and colleagues (Ford et
al., 1995; Maloney et al., 1999, 2000) have shown the existence of GABA neurons in
the mesopontine tegmentum and midbrain areas using an antibody against GAD. GAD
is the rate-limiting factor in the production of GABA (Soghomonian & Martin, 1998),
and is commonly used as an identifying factor. There are two GAD isoforms: GAD65
and GAD67, which are coded by independently regulated genes, and both are required
to support the production of GABA. However, the reason for this is unexplained so
identifying the role and distribution of each is important. Both are found in the CNS,
but are contained in different parts of the neuron, GAD67 is widely distributed
throughout the cell while GAD65 is found mostly in the cell membranes and nerve
endings (Soghomonian & Martin, 1998). GAD65 is thought to be the major GAD
isoform found in most regions of the brain and is responsible for vesicular GABA
production, but GAD67 is thought to be responsible for the synthesis of GABA in the
cell cytoplasm. While both GAD isoforms are thought to be necessary for GABA
production it seems that GAD67 may be the most critical of the two. In mice born
lacking the GAD67 gene, GABA levels were reduced to 7% while mice without the
GAD65 gene had normal levels of GABA, and general behaviour and locomotor
activity was comparable to wild type mice (Asada et al., 1996; Asada et al., 1997).
Given that it is possible that each has a different function within the cell, each isoform
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may be differentially distributed within the brain.
Each isoform is composed of 2 domains: a C-terminal which is 73% similar in both,
and an N-terminal which contains only 23% of the same amino acids. These differences
mean that antibodies can be raised either against the N-terminal to label each isoform
separately, or against the C-terminal which would label regions that contained either
one or the other or both. In this way the different distributions of the 2 isoforms can be
compared with the overall GAD distribution. Initial tests of a GAD67 antibody showed
a different, much reduced, pattern of labelling to previously published results of GAD
distribution in the mesopontine tegmentum (Ford et al., 1995). It was suggested (D. S.
Zahm; personal communication) that due to high GAD turnover, axonal transport
would have to be blocked with colchicine in order to visualise GAD in the cell soma. It
appeared that many previous studies failed to take into account that there are 2 different
isoforms of GAD, GAD65 and GAD67, plus a heteromer, GAD65/67, that should label
for both.
Ford et al., (1995), in an anatomical study, found GAD immunoreactivity in the
neurons of the LDTg and PPTg, SNc and VTA after blocking axon transport with
colchicine to maximise visualisation of GAD within the cell soma. However, the
antibody they used was not specific to either isoform. It is possible that this antibody
was raised against the C-Terminal of GAD65 or GAD67, meaning there is a 73%
chance that the antibody would label both isoforms. Gonzalez-Hernandez et al., (2001)
used both immunohistochemistry and in-situ hybridization (ISH) to localise GAD65
and GAD67 in the midbrain. They found GAD67 immunoreactivity in both the neuropil
(axons and dendrites) and somata of the SN, mainly in the SNr. Some sparse GAD67
labelling was also found in the SNc and VTA. In contrast, GAD65 was only found in
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axons and dendrites of the SN. Regardless of whether animals had been treated with
colchicine or not, no GAD65 immunoreactive somata were found in any part of the SN.
Despite the lack of GAD65 positive somata in the SN, immunoblotting procedures (a
method of protein detection involving gel electrophoresis) have found 2-3 times more
GAD65 and GAD67 in the SN than in the VTA (Sheikh et al., 1999). When using ISH,
a much higher proportion of neurons expressing GAD mRNA was found, than had been
immunoreactive for either GAD antibody. Similar distributions of GAD65 and GAD67
were seen throughout the SN except in the rostromedial part of the SNc, which
contained more neurons expressing GAD65 (Gonzalez-Hernandez et al., 2001). This is
inconsistent with an immunoblotting study which found that GAD65 accounted for 77
and 85% of the total GAD in the SN and VTA respectively (Sheikh et al., 1999).
However, if the amount of GAD mRNA does not correlate with the level of protein
found it could be due to GAD67 being synthesised at a higher rate but also being
moved out of the cell faster than GAD65, resulting in higher levels of GAD65 protein
remaining in the cell.
The few studies that have detailed the existence of the separate isoforms of GAD show
little consistency. The following experiment attempts to localise the different isoforms
in 4 regions that are thought to be critical to nicotine reinforcement: the LDTg, PPTg,
SNc and VTA. It was hypothesised that the different GAD isoforms, due to their
different regulatory roles in the synthesis of GABA, would have different distributions
within these regions. This was investigated by examining the staining that resulted from
antibodies raised against the N-terminals of GAD65 and GAD67; and 2 versions of
heteromer GAD65/67 (a monoclonal and a polyclonal antibody), raised against the C-
terminal.
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10.1.1 Methods
Animals
7 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 350-450g were
used in this experiment. 4 animals were treated with colchicine and 3 were given no
treatment. 1 experimental animal died during the course of the experiment due to
complications with colchicine treatment.
Surgical Procedure
Animals were anaesthetized as described in the General Methods. Animals were then
placed in a stereotaxic frame. Infusions of 12mg/ml colchicine (Sigma) were delivered
to the lateral ventricles in a volume of 5L to each site by pressure injection through a
glass micropipette. All injections were made with the stereotaxic frame set such that the
skull was level at bregma and lambda (Paxinos & Watson, 1997). Injections were made
at the following coordinates: -0.8, ±1.5, -3.5. The glass micropipette was left in situ for
300s after the infusion to allow for diffusion away from the tip. After surgery, animals
were given ip injections of 1mL Hartmans solution, a sodium lactate solution used to
replace fluids after blood loss, and monitored closely during recovery. Animals were
housed singly and given wet mash in a water bowl for easy access. After 48 hr rats
were anaesthetized with sodium pentobarbitone (‘Dolethal’, Univet Ltd, Bicester,
Oxon, UK; 200mg/ml) and perfused transcardially first with phosphate buffered saline
and second with 4% paraformaldehyde in 0.1M phosphate buffer. After removal, brains
were stored overnight in 20% sucrose prior to histological analysis.
Histological Analysis
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Histological analysis was performed as described in the General Methods. The normal
serum used in the ADS and blocking solution was raised in goat. Sections were single
labelled with a polyclonal GAD65 antibody (1:2000, made in rabbit, Chemicon), a
polyclonal GAD67 antibody (1:5000, made in rabbit, Chemicon), and the polyclonal
GAD65/67 antibody (1:1000, made in rabbit, Chemicon). Secondary antibody was
either anti-mouse (Vectastain). One set of sections were double labelled for ChAT
(1:500, made in goat, Chemicon) and a monoclonal GAD65/67 antibody (1:1000, made
in mouse, kindly donated by Ian Varndell at Biomol, UK). The normal serum used in
this case was raised in rabbit. Pilot studies showed that the polyclonal and monoclonal
GAD65/67 antibodies from different manufacturers resulted in different patterns of
labelling so both were used in order to assess these differences.
Quantification & Statistics
No quantification, and hence no statistics, were performed due to the indistinct nature
of much of the immmunohistochemical labelling. Sections were analyzed and neurons
were classified simply as present or not present.
10.1.2 Results
Mesopontine tegmentum
Figure 43 showed the mesopontine tegmentum in colchicine treated (A) and control (B)
animals. In both the LDTg and PPTg, GAD65 staining was seen regardless of whether
axon transport had been blocked with colchicine or not. In the LDTg blocking axon
transport resulted in more intense staining but fewer overall labelled neurons (Figure 44
A & B). In the PPTg, blocking axon transport resulted in fewer labelled neurons, but
the intensity of staining was not increased (Figure 44 B & C). Most surrounding
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GAD 67 labelled neurons in the mesopontine tegmentum with (A) and without (B) colchicine.  IC = Inferior colliculus,   
LDTg = Laterodorsal tegmental nucleus,   ml = medial lemniscus,   PPTg = Pedunculopontine tegmental nucleus,   
scp = superior cerebellar peduncle.
Figure 43:  Polyclonal GAD 67 in the mesopontine tegmentum
Scale bars = 200µm
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A : LDTg with colchicine,  B : LDTg without colchicine,  C : PPTg with 
colchicine,  D : PPTg without colchicine
A : LDTg with colchicine,  B : LDTg without colchicine,  C : PPTg with 
colchicine,  D : PPTg without colchicine
Figure 44:   Polyclonal GAD 65  
Figure 45:  Polyclonal GAD 67 
Scale bar = 50µm
A : LDTg with colchicine,  B : LDTg without colchicine,  A : PPTg with 
colchicine,  D : PPTg without colchicine
Double labelling of 
monoclonal GAD 65/67 and 
ChAT after colchicine in the
LDTg (A) as well as the 
posterior PPTg (B) and the 
anterior PPTg (C).  
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Figure 46:   Polyclonal GAD 65/67  
Figure 47:   Monoclonal GAD 65/67 & ChAT 
Scale bar = 50mm.
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regions, including the IC, Raphe nuclei, CnF and lateral lemniscus (ll) also showed
GAD65 staining before and after blocking axon transport.
In contrast, GAD67 was almost never found in the LDTg and PPTg of control animals
(Figure 1b). However, the surrounding regions, the IC and ll, showed staining
regardless of treatment (Figure 43A). After axon transport was blocked, the LDTg
contained considerably more GAD67 neurons than the LDTg in control animals (Figure
45 A & B). There was some increase in the number of neurons labelled in the PPTg
(Figure 45 C & D) although the contrast was less than in the LDTg.
After staining with a polyclonal antibody, neurons containing the heteromer GAD65/67
were almost never seen in control animals, except in the IC and lateral lemnisus. After
blocking axon transport, staining became more intense in most regions at the level of
the mesopontine tegmentum. The raphe nuclei and the CnF both had GAD65/67
immunoreactive neurons, as did the LDTg (Figure 46 A & B). The PPTg, on the other
hand, had no staining for GAD65/67 regardless of treatment (Figure 46 C & D). In
contrast, a second monoclonal GAD65/67 antibody did show some staining in the
posterior PPTg (Figure 47B) but not anterior PPTg (Figure 47C) after double labelling
with ChAT. Staining in the LDTg was consistent across both antibodies (Figure 47A).
Double labelling of GAD65/67 with ChAT showed that GABA neurons in the LDTg
(Figure 47A) and pPPTg (Figure 47B) were interdigitated with cholinergic neurons but
were not restricted to the boundaries of the LDTg and PPTg, as defined by the
cholinergic neurons.
SNc and VTA
Colchicine has very little effect on midbrain neurons containing GAD65, although there
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GAD 67 labelled neurons in the VTA, SNc and SNr with (A) and without (B) colchicine.  fr = fasciculus retroflexus,  mt = medial terminal 
nucleus of the accessory optic tract,  SNc = Substantia Nigra pars compacta, SNr = Substantia nigra pars reticulata,  VTA = Ventral 
tegmental area.
Figure 48:  Polyclonal GAD 67 in the ventral midbrain 
Scale bar = 200µm
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A : SNc with colchicine,  B : SNc without colchicine,  C : VTA with 
colchicine,  D : VTA without colchicine
A : SNc with colchicine,  B : SNc without colchicine,  C : VTA with 
colchicine,  D : VTA without colchicine.
Figure 49:  Polyclonal GAD 65
Figure 50:  Polyclonal GAD 67
Scale bar = 50mm.
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A : SNc with colchicine,  B : SNc without colchicine,  C : VTA with 
colchicine,  D : VTA without colchicine
A : SNc with colchicine,  B : SNc without colchicine,  C : VTA with 
colchicine,  D : VTA without colchicine.
Figure 51:  Polyclonal GAD 65/67
Figure 52:  Monoclonal GAD 65/67
Scale bar = 50mm.
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was some increase in the clarity of staining. Both the SNc (Figure 49 A & B) and VTA
(Figure 49 A & B) contained equal densities of neurons. GAD65 was found in the SNr
of both control and colchicines treated animals.
GAD67 showed a very different pattern of staining to GAD65. In control animals very
little staining was seen in the SNc (Figure 50B), while some occasional staining was
seen in the VTA (Figure 50D). In animals given colchicine no staining was found in the
SNc (Figure 50A), but in the VTA (Figure 50B) there was staining of both cell bodies
and the surrounding fibres. GAD67, like GAD65, was found in the SNr of all animals
regardless of whether axon transport had been blocked or not (Figure 48).
Neurons containing the heteromer GAD65/67 were not found in the SNc using either of
the 2 antibodies in control (Figure 51B & 52B) or in colchicine treated animals (Figure
51A & 52A). In the VTA, GAD65/67 containing neurons were only found after axon
transport had been blocked (Figure 51 C & D, Figure 52 C & D). In the SNr,
GAD65/67 was only found in control animals and not in animals treated with
colchicine.
10.1.3 Discussion
The aim of this experiment was to examine the distribution of the 2 isoforms of GAD,
GAD65 and GAD67, as well as the heteromer GAD65/67 in the brain at the level of the
mesopontine tegmentum and the midbrain. GAD65 was found in the cell soma
throughout these regions, both before and after axon transport had been blocked. This
could be due to the lack of transport of GAD65 from the cell body. GAD65 appears not
to be have been previously examined in the mesopontine tegmentum, however GAD
labelled neurons have been found previously in these regions (Ford et al., 1995;
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Maloney et al., 1999, 2000). The midbrain was found to express GAD65 only in the
neuropil, while no immunoreactivity was found in the somata (Gonzalez-Hernandez et
al., 2001). Despite ubiquitous staining by the polyclonal GAD65 antibody in this
experiment, some test staining has suggested that a monoclonal GAD65 antibody may
result in more specific staining. This suggests that either the antibody used in this
experiment was more sensitive and could detect smaller amounts of GAD65, indeed
GAD65 mRNA was detected in the SNc when no GAD65 immunoreactivity was found
(Gonzalez-Hernandez et al., 2001). Alternatively it is possible that it was not selective
for GAD65 at all, and is in fact staining for some other protein present in the cell.
However, it was impossible to test the specificity of the antibody as no control peptide
was available from the manufacturer.
GAD67 appears to label neurons much more selectively than GAD65. In control
animals very few GAD67 labelled neurons were found in the mesopontine tegmentum
and midbrain. After axon transport was blocked, intensely stained neurons could be
found in both the LDTg and PPTg, but in the dopaminergic regions of the midbrain
only the VTA contained GAD67 neurons. In the SNc there appeared to be darker
background staining in control animals which could indicate GAD67-containing
neuropil. Blocking axon transport would prevent staining of the surrounding dendrites
as any GAD would be limited to the neuron where it was synthesized. GAD67 staining
appears to be difficult to detect as there is little consensus as to its distribution in the
midbrain. However, this could be due to changes in the rate of synthesis and the rate at
which GAD67 is removed from the somata. The rapid transport of GAD67 away from
cell bodies could also account for why GAD67 is affected more strongly by colchicine,
as the effects of blocking axon transport would only be noticeable when there was
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normally a high level of transport. Both this study and Maloney et al., (2002) found that
the majority of GAD67 containing neurons were in the VTA, not the SNc. This
contrasts somewhat with Gonzalez-Hernandez et al., (2001) who did find GAD67
labelling in the SNc and with Sheikh et al., (1999) who found a higher level of GAD67
protein in the SN. It is possible that Maloney et al., (2002) failed to find any GAD67
immunoreactive neurons in the SNc because they did not block axon transport with
colchicine as it was a behavioural study. However both this study and Gonzalez-
Hernandez et a (2001) did use colchicine, so the only differences lie in the amount of
time between receiving colchicine and perfusion of the animal. Because this study left
the animals 48h, rather than 24h, it is possible that some neurons were beginning to
recover. Gonzalez-Hernandez et al., (2001) also used in-situ hybridization to visualise
GAD67 neurons in the midbrain and found that while the SNc did contain some
GAD67 mRNA, the majority was in fact GAD65. Sheikh et al., (1999) found 3 times
more GAD67 in the SN than the VTA, but as immunoblotting has no cellular resolution
they could not distinguish between the SNc and SNr, which contains large numbers of
GAD containing neurons.
Neurons were labelled by heteromer GAD65/67 in the LDTg and VTA after axon
transport was blocked but not in the PPTg or SNc. This is difficult to explain as the
polyclonal GAD65/67 antibody was raised against part of the C-terminal domain of
GAD which is 73% identical between GAD65 and GAD67. It would be expected
therefore that GAD65/67 would label neurons that contain either GAD65 or GAD67.
But it appears not to have labelled the PPTg or the SNc which both contain one or both
of GAD65 and GAD67. A second monoclonal GAD65/67 antibody was also used to
compare results and a slightly different distribution was found. In addition to
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GAD56/67 neurons in the LDTg and VTA, some labelled neurons were also found in
the posterior PPTg but not the anterior PPTg after blocking axon transport. The major
difference between the staining of the two GAD65/67 antibodies was the appearance of
the labelled neurons. The first antibody appeared to stain the cell cytoplasm as well as
the surrounding dendrites, whereas the second antibody appeared to label only the cell
membrane. This could be due to the fact that this is a monoclonal antibody and hence
will be targeting a more specific antigen. A polyclonal antibody, like the first
GAD65/67 antibody, is raised against multiple cells so will not be so specific.
Due to the inconsistency of immunohistochemical staining it seems that in-situ
hybridisation is a better option in order to get a clearer idea of the distribution of GAD.
A further problem with using immunohistochemistry is the lack of staining in control
animals due to the high turnover of GAD in the cell. Although colchicine can be used to
increase staining in the cell soma, it is not a practical intervention in a behavioural
study as blocking axon transport also results in the loss of motor control in the animals.
Because in-situ hybridisation staining is directed at the mRNA or DNA in a cell it is
more reliable marker for proteins produced in the cell.
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10.2 Dermorphin saporin
10.2.0 Introduction
The aim of this experiment was to find a method of inducing a GABA specific lesion in
the VTA using a neuropeptide-toxin conjugate. Dermorphin Saporin is a conjugate of a
potent opioid receptor agonist and Saporin, a ribosome inactivating cytotoxin.
Dermorphin-Saporin has been successfully used to selectively lesion opioid receptor
containing neurons in the striatal patch compartment of the striatum (Tokuno et al.,
2002) and in the rostroventral medulla (Burgess et al., 2002).
opioid receptors in the VTA are thought to contribute to the reinforcing effects of
opiates through the disinhibition of dopamine neurons. The opioid receptor agonist
DAMGO was found to excite dopamine neurons in the VTA by reducing the frequency
of firing of GABAergic interneurons by hyperpolarisation. This releases the dopamine
neurons from tonic inhibition, thus increasing dopamine release (Johnson & North,
1992a). They also found that dopamine neurons are unresponsive to opiates, suggesting
that in the VTA, opioid receptors are selective to GABAergic neurons. When VTA
dopaminergic neurons were selectively lesioned there was a 65% reduction in
neurotensin binding, specific to dopamine neurons, but no effect on the density or
distribution of opioid receptors. However non-specific lesions of the VTA resulted in
a 50% reduction in opioid binding (Dilts & Kalivas, 1989) suggesting that u-opioid
receptors are not found on dopaminergic cells. Garzon & Pickel (2001) found a similar
distribution of opioid receptors thoughout the paranigral and parabrachial
subdivisions of the VTA, comprising of 50% of labelled structures. However they did
find that 10% of opioid immunolabelling was contained in TH labelled dendrites.
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It was hypothesised that, due to the relative specificity of -opioid receptors to GABA
neurons, Dermorphin-Saporin microinjections into the VTA at the correct concentration
would result in a GABA specific lesion. In order to lesion neurons containing the -
opioid receptor in the striatum Tokuno et al., (2002) injected 0.5ul of Dermorphin-
Saporin at a concentration of 17ng/ul. A lesion of -opioid receptor containing neurons
in the VTA was examined by using a range of concentrations of Dermorphin Saporin to
create a dose-response of lesion specificity, both unilaterally and bilaterally.
10.2.1 Methods
Animals
19 drug naïve adult male Lister Hooded rats (Harlan Olac Ltd) weighing 290-420g
were used.
Unilateral Co-ordinates n Bilateral Co-ordinates n
50ng/l +3.8, +1.0, -7.0 2 50ng/l
25ng/l +3.8, +1.0, -7.0 2 25ng/l
20ng/l +3.6, +1.0, -7.2 2 20ng/l
20ng/l +3.6, +1.0, -7.0 2 20ng/l
15ng/l +3.6, +1.0, -7.0 2 15ng/l
10ng/l +3.6, +1.0, -7.0 2 10ng/l +3.6, ±1.0, -7.0 3
5ng/l +3.6, +1.0, -7.0 2 5ng/l +3.6, ±1.0, -7.0 2
Total 14 Total 5
Surgical Procedure
Animals were anaesthetized as described in the General Methods. Animals were then
placed in a stereotaxic frame. Infusions of Dermorphin Saporin (Advanced Targeting
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Systems, Ca.) were delivered in a volume of 500nL to each site by pressure injection
through a glass micropipette (tip diameter 35-40 microns). All injections were made
with the stereotaxic frame set such that the skull was level at bregma and lambda
(Paxinos & Watson, 1997). Animals were given unilateral injections into the VTA,
made at the following coordinates: four animals at +3.8, +1.0, -7.0; two animals at
+3.6, +1.0, -7.2; eight animals at +3.6, +1.0, -7.0. Five animals had bilateral lesions into
the VTA made at +3.6, ±1.0, -7.0. The glass micropipettes were left in situ for 300s
after the infusion to allow for diffusion away from the tip. Finally animals were given
1mL Hartmans solution and monitored during recovery. After 17 days rats were
anaesthetized with sodium pentobarbitone (‘dolethal’, Univet Ltd, Bicester, Oxon, UK;
200mg/ml) and perfused transcardially first with phosphate buffered saline and second
with 4% paraformaldehyde in 0.1M phosphate buffer. After removal brains were stored
overnight in 20% sucrose prior to histological analysis.
Histological Analysis
Histological analysis was performed as described in the General Methods. The normal
serum used in the ADS and blocking solution was raised in goat. Sections were single
labelled for GAD67 (1:5000, made in rabbit; Chemicon), MOR (-opioid receptor;
1:5000, made in guinea pig; Chemicon), NeuN (1:1000, made in mouse, Chemicon)
and TH (1:25,000, made in mouse; Chemicon). Secondary antibody was either anti-
mouse or anti-guinea-pig (Vectastain, Vector Labs). Sections that were immuno-
labelled for NeuN were also stained for Cresyl Violet to highlight lesion area.
Quantification & Statistics
Lesion size was analyzed by measuring the largest point of each lesion on the sections
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labelled with NeuN and Cresyl Violet. Lesion specificity was analyzed using sections
labelled with TH, MOR, and GAD67.
10.2.2 Results
The first lesion was made at the co-ordinates +3.8 +1.0 -7.0 using a 50 ng/l
concentration of Dermorphin Saporin toxin (Table 5). This resulted in a large amount
of non-specific damage, which at the largest point was on average 1450m in width
and 1212m in height (Figure 53 A & B). The lesion was visible through, on average, 6
sections meaning the total depth of the lesion was greater that 950 l. There was also a
substantial amount of TH damage in both the SNc and VTA though approximately 8
sections (Figure 53G). Very few GAD67 immunoreactive neurons were visualised on
the unlesioned side of the brain, but none were seen in the VTA of the lesioned side
(Figure 53 E & F). After staining for opioid receptor, neurons were seen in the
unlesioned side of the VTA. In the lesioned side of the VTA there were fewer cell
bodies containing MOR, but a greater number of fibres (Figure 53 C & D).
In the second set of lesions, made at the same co-ordinates, the concentration of
Dermorphin-Saporin was halved to 25 ng/l. The subsequent lesions were very similar
to those after 50 ng/l. There were large amounts of non-specific damage,
approximately 1225m by 1125m, and also liberal damage to TH containing neurons
through 4-6 sections.
In the third set of lesions, of 20 ng/l, the co-ordinates were changed to ensure that the
neurons lost would be contained in the posterior regions of the VTA. These coordinates
(+3.6 +1.0 -7.2) corrected the anterior-posterior position but resulted in the lesions
being too low so that no damage was done. Another set of lesions was made
Table 5: Amount of non-specific damage caused by dermorphin-saporin after unilateral or bilateral lesions.
Width Height Depth Width Height Depth
1600μm 1150μm >1440μm - - -
1300μm 1275μm >960μm - - -
1250μm 1050μm >1200μm - - -
1200μm 1200μm >1440μm - - -
- - - - - -
- - - - - -
1300μm 1400μm >960μm - - -
1400μm 1700μm >1680μm - - -
550μm 1350μm >480μm - - -
1300μm 1250μm <240μm - - -
700μm 700μm >720μm - - -
700μm 1400μm >480μm - - -
250μm 1450μm >240μm - - -
500μm 900μm >240μm - - -
800μm 1450μm >240μm 950μm 1050μm >960μm
850μm 1400μm <240μm 900μm 1250μm >240μm
1050μm 1450μm >480μm 900μm 1000μm >480μm
900μm 1350μm >240μm 1000μm 1000μm >960μm
750μm 400μm >240μm 650μm 1050μm >480μm
±1.0
5ng/ml
-7.0
15ng/ml
10ng/ml
5ng/ml
10ng/ml
bilateral +3.6
+3.6 +1.0 -7.2
+3.6 +1.0 -7.0
Left Right
Coordinates
50ng/ml
unilateral
+3.8 +1.0 -7.0
25ng/ml
20ng/ml
Figure 53:  Unilateral 50ng/µl dermorphin-
saporin lesion of the VTA
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Scale bars:   A & G = 500µm;  B-F = 100µm
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. C & E show the 
site of the lesion, while D 
& F show unlesioned tissue 
in the same animal. TH 
staining in the ventral 
midbrain (G).
* = fasciculus retroflexus
GScale bars:   A & G = 500µm;  B-F = 100µm
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C D
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. C & E show the 
site of the lesion, while D 
& F show unlesioned tissue 
in the same animal. TH 
staining in the ventral 
midbrain (G).
* = fasciculus retroflexus
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BFigure 54:  Unilateral 20ng/µl dermorphin-
saporin lesion of the VTA
Figure 55:  Unilateral 10ng/µl dermorphin-
saporin lesion of the VTA
A
C D
E F
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Scale bars:   A & G = 500µm;  B-F = 100µm
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. C & E show the 
site of the lesion, while D 
& F show unlesioned tissue 
in the same animal. TH 
staining in the ventral 
midbrain (G).
* = fasciculus retroflexus
B
Figure 56:  Unilateral 5ng/µl dermorphin-
saporin lesion of the VTA
A
C D
E F
G
Scale bars:   A & G = 500µm;  B-F = 100µm
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. C & E show the 
site of the lesion, while D 
& F show unlesioned tissue 
in the same animal. TH 
staining in the ventral 
midbrain (G).
* = fasciculus retroflexus
B
Figure 57:  Bilateral 10ng/µl dermorphin-
saporin lesion of the VTA
A
C D
E F
G
Scale bars:   A & G = 500µm;  B-F = 100µm
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. TH staining in 
the ventral midbrain (G).
* = fasciculus retroflexus
B
Figure 58:  Bilateral 5ng/µl dermorphin-
saporin lesion of the VTA
A
C D
E F
G
Scale bars:   A & G = 500µm;  B-F = 100µm
NeuN & Cresyl Violet 
staining in the ventral 
midbrain (A) indicating
the extent of non-specific
damage.  Inset, a close up 
of lesioned versus 
unlesioned tissue (B).  
MOR (C & D) and GAD 67 
(E & F) staining in the VTA,
indicating the extent of 
toxicity to GABAergic
neurons. TH staining in 
the ventral midbrain (G).
* = fasciculus retroflexus
B
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maintaining the +3.6 anterior-posterior location but reducing the depth of the injection
back to DV -7.0. Despite the reduction in concentration, there was a large amount of
non-specific damage at the injection site, approximately 1350m in width and 1550m
in height (Figure 54 A & B). Damage could be seen through 5 sections, a depth of
about 950m. There was a slight decrease in the amount of TH damage relative to the
lesion resulting from 50 ng/l of Dermorphin Saporin, but there was still only half the
density of the unlesioned side remaining (Figure 54G). GAD67 staining showed that
GAD67 containing neurons were still present on the lesioned side (Figure 54 E & F).
MOR staining showed no difference between the lesioned and non-lesioned side
(Figure 54 C & D).
The concentration of Dermorphin Saporin was reduced by half again to 10 ng/l which
resulted in a reduction of non-specific damage by about half. The damaged area
measured approximately 700m by 1050m (Figure 55 A & B). TH containing neurons
appeared to be undamaged by this concentration, although the increased staining of
fibres indicated some damage (Figure 55G). GAD67 staining showed that some
neurons on the unlesioned side of the VTA but none on the lesioned side, but MOR
containing neurons were not seen on either side (Figure 55 C - F).
The lowest concentration of Dermorphin Saporin used for a unilateral lesions was 5
ng/l. This resulted in a very small amount of damage at the injection site,
approximately 375m by 1175m. However, this was mostly damage contained within
the tract of the micropipette (Figure 56 A & B). The TH containing neurons of the SNc
and VTA appeared to be intact (Figure 56G). It is possible that this concentration was
too low to have any toxic effect as GAD67 immunoreactive neurons were seen on both
the lesioned and unlesioned side of the brain (Figure 56 E & F). It was impossible
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to tell the extent of the damage fully as the lack of MOR staining indicates that these
neurons may have been eliminated (Figure 56 C & D).
Bilateral lesions were attempted at concentrations of 10 ng/l and 5 ng/l. Both
resulted in large areas of non-specific damage at the injection site, approximately
870m by 1130m (Figure 57/58 A & B), similar in size to the unilateral lesions that
resulted from twice the dose. There didn’t appear to be a large amount of TH damage at
either dose, although more TH neurons were visible after 5 ng/l indicating less
damage than after 10 ng/l (Figure 57/58G). These doses also failed to damage GAD67
containing neurons, which suggested that they are not concentrated enough to damage
GABA neurons (Figure 57/58 E & F). However, MOR containing neurons were not
visible after bilateral lesions (Figure 57/58 C & D).
10.2.3 Discussion
The aim of this experiment was to make a specific GABA-neuron lesion in the VTA.
The results suggested that a concentration of 5 ng/l Dermorphin Saporin may have
been an appropriate concentration of toxin to make a unilateral lesion in the VTA. The
NeuN and cresyl stained sections showed that in the animals given unilateral lesions,
the size of the lesion was reduced from over 1200m2 down to 250m2 in some
animals. The lesions made using concentrations over 20 ng/l resulted in non-specific
lesions over a large area. The 10 and 5 ng/l concentrations showed much smaller
lesions with less non-specific damage. In the animals with bilateral lesions, the size of
the non-specific lesion damage increased relative to the equivalent concentration of the
toxin in the unilateral lesion. This was probably due to large numbers of contralateral
connections between the two sites increasing the effect of the toxin (Geisler & Zahm,
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2005).
Despite reducing the area of non-specific damage, the specificity of the lesion is still to
be determined. The amount of TH damage was reduced with the concentration of the
toxin. However, due to the fact that 10% of dopamine neurons are thought to contain
opioid receptors (Garzon & Pickel, 2001), TH damage is unlikely to be eliminated.
The amount of GABA specific damage was not able to determined. The techniques
available were not able to label the intended neurons with acuity, so it was impossible
to detect missing cells with accuracy. The opioid receptor antibody appeared to only
weakly label cells in the VTA. Even when concentrations of all the solutions in the
‘ABC’ procedure were doubled, the staining was extremely indistinct. It is possible that
the integrity of the antibody was compromised as the quality of staining seemed to
decrease over time. Also intended to label GABA neurons in the VTA was the GAD67
antibody. However, as determined in Experiment 5: GAD Histology, the turnover of
GAD67 is such that little remains in the cell soma after the animal has been perfused.
GAD65 and GAD65/67 antibodies were also tested on a few sections but the results
were the same.
As concluded after examining GAD Histology, it is possible that in-situ hybridisation
of either the opioid receptor or of GAD will give a more accurate picture of the
GABA neurons in the VTA and hence the loss of these neurons due to the Dermorphin-
Saporin toxin could be more easily visualised. However considering that this is the first
time a GABA specific toxin has been attempted in the VTA with the Dermorphin-
Saporin toxin, considerable progress has been made in finding a concentration of
Dermophin-Saporin that results in a GABA specific lesion.
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10.3 Conclusion
Experiments to localise the distribution of GABAergic neurons in the mesopontine
tegmentum and midbrain showed different distributions of the different isoforms of
GAD. GAD65 staining was found in all four regions examined, the LDTg, PPTg, SNc
and VTA, regardless of whether axon transport was blocked. GAD67 containing
neurons were only found in the LDTg, PPTg and VTA after axon transport was
blocked. This suggests that while GAD65 is synthesized and stored in the same cell,
GAD67 synthesized in one cell but rapidly transported to another site. The heteromer
GAD65/67 was expected to show the distribution of GAD65 and GAD67, however this
did not occur. The LDTg and VTA both showed labelling after axon transport was
blocked, but very little labelling was found in the PPTg or SNc.
Because of the need to block axon transport in order to visualise neurons, this makes
GAD immunohistochemistry an unsatisfactory procedure for use in behavioural
experiments. Because Fos is a measure of neural activity it is possible that blocking
axon transport would lead to changes in patterns of activity (Ceccatelli et al., 1989).
The interaction of nicotine induced locomotor changes and loss of motor control due to
colchicine would also lead to unpredictable changes in the patterns of activity in the
brain. A reliable marker for GABA neurons in the LDTg/PPTg and SNc/VTA still
needs to be found in order that the neurochemical identity of activated neurons after
acute and chronic nicotine can be determined. A method such as in-situ hybridisation,
which stains for mRNA or DNA, would allow cells to be identified in a much more
reliable fashion than immunohistochemistry which attempts to identify cells by staining
proteins which can move from neuron to neuron. This is especially true when using a
GAD antibody to identify GABA cells, as GAD has a high turnover. Labelling neurons
181
by ISH would result in a much higher resolution picture of GAD distribution
(Gonzalez-Hernandez et al., 2001).
The attempt to develop a GABA specific lesion in the VTA was only partly successful.
In undertaking a Dermorphin-Saporin dose-response, a dose that resulted in little non-
specific damage was found, but this was only for the unilateral lesion. In order to make
a bilateral lesion the dose needs to be smaller still. Despite this, the specificity of the
lesions was still unable to be determined due the lack of staining for GABA neurons.
However, once a reliable marker for the midbrain GABAergic neurons is found it
should be a relatively simple task to measure the specificity of the lesions.
The success of labelling GABA neurons specifically and reliably and the development
of a GABA specific lesion would mean that the role that local GABA interneurons play
in mediating dopamine neurons both in normal behaviour and after nicotine
administration could be determined. GABA is thought to hold dopamine neurons under
tonic inhibition (Johnson & North, 1992a), so removing the local GABA inhibition
should lead to an increase in dopamine release and Fos expression as well as increased
behaviours associated with dopamine such as locomotion and responding for a drug. A
small specific lesion would also allow us to elucidate the regional differences in GABA
interneurons in the VTA. However, one problem with lesioning a group of lesions with
a largely modulatory role is that the lack of input to dopamine neurons could lead to
compensatory changes or even the death of these cells. It is also possible that the 10%
of dopamine neurons that do contain opioid receptors play an important role in the
VTA which cannot be compensated for by the surrounding dopamine neurons.
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Chapter 11: Conclusion
11.0 Summary of findings and conclusions
The aim of this thesis was to examine the extent and neurochemical identity of neurons
in the cholinergic regions of the mesopontine tegmentum and dopaminergic midbrain
that showed IEG expression after systemic nicotine. Despite a wealth of information on
the behavioural and cognitive effects of nicotine, very little is understood about the
basic mechanisms of nicotine at a cellular and molecular level.
The reinforcement processes associated with nicotine are thought to be regulated by the
midbrain dopamine projections to the NAcc (Corrigall et al., 1994; Louis & Clarke,
1998). Motivationally relevant information is thought to be conveyed by these neurons
by burst firing because it increases the probability that dopamine is released from the
cell. Burst firing depends on EAA afferents from a number of regions including the
mesopontine tegmentum. Inactivation of the LDTg inhibits burst firing in the VTA
(Lodge & Grace, 2006). The prominence of the cholinergic neurons in the LDTg and
PPTg has led to the widespread belief that they are responsible for the regulation of
midbrain dopamine activity (Lanca et al., 2000a). However, research has showed that
mechanisms other than cholinergic may play a larger role that anticipated (Corrigall et
al., 2000; Lanca et al., 2000b; Corrigall et al., 2001).
Fos expression after acute and chronic nicotine
These experiments confirm findings that cholinergic neurons of the LDTg and PPTg
were not activated, as measured by Fos expression, by acute or chronic systemic
nicotine. However, there was a substantial population of non-cholinergic neurons that
did express Fos. Fos expression has been previously found in cholinergic neurons in the
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mesopontine tegmentum indicating that these neurons do contain the c-fos gene
(Kayalioglu & Balkan, 2004). This could lead us to two conclusions: either that
cholinergic neurons are excited by nicotine, but that this does not result in activation of
Fos expression to a degree that can be visualised by immunohistochemistry, or that
cholinergic neurons are not activated by nicotine. Evidence that shows an increase in
ACh release in the VTA without activating Fos expression in the LDTg suggests the
former conclusion is possible (Nakahara et al., 2001). Regardless, it suggests a larger
role for non cholinergic neurons in the LDTg and PPTg than previously thought. The
neurochemical profile of these neurons has yet to be identified. Both GABAergic and
glutamatergic populations have been described as interdigitated with the cholinergic
neurons of the mesopontine tegmentum (Clements & Grant, 1990; Ford et al., 1995).
We also established, contrary to previous reports (Pang et al., 1993; Mathieu-Kia et al.,
1998), that both acute and chronic nicotine did induce Fos expression in the SNc and
VTA. However, the majority of activity in this region was non-dopaminergic. Systemic
injections of nicotine have been shown to increase both firing rate and burst firing in
dopamine neurons in the midbrain, resulting in increased dopamine release in both the
midbrain and in terminal fields (Nisell et al., 1994; Nisell et al., 1997; Erhardt et al.,
2002; Rahman et al., 2003). Once again, these neurons have been established to be
capable of expressing the Fos protein (Maloney et al., 2002; Jomphe et al., 2003)
suggesting that these neurons are being inhibited during nicotine administration. This is
thought to be due to D2 autoreceptors, local GABA interneuron inhibition, or inhibitory
GABAergic feedback from the striatum.
Fos expression after d-amphetamine
It was possible that the effect of nicotine on Fos activity in the SNc and VTA was
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simply due to the locomotor activating effects of the drug rather than the reinforcing
effect of nicotine. However, an acute dose of d-amphetamine that resulted in a similar
level of locomotor activity to 0.8mg/kg chronic nicotine inhibited Fos expression in the
SNc and VTA. This suggests that the effect of nicotine on dopamine and non-
dopaminergic neurons are not simply the effect of enhanced motor activity. It also
suggests that increased Fos expression in the non-dopaminergic neurons of the
midbrain was an effect specific to nicotine.
Fos expression after haloperidol pre-treatment and acute nicotine
The mechanism by which nicotine inhibits Fos expression in the dopamine neurons of
the midbrain is unknown. It was thought that D2 autoreceptors were activated by an
initial facilitatory effect of nicotine on dopamine neurons, thus preventing subsequent
engagement of the second messenger cascade. However, blocking the D2 receptor had
no effect on nicotine induced Fos expression in dopamine neurons in the VTA.
Haloperidol did have a small effect on nicotine induced Fos expression in the SNc, but
the total number of activated neurons was very small. This indicates that there is some
additional mechanism acting to inhibit Fos expression in dopamine neurons in the
VTA.
GAD immunohistochemistry in the mesopontine tegmentum and midbrain
One of the aims of this thesis was to identify the type of neuron that was activated by
nicotine. However, there appears to be no consistency in the results when staining for
GABAergic neurons in the midbrain. An immunohistological study was carried out in
an attempt to methodically localise GABA neurons in the mesopontine tegmentum and
midbrain using an antibodies against GAD65, GAD67 and the heteromer GAD65/67. It
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was determined that GAD65 was present in all four regions examined; the LDTg,
PPTg, SNc and VTA, regardless of whether axon transport had been blocked. GAD67,
on the other hand, was only present in the LDTg, PPTg and VTA after axon transport
was blocked. This suggests that GAD65 and GAD67 play different roles in the
production of GABA. GAD65, which may not be critical for GABA production (Asada
et al., 1996; Asada et al., 1997), appears to be stored in the cell in which it was
produced. GAD67 was only seen after axon transport was blocked suggesting a high
turnover and efficient transport out of the cell. It was expected that the heteromer
GAD65/67 would be found in a similar distribution to GAD65 and GAD67 as the
antibody is produced from the part of the gene that is similar in both isotopes. However,
the pattern of staining more closely resembled that found after GAD67, as GAD65/67
was only found after axon transport was blocked. This could suggest that the GAD65
antibody is not specific, or that the heteromer antibody simply was more similar to
GAD67. Double labelling with ChAT revealed that GAD65/67 labelled neurons were
interdigitated with cholinergic neurons throughout the length of the LDTg and pPPTg,
but not the aPPTg. However, these presumed GABA neurons were not restricted to the
boundaries of the LDTg and PPTg as defined by the cholinergic neurons. The lack of
clear staining without pre-treatment to block axon transport in the brain means that
these antibodies are not suitable for use in behavioural experiments due to the disabling
effect of colchicine on motor activity.
Dermorphin-Saporin lesion in the VTA
One of the methodological issues with using systemic injections of haloperidol to
determine the effect of local autoreceptors in the midbrain is that there are a large
number of D2 receptors in the striatum which, when blocked could have an effect on
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activity in the midbrain. In order to prevent this it would be preferable to manipulate a
single type of cell or a single receptor type in a very localised area of the brain.
GABAergic neurons in the VTA are thought to regulate dopamine activity through
tonic inhibition (Johnson & North, 1992a). In order to determine the effect of local
GABAergic neurons in the VTA on nicotine induced activity in dopamine neurons, we
attempted to establish a procedure for inducing a GABA specific lesion in the VTA.
Dermorphin-saporin is a neuropeptide-toxin conjugate that binds to the -opioid
receptors. In the midbrain the -opioid receptor is thought to be specific to GABA
neurons. Concentrations of dermorphin-saporin greater than 10ng/l resulted in large
non-specific lesions, while lesions of 5ng/l or 10ng/l concentration resulted in small,
relatively specific lesions that were localised in the VTA. Unfortunately, as was
showed by the last experiment, the GAD67 and GAD65/67 antibody can only be
visualised after axon transport has been blocked, and the GAD65 antibody may not be
specific for GABA neurons. The MOR antibody was also found not to clearly label
GABA neurons in the midbrain. If an alternative method of visualising MOR
containing neurons is found, then the dermorphin-saporin lesion may be a valuable tool
in determining the contribution of the GABA neurons to nicotinic mechanisms in the
midbrain.
11.1 Methodological Issues
A number of methodological problems were encountered during these experiments that
must be taken into account when interpreting results. Two different Fos antibodies were
used during the acute nicotine experiment which resulted in high variance. The acute
nicotine experiments were done over the course of two years, this also resulted in
increased variance compared with the chronic nicotine experiments which were
187
completed within a much shorter timeframe. We attempted to solve this by analysing
the data as percent difference from a baseline (the control animal) rather than total Fos
expression. Despite the high variance in the data, significant results were still found.
It is possible that the timeframe used in these experiments of 1hr between nicotine
injections and sacrifice was not sufficient to visualise Fos expression in substantial
numbers of dopamine neurons. Rahman et al., (2003) found that both acute and chronic
nicotine increased dopamine efflux in the VTA by over 100%, but this did not occur
immediately. After both acute and chronic nicotine the maximum dopamine release
occurred at 60 to 80min after systemic injection of nicotine (0.3mg/kg) so this large
increase would not be measured by Fos expression after 60min. This could account for
the lack of Fos expression seen in dopamine neurons after both acute and chronic
nicotine because less substantial dopamine release may result in weaker Fos staining.
However, when looking at Fos expression in the LDTg and PPTg, Lanca et al., (2000b)
found that Fos expression was at its highest after 60 min and decreased by 90 min. As
Experiment 1 was attempting to replicate results found by Lanca et al., (2000b), for
consistency a 60min sacrifice time was used for all the experiments measuring Fos
expression.
11.2 Future experiments
One question that this thesis failed to answer was the neurochemical identity of the
neurons that showed Fos activity after nicotine administration. Due to the inability of
the GAD antibodies to label GABA neurons without blocking axon transport, an
alternative method must be found. In situ hybridization, which labels mRNA in the cell,
is a method that may be useful in this case. It has been successfully used to label
GABA neurons in the midbrain and labelled a much higher proportion of cells
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compared with immunohistochemistry procedures (Gonzalez-Hernandez et al., 2001).
A recent experiment has also established the presence of VGlut2 mRNA in the VTA as
a marker for glutamatergic neurons (Yamaguchi et al., 2007). Double labelling for
VGlut2 and Fos will determine if glutamate neurons are being activated by nicotine.
Regional variation has also been found when examining the effects of nicotine on IVSA
behaviour. Microinjections of nicotine in the posterior but not the anterior VTA was
found to be reinforcing (Ikemoto et al., 2006). Differences in connections have also
been found between the dorsal and ventral regions within the VTA. Future experiments
should take this into account when quantifying Fos expression. Alternatively, to
determine the neural pathways involved in nicotinic mechanisms, labelling for Fos
expression could be combined with retrograde tracing techniques. This has previously
been demonstrated using double labelling for cholera toxin  subunit (CTb) and Fos
after systemic injections of d-amphetamine (Colussi-Mas et al., 2007). This meant that
neurons that showed Fos expression after d-amphetamine that also projected to the
VTA could quantified.
GABA neurons of the LDTg/PPTg and SNc/VTA are important in nicotinic
mechanisms (Ikemoto et al., 1997a; Ikemoto et al., 1997b; Corrigall et al., 2001); and
perhaps play a part in the nicotine induced suppression of midbrain dopamine activity,
as measured by Fos expression. There are two ways that future experiments can address
this question: firstly does acute nicotine activate GABAergic neurons in the LDTg,
PPTg, SNc and VTA. This could be tested using the previously established acute
nicotine procedure and subsequently double labelling sections for Fos expression and
GABA neurons. Secondly, does removing the local GABAergic modulatory effect,
through a GABA specific toxin, disinhibit midbrain dopamine neurons and
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consequently increase Fos expression in dopamine neurons. While previous
experiments looking at dopamine/GABA interactions have focused on individual
receptor subtypes, removing the whole interneuron will give us an idea of how the net
output from this cell affects dopamine activity.
Glutamatergic mechanisms in the VTA have also been proposed as part of a mechanism
that may inhibit dopamine activity after acute nicotine. Balfour et al., (1996) found that
blockade of NMDA receptors disinhibited dopamine release in the NAcc after acute
nicotine but attenuated dopamine release after chronic nicotine. The locomotor
response to acute and chronic nicotine were unchanged by NMDA antagonism. Future
experiments could address this issue by measuring nicotine induced Fos expression
after pre-treatment with an NMDA antagonist. Preliminary results from this lab suggest
that NMDA antagonist 0.4mg/kg D-CPPene does in fact suppress acute and chronic
nicotine induced locomotor activity compared with nicotine alone
11.3 Conclusion
Together the findings of this thesis suggest an important role for the non-cholinergic
neurons of the LDTg and PPTg in regulating dopamine activity in the midbrain after
both acute and chronic nicotine. The PPTg has previously been implicated in learning
about reward (Alderson et al., 2004a) as well as expectation of reward (Dormont et al.,
1998; Kobayashi & Okada, 2007). It is unknown exactly what part the LDTg and PPTg
play in the mediation of nicotine addiction, but it is thought that they may, at the very
least, relay fast sensory information. Recent evidence suggests that a subset of PPTg
neurons respond both to the stimulus and the reward itself (Kobayashi & Okada, 2007).
It is possible that the non-cholinergic neurons participate directly in relaying
information about the stimulus and reward, or alternatively that they regulate other
190
neurons that are involved in this process.
The non-dopaminergic neurons of the VTA and SNc are also implicated in the
mechanism that regulates the actions of nicotine in the brain. Theories about reward
stimulus association, reward expectation and incentive sensitization all involve the
midbrain dopamine neurons in some manner (Waelti et al., 2001; Robinson & Berridge,
2003). Nicotine clearly increases both electrophysiological activity as well as dopamine
release (Erhardt et al., 2002; Rahman et al., 2003), therefore the lack of Fos expression
in midbrain dopamine neurons should not be interpreted as a lack of activity. It is
possible that the mechanism by which nicotine increases activity in these neurons does
not require the activation of the c-fos gene. However, it is clear that a large number of
non-dopamine neurons are also activated. It can be concluded that both the
dopaminergic and non-dopaminergic activity that did occur was specific to nicotinic
mechanisms as they were not activated by a dose of d-amphetamine that resulted in
increased locomotor activity. The lack of Fos expression may indicate that dopamine
neurons are being tonically inhibited and that the dose of nicotine and procedure used
were not sufficient to activate second messenger systems in these neurons. As blocking
autoreceptors did not increase Fos expression in midbrain dopamine neurons after
nicotine it seems that autoreceptors may not participate in the mechanism of inhibition.
What is clear from this research is that presumed GABAergic and glutamatergic
neurons within both the LDTg/PPTg and SNc/VTA may play a larger role in regulating
processes involved in nicotine reinforcement than previously thought.
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